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ABSTRACT
It has been suggested that a multiplicity of neurotransmitter systems regulate the 
release of gonadotrophin-releasing hormone (GnRH) from their neurons in the 
hypothalamus which in turn control luteinising hormone (LH) secretion from the 
anterior pituitary. An example of such neurotransmitter systems is that secreting 
the endogenous opioid peptides which have a profound inhibitory influence on the 
LH secretion. Recently, it has been reported that a reduction in the activity of these 
peptides in the hypothalamus may be the initial neural stimulus for the generation of 
the pre-ovulatory LH surge which induces ovulation. Furthermore, this inhibitory 
opioidergic action may involve alterations in the activity of monoaminergic neurons 
which make synaptic contacts with the GnRH neurons in the hypothalamus. 
Naloxone-, the opioid antagonist, induced LH release can be prevented by prior 
administiation of a-adrenergic blockers. The central noradrenergic system is 
believed to be an essential component of the GnRH pulse-generating mechanism. 
The present study was undertaken to determine (i) the modulating effects of specific 
\ i - ,  K - and 5-opioid receptor agonists and antagonists on hypothalamic 
monoaminergic content and on LH release and (ii) the inter-relationship between the 
opioid peptidergic and aminergic systems in the control of GnRH activity.
Intact female rats were employed in the first two sets of the experiments. Vaginal 
smeai'ing was performed each morning and the morphology of the cells present used 
to identify the different stages of the oestrous cycle. Only those animals which had 
exhibited at least three consecutive oestrous cycles were selected for 
experimentation. On the day of pro-oestrus at around 12 noon, the right caiotid 
aitery was cannulated under urethane anaesthesia. Blood samples (200p,l) were 
collected via the heparinised cannula at hourly intervals commencing at 13.00h. 
Animals were injected intraperitoneally (IP) with p-, k -  and 5-opioid receptor 
agonists and antagonists at 13.00h. Controls received saline (Iml/kg, IP) alone. 
At 19.00h the rats were decapitated and the medial preoptic ai*ea (MPOA), 
suprachiasmatic nucleus (SON), median eminence (ME) and arcuate nucleus (ARN) 
surgically isolated by micropunch. While attempting to achieve the objectives in 
Experiment I, it became cleai- that urethane itself abolished the expected pre­
ovulatory LH surge. Therefore, in the second series of the experiments, blood 
samples (200pl) were collected from freely-moving conscious animals following 
cannulation of the right femoral artery under halothane anaesthesia. The animals
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were allowed to recover prior to the blood sampling commencing at 13 .OOh, They 
were subsequently treated as in the first set of the experiments.
The third set of experiments involved intracerebroventricular (icv) administration 
and co-administration of various opioid agonists and antagonists to ovaiiectomised 
and steroid-primed rats on the afternoon of the anticipated LH surge. Serial blood 
samples were collected from the femoral artery of the ketamine-anaesthetised rats via 
an indwelling cannula. The decapitation and micropunch procedures were carried 
out as explained above.
The monoamine content of the specific hypothalamic regions was deteimined by 
high peifomiance liquid chromatography with electrochemical detection. Plasma 
LH levels were measured by radioimmunassay.
In the urethane-anaesthetised rats, the expected pre-ovulatory surge was totally 
inhibited in all animals. Furthermore, concentrations of noradrenaline and its 
metabolite, 3,4-dihydroxyphenylglycol, were reduced in all the hypothalamic 
regions examined.
It was found that all three opioid agonists (diamorphine, U-50488H and DPDPE) 
administered to the conscious animals inhibited the pre-ovulatory surge on the 
afternoon of pro-oestrus. The inhibitory effects of diamorphine and DPDPE on LH 
release were negated by co-administration with naloxone. However, the K-opioid 
antagonist, MR2266, failed to elevate plasma LH levels following its co­
administration with U-50488H.
Suppression of the LH surge was consistently associated with decreased NA release 
and/or turnover in the MPOA, SON, ME and ARN at 19.00h on the afternoon of 
pro-oestrus. These inhibitory effects of the \i-, K - and 5-agonists on hypothalamic 
noradrenergic activity were prevented by their respective opioid antagonists. 
Naloxone enhancement of the pre-ovulatory LH surge occurred concomitantly with 
an increase in dopamine release in the MPOA, ME and ARN. Concentrations of 
serotonin and/or 5-hydroxyindoleacetic acid were selectively increased by naloxone 
at the time of the LH surge.
The inhibitory effects of all the opioid agonists on the hypothalamic monoamine 
content were confirmed following icv administration of diamorphine, DPDPE and
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U-69593 to the ovariectomised and steroid-primed rats. Prevention of these 
suppressive effects on amine release and/or turnover by naloxone, MR2266 and ICI 
154, 129 indicates that specific opioid receptor subtypes are involved in mediating 
these actions. However, the observations could not be correlated with the 
anticipated LH surge due to unexpected interference on this by ketamine 
anaesthesia.
In conclusion, the present results indicate that multiple opioid receptor subtypes are 
involved in the opioid suppression of the pre-ovulatory LH surge. It appears that 
opioid modulation of noradrenaline, dopamine and serotonin release and/or turnover 
within the specific areas of the hypothalamus via |i-, k -  and 5-opioid receptors is 
inhibitory at the time of the LH surge. This study supports the concept that an 
increase in the hypothalamic noradrenergic activity is a critical event in triggering the 
surge release of GnRH and LH. Both the dopaminergic and serotonergic 
neurotransmitter systems may also facilitate the pre-ovulatory LH surge, although 
their effects are thought to be of minor importance in this process. In view of the 
unexpected interference by both urethane and ketamine anaesthesia on plasma LH 
levels, it is recommended that use of general anaesthetics in neuroendocrine studies 
should be avoided if at all possible.
IX
LIST OF ABBREVIATIONS
5-HIAA 5-hydroxyindoleacetic acid
5-HT Serotonin
5-HTP 5-hydroxytryptophan
6-OHDA 6-hydroxydopamine
ACh Acetylcholine
ACTH Adrenocorticotrophic hormone
ADH Aldehyde dehydrogenase
ADR Adrenaline
AHA Anterior hypothalamic area
ARN Arcuate nucleus
BSA Bovine serum albumine
CNS Central nervous system
COMT Catechol-O-raethyltransferase
CRF Corticotropin releasing factor
DA Dopamine
DHBA 3,4-dihydroxybenzy lamine
DHPG 3,4-dihydroxypheny Igly col
DMN Dorsomedial nucleus
DNAB Dorsal noradrenergic bundle
DOMA Dihydroxymandehc acid
DOPAC 3,4-dihydroxyphenylacetic acid
DPDPE D-Pen^,D-Pen^-Enkephalin
DRN Dorsal raphe nucleus
E2 Oestradiol
EAA Excitatory amino acid
ECD Electrochemical detection
EDTA Ethylenediamine tetra-acetic acid
EME External layer of median eminence
EOP Endogenous opioid peptide
EW Egg white
FSH Follicle stimulating hormone
GABA y-aminobutyric acid
GABA-T GABA transaminase
GAD Glutamic acid decarboxylase
GnRH Gonadotrophin-releasing hormone (LHRH)
XHA
HPLC
HVA
ICI 154,129
ICI 174,864
ICV
IM
IP
IS
LC
LH
LHRH
MAO
MBH
ME
MHPG
MMN
MPOA
MPS
MRI452
MR2266
MRN
NA
NAL
NaOH
NM
NMDA
NO
NOS
NPY
NRS
NSB
OVLT
OVX
P
Histamine
High performance liquid chromatography 
Homovanillic acid
N, N, diallyl-Tyr-Gly-Gly (CH2S) Phe-Leu 
N, N, diallyl-Tyr-Aib-Aib-Phe-Leu 
Intracerebroventricular 
Intramuscular’
Intraperitoneal 
Internal standard 
Locus coeruleus 
Luteinising hormone
Luteinising hormone-releas ing hormone (GnRH) 
Monoamine oxydase 
Medial basal hypothalamus 
Median eminence
3-methoxy,4-hydroxyphenylglycol
Medial mammillary nucleus
Medial preoptic area
Modified physiological saline
(-)-(IR, 5R, 9R)-5,9-Dimethyl-2-(3- furylmethyl)-2
hydroxy-6,7-benzomorphan methanesulfonate.
(-)-5,9 alpha-Diethyl-2-(3-furylmethyl)-2'-hydroxy-
6,7-benzomorphan.
Medial raphe nucleus 
Noradrenaline 
Naloxone 
Sodium hydroxide 
Normetanephrine 
N-methyl-D-aspartate 
Nitric oxide 
Nitric oxide synthase 
Neuropeptide Y 
Normal rabbit ser’um 
Non-spesific binding
Organum vasculosum of the lamina terminalis
Ovariectomised
Progesterone
XI
PACAP
PCP
PeVN
PMN
PNMT
POA
POMC
PPS
PVN
SCN
SD
SEM
SON
SP
TH
UDA
U-50488H
U-69593
VIP
VMN
VNAB
ZI
Pituitary adenylate cyclase-activating polypeptide
Phencyclidine
Periventricular nucleus
Premammillaiy nucleus
Phenylethanolamine-N-methyltransferase
Preoptic ar ea
Proopiomelanocortin
Precipitating semm
Paraventricualr nucleus
Suprachiasmatic nucleus
Semm diluent
Standard error of the mean
Supraoptic nucleus
Substance P
Tyrosine hydroxylase
Tuberoinfundibular dopamine
trans-(±)-3,4-dichloro-N-methyl-N-[2~(l-pyrrolidinyl)
cyclohexyl]-benzene-acetamide methane sulfonate.
(5a, 7a, 8B)-(+)-N-methyl-N[7-(l-pyrrolidinyl)-l-
oxaspiro(4,5)-deC“7-8-yl] benzeneacetamide
Vasoactive intestinal peptide
Ventromedial nucleus
Ventral noradrenergic bundle
Zona incerta
XII
LIST OF FIGURES
Introduction
Figure 1.1. Hormone secretion profiles throughout the oestrous cycle 4
Figure 1.2. Diagram of the rat hypothalamus and the pituitary gland 8
Figure 1.3. Hypothalamo-hypophyseal connections 12
Figure 1.4. The ventriculai* system of the rat brain 14
Figure 1.5. Neural control of LH secretion 17
Figure 1.6. Biosynthesis of catecholamines 21
Figure 1.7. Metabolism of transmitter amino acids in the brain 22
Figure 1.8. Processes of monoaminergic transmission 24
Figure 1.9. NA metabolism in the brain and periphery 25
Figure 1.10. DA metabolism in the brain 25
Figure 1.11. Noradrenergic projections in the rat brain 28
Figure 1.12. Dopaminergic projections in the rat brain 28
Figure 1.13. Serotonergic projections in the rat brain 36
Figure 1.14. Synthesis and metabolism of serotonin 36
Materials and Methods
Figure 2.1. Removal of the brain 69
Figure 2.2. Placement of the brain on microtome 69
Figure 2.3. Coronal section through the rat brain 71
Figure 2.4. Micropunch technique 72
Figure 2.5. Co-ordinates of the bregma 74
Figure 2.6.a. Fixation of rat in the stereotaxic appaiatus 75
Figure 2.6.b. Icv infusion technique 75
Figure 2.7. Diagram of the HPLC-ECD set-up 79
Figure 2.8.a Chromatograms of a composite mixture 80
Figure 2.8.b Chromatograms of a sample 80
Figure 2.9. Standard BSA curve for protein estimation 87
Experiment I
Figure 3.1. NA concentrations in MPOA and SCN 106
Figure 3.2. NA concentrations in ME and ARN 107
XIII
Figure 3.3. DHPG concentrations in MPOA and SCN 108
Figure 3.4. DHPG concentrations in ME and ARN 109
Figure 3.5. DA concentrations in MPOA and SCN 110
Figure 3.6. DA concentrations in ME and ARN 111
Figure 3.7. 5-HIAA concentrations in MPOA and SCN 112
Figure 3.8. 5-HIAA concentrations in ME and ARN 113
Figure 3.9. 5-HT concentrations in MPOA and SCN 114
Figure 3.10. 5-HT concentrations in ME and ARN 115
Figure 3.11. Ratio of DHPG/NA in MPOA and SCN 116
Figure 3.12. Ratio of DHPG/NA in ME and ARN 117
Figure 3.13. Ratio of 5-HIAA/5-HT in MPOA and SCN 118
Figure 3.14. Ratio of 5-HIAA/5-HT in ME and ARN 119
Experiment II
Figure 4.1. NA concentrations in MPOA and SCN 148
Figure 4.2. NA concentrations in ME and ARN 149
Figure 4.3. DHPG concentrations in MPOA and SCN 150
Figure 4.4. DHPG concentrations in ME and ARN 151
Figure 4.5. DA concentrations in MPOA and SCN 152
Figure 4.6. DA concentrations in ME and ARN 153
Figure 4.7. 5-HIAA concentrations in MPOA and SCN 154
Figure 4.8. 5-HIAA concentrations in ME and ARN 155
Figure 4.9. 5-HT concentrations in MPOA and SCN 156
Figure 4.10. 5-HT concentrations in ME and ARN 157
Figure 4.11. Ratio of DHPG/NA in MPOA and SCN 158
Figure 4.12. Ratio of DHPG/NA in ME and ARN 159
Figure 4.13. Ratio of 5-HIAA/5-HT in MPOA and SCN 160
Figure 4.14. Ratio of 5-HIAA/5-HT in ME and ARN 161
Experiment III
Figure 5.1. NA concentrations in MPOA and SCN 189
Figure 5.2. NA concentrations in ME and ARN 190
Figure 5.3. DHPG concentrations in MPOA and SCN 191
Figure 5.4. DHPG concentrations in ME and ARN 192
Figure 5.5. DA concentrations in MPOA and SCN 193
XIV
Figure 5.6. DA concentrations in ME and ARN 194
Figure 5.7. 5-HIAA concentrations in MPOA and SCN 195
Figure 5.8. 5-HIAA concentrations in ME and ARN 196
Figure 5.9. 5-HT concentrations in MPOA and SCN 197
Figure 5.10. 5-HT concentrations in ME and ARN 198
Figure 5.11. Ratio of DHPG/NA in MPOA and SCN 199
Figure 5.12. Ratio of DHPG/NA in ME and ARN 200
Figure 5.13. Ratio of 5-HIAA/5-HT in MPOA and SCN 201
Figure 5.14. Ratio of 5-HIAA/5-HT in ME and ARN 202
Figure 5.15 (a) NA cons, in the MPOA, SCN, ME and ARN 203
Figure 5.15 (b) DHPG cons, in the MPOA, SCN, ME and ARN 203
Figure 5.15 (c) DA cons, in the MPOA, SCN, ME and ARN 203
Figure 5.15 (d) 5-HIAA cons, in the MPOA, SCN, ME and ARN 203
Figure 5.16 (a) 5-HT cons, in the MPOA, SCN, ME and ARN 204
Figure 5.16 (b) Ratio of 5-HIAA/5-HT in MPOA, SCN, ME and ARN 204
Figure 5.16 (c) Ratio of DHPG/NA in MPOA, SCN, ME and ARN 204
LIST OF TABLES
Introduction
XV
Table 1,1. CNS distribution of opioid receptors 53
Materials and Methods
Table 2.1. Assessment of oestrous cyclicity by vaginal cytology 64
Table 2.2. Dmgs used and their receptor properties 66
Table 2.3. HPLC amine concentration calculation 82
Table 2.4. The schedule and reagents used for RIA 85
Experiment I
Table 3.1. Experiment I: Amine concentrations in MPOA 102
Table 3.2. Experiment I: Amine concentrations in SCN 103
Table 3.3. Experiment I: Amine concentrations in ME 104
Table 3.4. Experiment I: Amine concentrations in ARN 105
Experiment II
Table 4.1. Experiment II: Amine concentrations in MPOA 140
Table 4.2. Experiment II: Amine concentrations in SCN 141
Table 4.3. Experiment II; Amine concentrations in ME 142
Table 4.4. Experiment II: Amine concentrations in ARN 143
Table 4,5. LH levels in the control group 144
Table 4.6. LH levels in the diamoiphine group 144
Table 4.7. LH levels in the U-50488H group 145
Table 4.8. LH levels in the DPDPE group 145
Table 4.9. LH levels in the diamoiphine+naloxone group 146
Table 4.10. LH levels in the U-50488H+MR2266 group 146
Table 4.11. LH levels in the DPDPE+naloxone group 147
XVI
Experiment III
Table 5.1. Experiment III: Amine concentrations in MPOA 179
Table 5.2. Experiment III: Amine concentrations in SCN 180
Table 5.3. Experiment III: Amine concentrations in ME 181
Table 5,4. Experiment IE: Amine concentrations in ARN 182
Table 5.5. Saffan group: Amine concentrations 183
Table 5.6. LH levels in the control group 184
Table 5.7. LH levels in the diamoiphine group 184
Table 5.8. LH levels in the U-69593 group 185
Table 5.9. LH levels in the DPDPE group 185
Table 5.10. LH levels in the diamoiphine+naloxone group 186
Table 5.11. LH levels in the U-69593+MR1452 group 186
Table 5.12. LH levels in the DPDPE+naloxone group 187
Table 5.13. LH levels in the DPDPE+ICI 154,129 group 187
Table 5.14. Saffan group LH results 188
INTRODUCTION
The understanding of how neuroendocrine mechanisms control gonadotrophin 
secretion is complicated because of the involvement of several different 
neurotransmitter/neuromodulator systems within the brain and of the modulatory 
effects of gonadal steroids. This chapter briefly reviews the current concept of the 
neuronal circuit involved in the cential regulation of luteinising hormone (LH) 
release including the pre-ovulatory LH surge. This will include the participation of 
endogenous opioid peptides (EOPs), monoamines, amino acids, several other 
neuropeptides and gonadotrophin-releasing hormone (GnRH) neuronal systems 
and their interactions in controlling LH secretion at the hypothalamic level. 
However, before evaluating the role of these systems in the neuroendocrine 
regulation of LH release, the oestrous cycle of the rat, the anatomical organisation 
of the hypothalamo-pituitary axis and of the brain ventricular system will be briefly 
noted.
Oestrous Cycle of the Rat
The rat is a poly oestrous animal with approximately one year of sexually active life. 
As in the human, the rat is spontaneous ovulator but has a very short oestrous cycle 
of four or five days. Its oestrous cycle comprises of two or three days of 
dioestrus and one day each of pro-oestms and oestrus. Metoestrus is sometimes 
seen between late oestras and early dioestrus in five-day cycling rats and lasts only 
about six hours. Each of these stages is characterised by periodic histological 
changes in the epithelium of the uterus and the vagina, as well as specific 
behavioural changes. A classic description of the rat oestrous cycle was given by 
Long and Evans (1922).
Follicle stimulating hormone (FSH) is essential for follicular development and 
maturation. In general, it is secreted at low levels and in a pulsatile fashion 
throughout the oestrous cycle; however, there is a marked increase around the time 
of ovulation (Lumpkin etal, 1984). Concomitant with basal discharge of LH, the 
release of FSH from the anterior pituitary and the consequent rise in circulating 
levels bring about the final growth of the ripening follicles and their peak 
production of oestradiol (E2 ) (Fortune, 1994). This brings the animal into heat, 
i.e. sexual receptivity. During the mid-follicular phase, E2 and FSH together 
appear to stimulate production of LH receptors from granulosa cells, and therefore 
render the follicle sufficiently sensitive for LH to achieve ovulation and 
lutéinisation (Zelezniketal, 1974).
In early dioestrus plasma E2  release from the Graafian follicle is low, but it 
increases gradually during late dioestms. It finally peaks on the morning of pro­
oestrus. This release of E2 , accompanying follicle maturation, is thought to be the 
initial stimulus for "the pre-ovulatory LH surge" from the anterior pituitary on the 
afternoon of pro-oestrus (Levine et al, 1985). The high levels of LH then inhibit 
further production of E2 , and at the same time stimulate an increase in progesterone 
(P) secretion. Indeed, this causal relationship has been clearly shown by the 
ability of antiserum to E2 to suppress the surge (Ferin et at, 1970). P has no such 
important role in the LH surge. However, during the final maturation of follicles, 
a small amount of P is produced, which appears to facilitate ovulation (Espey, 
1994).
The profiles of secretion of LH, FSH, E2  and P during the oestrous cycle of the rat 
are illustrated in Figure 1.1.
The LH surge itself stimulates ovulation, which occurs after midnight between pro­
oestrus and oestrus. The highly vascularised ovulatory follicles bulge from the 
ovarian surface. LH appears to combine with specific receptors on the surface of 
the Graafian follicle, stimulating adenyl cyclase, cyclic adenosine monophosphate 
production, and P output. P then induces synthesis or activation of a collagenase 
enzyme which, acting on the collagen framework of the follicle wall, increases 
distensibility and lowers breaking strength. Consequently, tire rupture of the wall 
and release of the oocyte take place (Espey and Lipner, 1994). The role of P is 
crucial in this process since P antagonists delay or block ovulation (Sanchez-Criado 
et at, 1990). At this stage, coitus is necessary to maintain a fully functional corpus 
luteum whose life span is normally only one day in the rat. If coitus does not 
occur, the corpus luteum fails to become functional and only a small amount of P is 
secreted before luteal regression. As a result no luteal phase takes place and the 
oestrous cycle continues.
Gonadotrophin Secretion Profiles During The Oestrous Cycle
Secretion of FSH during the oestrous cycle of the rat consists of two different 
patterns; i.e. basal and surge release. The surge pattern of FSH secretion occurs 
during the pre-ovulatory period from the afternoon of pro-oestras to the morning of 
oestrus and the basal pattern at other stages of the oestrous cycle (Noguchi et al, 
1993).
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Figure 1.1. Schematic representation of the hormone changes in the systemic 
circulation of the rat throughout the 4-day oestrous cycle. Light phase occurs between 
06.00h and 18.OOh. Adapted from Takeo, 1984.
LH is released in a pulsatile manner during the rat oestrous cycle rather than at a 
steady rate (Gallo, 1981; Fox and Smith, 1985). The frequency and amplitude of 
these LH pulses depend upon the time of day (circadian) and the stage of the 
oestrous cycle (cyclic) (Leipheimer et al, 1985). There are two distinct patterns of 
LH release during the oestrous cycle; basal (or episodic) and surge (or phasic) 
release. LH pulses show little change on dioestrus day 1, day 2 and pro-oestms 
before the LH surge while they aie never seen during oestrus (Fox and Smith, 
1985). During the transition from the episodic LH secretion to the LH surge, 
abrupt changes occur in the LH pulse frequency and amplitude, and this is 
described as the characteristic LH surge. When rats are kept in a lighting schedule 
of 14 hours light and 10 hours dark, the frequency and amplitude of the LH pulses 
increases on pro-oestms. This initiates a lineai' rise in plasma LH levels 
approximately seven hours after the onset of the light. The increase in plasma LH 
levels continues and accelerates to a plateau some two to four hours later. It then 
drops rapidly but the decline is commonly intermpted by one or more rapid rises in 
plasma LH concentrations (Blake, 1976).
Acute timing of the LH surge and involvement of a neural signal in its control was 
first demonstrated in the spontaneously ovulating rat by Everett and his colleagues 
in a series of experiments (1949). Pharmacological suppression of this central 
stimulus consistently resulted in the blockade of the pre-ovulatory LH surge and 
hence of ovulation. The LH surge was delayed by 24 hours, but only if the drugs 
were administered during a particular time period. Thus the existence of a critical 
period of two to three hours on the afternoon of pro-oestrus, beginning at 
approximately 14.00h was indicated. After this time, the LH surge was found to 
be resistant to pharmacological blockade.
It has since become evident from a variety of experiments that the anatomical site of 
this neural stimulus lies within the hypothalamus. Indeed, a hypothalamic peptide 
(GnRH) with selective releasing action on LH and FSH, along with several other 
hypothalamic releasing factors have been identified in the mammalian hypothalami 
(Everett, 1994). The close functional relationship between GnRH and 
gonadotrophin secretion will be reviewed later in this chapter.
Feedback Control of Gonadotrophin Secretion
The neurosecretory activity of the hypothalamus is controlled by long, short and 
ultra-short loop feedback systems. The best documented of these is the long-loop 
feedback mechanism in which the steroid hormones secreted from the gonads exert 
their regulatory effects at the level of the anterior pituitary gland and/or the 
hypothalamus. The short-loop feedback mechanism refers to an action of pituitary 
hormones to regulate their own secretions by acting within the hypothalamus to 
which they are delivered by retrograde-flow of the portal blood up to the pituitary 
stalk. The hypothalamic hormones also regulate their own secretions by the ultra- 
short-loop feedback mechanism (see Karsch, 1990).
Circulating gonadal steroid hormones (E%, P and androgens) have powerful 
negative feedback effects on the tonic mode of GnRH secretion. However, E2  
exerts a positive feedback function by eliciting the surge release of GnRH in 
females. P also appears to enhance the LH surge on the afternoon of pro-oestms 
in the rat (Lee et al, 1990). These steroids may act within the hypothalamus to 
modify the rate of GnRH secretion; they may act at the anterior pituitary gland to 
alter its response to the hypothalamic GnRH, or they may act upon both sites 
(Kalra, 1993). The gonadal steroids ar’e apparently tire primary hormonal signals 
that regulate and sustain the complicated balance within the closed feedback loop of 
the hypothalamo-pituitary-gonadal axis.
The Steroid-Primed Ovariectomised Rat as a Model for the Study o f 
the Pre-ovulatory LH Surge
Ovariectomy removes the gonadal steroid feedback to the hypothalamus and 
anterior pituitary and results in the loss of oestrous cycles. As a consequence of 
this, increased amounts of gonadotrophins are secreted into the blood. The rise in 
hormone levels is delayed and occurs only after several days, depending on the 
circulating levels of E2 at the time of ovariectomy.
Acute treatment of ovariectomised (ovx) rats with E2  brings about a decrease of 
plasma LH levels, whereas chronic treatment of these animals with E2 can stimulate 
a pre-ovulatory-type LH surge. Administration of P to E2-primed ovx rats 
potentiates the afternoon LH surge. The E2-fP induced LH surges are similar- in
timing, duration and magnitude to the pro-oestrous LH discharge. Moreover, this 
can be timed more reliably than the spontaneous surge of intact animals.
The ovx and steroid-primed animal model has been used extensively in 
investigating the neuroendocrine control of surge release of LH (See Ramirez et al, 
1984; Kalra, 1993, Barraclough, 1994).
Anatomical Organisation of the Hypothalamo-Pituitary Axis 
Hypothalamus
The hypothalamus is a part of the diencephalon lying ventral to the thalamus and 
forms the walls and floor of the third ventricle. The lamina terminalis, a thin 
complex structure of capillaries, neurons, glia and tanycytes, constitutes the 
midline rostral border of the hypothalamus and the rostral wall of the third 
ventricle. The floor of the third ventricle evaginates ventrally, caudal to the optic 
chiasm, to form the infundibular portion of the neurohypophysis known as the 
median eminence (ME). The adenohypophysis, arising as a dorsal évagination 
from the embryonic pharyngeal roof, surrounds all parts of the neurohypophysis 
and also forms the anterior lobe of the pituitary. Rostrally the hypothalamus is 
bounded by the lamina terminalis.
The hypothalamus may anatomically be divided into two major areas: a medial area 
and a lateral area. The areas are defined and named in accordance with tire 
topographic region of the hypothalamus within which they lie (Bleier and Byne, 
1985). A schematic diagram of the rat hypothalamus is shown in Figure 1.2.
Medial Area
The medial area is predominantly central in position, and it is itself subdivided into 
four groups:
1) Medial preoptic-anterior hypothalamic region
This is a rostral or anterior group of nuclei which includes;
a) Vascular organ of the lamina terminalis
b) Median preoptic nucleus (MnPO)
c) Medial preoptic area (MPOA)
Corpus Callosum
Posterior
Commissure
Anterior 
Commissure
Thalamus
Optic
Chiasma
Neural lobe 
of the pituitary
Anterior 
Pituitary
Figure 1 . 2 .  Schematic diagram of the rat hypothalamus and the pituitary gland. 
Those regions indicated in gray are the areas of interest in the present study.
AHA: Anterior hypothalamic area 
ARN: Arcuate nucleus 
DMN: Dorsomedial nucleus 
MBH: Medial basal hypothalamus 
ME: Median eminence 
MMN: Medial mammillary nucleus
MHOA: Medial pretoptic area 
PMN: Premammillaiy nucleus 
PVN: Paraventricualr nucleus 
SCN: Siiprachiasmatic nucleus 
SON; Supraoptic nucleus 
VMN; Ventromedial nucleus
d) Medial preoptic nucleus (MePO)
e) Anterior hypothalamic nucleus (AHy)
f) Anterior hypothalamic area (AHA)
g) Suprachiasmatic nucleus (SCN)
h) Lateral anterior nucleus (LA)
i) Caudal anterior nucleus (CA)
j) Paraventricular' nucleus (PVN)
2) Region of the tuber cinereum (Infundibulum)
The tuber cinereum is the middle part of the hypothalamus to which the pituitary 
gland is ventrally attached. As previously noted, the embryonic third ventricular 
floor evaginates ventrally and becomes the neurohypophysis.
a) Ventromedial nucleus (VMN)
b) Dorsomedial nucleus (DMN)
c) Perifornical nucleus (PeF)
d) Ar'ea of the tuber cinereum (TuC)
e) Dorsal tuberal nucleus (DTu)
f) Tuberal magnocellular nucleus (TMC)
g) Arcuate nucleus (ARN)
h) Retrochiasmatic area (RCh)
The VMN and DMN are very prominent in the tuber cinereum. The ARN lies just 
above the ME and is adjacent to the third ventricle. The region of the tuber 
cinereum is generally believed to be the area containing most of the neurons 
producing the various hypothalamic hormones.
3) Posterior or mammillary region and mammillary recess
The caudal third of the hypothalamus includes the posterior hypothalamic area, the 
mammillary complex, and two magnocellular groups.
a) Posterior hypothalamic area (PHA)
b) Ventral premammillaiy nucleus (PMV)
c) Dorsal premammillaiy nucleus (PMD)
d) Submammillohypothalamic nucleus (SMT)
e) Medial mammillary nucleus (MMN)
f) Lateral mammillaiy nucleus (LMN)
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g) Supramammillary nucleus (SuM)
h) Nuclei gemini (Gem)
i) Caudal magnocellulai* nucleus (CMC)
In addition to these subdivisions, there is a naiTOW group of cells lying just beneath 
the third ventiicular ependyma, extending the entire length of the third ventricle. 
These neurons are termed the periventricular" system of the hypothalamus.
4) Dorsal region
The dorsal region overlies the anterior region and the tuber cinereum, and extends 
from the caudoventral border of the anterior commissure rostrally to the posterior 
hypothalamic area and mesencephalon caudally.
a) Dorsal hypothalamic area (DHA)
b) Dorsal nucleus (DN)
c) Paraventricular nucleus, dorsal division.
Lateral Area
This region of the hypothalamus lies lateral to the entire medial division of the 
hypothalamus and is the site at which the medial forebrain bundle enters the 
hypothalamus. This nerve tract contains the projections between the hypothalamus 
and the rest of the brain. The lateral hypothalamic aiea is also subdivided into 
three groups; 1) Preoptic-anterior region 2) Region of the tuber cinereum and 3) 
Posterior region.
The lateral hypothalamic area and supraoptic nucleus (SON) are located in the pre­
optic anterior region. The ME lies directly below the ARN in the posterior region 
of the hypothalamus and is composed of two parts; an external layer and an internal 
layer. It contains few, if any, nerve cell bodies, but consists of axons and 
tei-minals of both hypothalamic and extrahypothalamic neurons, glial cells, and 
specialised ependymal cells called tanycytes. It is the final common pathway 
through which the neural control of the anterior pituitary hormone secretions aie 
exercised.
Pituitary gland
The pituitaiy gland (hypophysis) is situated beneath the brain at the 
mesodiencephalic junction and formed by two distinct parts: the neurohypophysis
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(posterior lobe) and the adenohypophysis (anterior lobe). The latter is further 
subdivided into the pars distalis, pars intermedia, and pars tuberalis.
The neurohypophysis is made up of neural tissue and is connected to the rest of the 
brain via the pituitary stalk. It contains terminals of neurons whose cell bodies 
reside in the hypothalamus. Thus there is a direct neuronal link between the 
posterior pituitary and the brain. This is an important mechanism for the secretion 
of hormones from the posterior lobe. The adenohypophysis is of glandular origin 
and surrounds the posterior lobe ventrally and laterally; it is composed of several 
types of hormone-secreting cells. Unlike the posterior pituitary, the anterior 
pituitaiy has no neiwe fibres and teiminals and so is not in direct neuronal contact 
with the hypothalamus. Instead, there is a vasculai* connection between it and the 
brain, "the hypothalamo-hypophyseal portal system". Figure 1.3. illustrates the 
anatomical relationship of the hypothalamus and the pituitary.
The hypothalamo-hypophyseal portal system
This system has its primaiy plexus in the external layer of the median eminence 
(EME). Its vessels course down the pituitary stalk and teiminate in the secondary 
capillaty plexus in the pars tuberalis. Most of the blood supplied to the anterior 
pituitaiy comes from this portal system. The capillaries deliver substances to the 
anterior lobe which are secreted by axons of the pai vocellular neurosecretory cells 
teiminating in the EME and which influence the release of the anterior pituitary 
hormones (Jeunes and Stumpf, 1986). The endothelium in these capillary loops is 
highly fenestrated and flattened. Its basement is very thin, thus peimitting 
macromolecules to enter without a functional blood brain baiTier. Therefore, all of 
the known hypothalamic peptides and some biogenic amines are found in high 
concentrations in the portal blood. The tanycytes in the ME also extend the lumen 
of the third ventricle to the EME. They thus serve an important role in active 
transport in either direction between the ventricular compai’tment and the portal 
system (for review see Page, 1994).
The existence of a vascular" connection between the hypothalamus and the pituitary 
gland was first recognised by Popa and Fielding (1930). This basic finding was 
subsequently substantiated and completed by Wislocki and King (1936), who also 
concluded that blood in this portal system was flowing from the hypothalamus 
toward the pituitary gland. In the following decade. Green and Harris (1947)
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Figure 1 .3 .  Diagram of the anatomical basis of vascular and neural communications 
between the hypothalamus and pituitary gland. Adapted fiom Guiliemin, 1980.
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realised functional implications of the portal circulation by demonstrating the 
downward direction of blood flow in the portal vessels of the living rat. More 
recently, it has been shown that, in addition, a small proportion of blood may 
actually flow up the stalk, thus providing a direct vascular link from the anterior 
pituitary back to the hypothalamus (Oliver et al, 1977). This retrograde blood 
circulation may be an important mechanism in the short-loop feedback regulation of 
gonadotrophin secretion, and it was first proposed by Halasz and Szentagothai 
(1960).
The Ventricular System of the Brain
The brain consists of lobulai" outgrowths from the walls of the fluid-filled neural 
tube. The central cavities of these outgrowths are called ventricles.
The embiyonic neural tube originates from the primitive ectodeim, which then 
expands to form the cerebral ventricles. In early stages of fetal life, the nervous 
system is composed of a cylinder of cells surrounding a central cavity. The 
complex structure of the adult central nervous system is only a series of 
permutations on this basic organisation. These permutations occur as a 
consequence of a differential rate of cellular proliferation along the neural tube and 
the growth of neuronal processes.
With the growth of the brain, four brain vesicles aie fonned; the lateral ventricles in 
the telencephalon, the third ventricle in the diencephalon, the cerebral aqueduct in 
the mesencephalon, and the fourth ventricle in the pons and the medulla. The 
central canal of the spinal cord is seen as a minute hole in the centre of the grey 
matter in transverse sections. It widens out anteriorly into the medulla oblongata 
to forai the fourth ventricle. This nairows forward into a canal in the dorsal third 
of the mid-line of the midbrain as the cerebral aqueduct and continues as the third 
ventricle in the diencephalon. It then extends into each half of the cerebrum as the 
lateral ventricles through the interventricular foramen (Figure 1.4.).
The third ventricle is a high narrow slit with a rather thin floor, a membranous 
roof, and a massive lateral wall formed by predominantly thalamic and 
hypothalamic nuclei on each side. There are three recesses of the third ventricle; 
optic, infundibular and pineal. The first lies above the optic chiasma, the second 
extends through the infundibulum to the hypophysis, and the pineal recess passes
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Figure 1 .4 .1'hc ventricular system of the rat brain. Adapted from Zcman and Innes, 1963.
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into the stalk of the pineal body. In front, the third ventricle communicates with 
the lateral ventricle on each side through the interventricular- foramen (Zeman and 
Innes, 1963).
The entire surface of the ventricular system is covered by a lining of special 
differentiated neuroglial cells, with columnar- ciliated epithelium, called ependyma. 
These cells are similar in all areas of the ventricular system except at the bottom of 
the third ventricle, where the specialised ependymal cells (the tanycytes) are found. 
The ependyma is continuous with the layer of short cuboidal epithelium which 
covers the choroid plexuses with their choroidal villi. The cerebrospinal fluid is 
initially fot-med by an active secretory process of the choroid plexuses within the 
ventricles. This fluid leaves the ventricular- system through apertures in the 
posterior medullary velum. It circulates through the subarachnoid space of brain 
and spinal cord and is removed over the convexity of the cerebral hemisphere from 
the arachnoid villi projecting into large durai venous sinuses. Some interchange of 
water and solutes occurs between the brain and the cerebrospinal fluid.
In the rat brain, it has been found that the average volume of a lateral ventricle is 
43pl, the third ventricle 38pl, and the fourth ventricle lOjal (Levinger, 1971).
Gonadotrophin-Releasing Hormone
The direct neurohumoral stimulus for the secretion of LH from the anterior pituitary 
is GnRH, also known as luteinising hormone-releasing hormone (LHRH). 
GnRH is released from the ME into the primaiy plexus of the hypophyseal portal 
blood system, where it is transported through portal veins to the second capillary 
bed in the anterior pituitary. Here it not only stimulates the secretion of LH, but, 
to a lesser extent, that of FSH as well.
The peptide sequence of GnRH was first determined from porcine hypothalami 
(Schally et al, 1971) and, soon afterwards from ovine hypothalami (Burgus et al, 
1971) as the decapeptide: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 . 
Identification of the amino acid structure of this hypothalamic hormone then led to 
the production of synthetic GnRH, and it thus became available for clinical and 
research purposes. In most mammals, including the rat, only one molecular form 
of GnRH has been isolated, in spite of the chaiacterisation of several moleculai- 
forms from non-mammalian vertebrate classes (King et al, 1988). However,
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existence of a second molecular form of mammalian GnRH in the marsupial brain 
has recently been reported (King et al, 1989).
The distribution of GnRH-producing neurons in the rat brain has been extensively 
investigated (Palkovits et al, 1984). In the rat, high numbers of perikaiya and 
fibres containing GnRH have been visualised in the MPOA, and high 
concentrations of GnRH itself have been found in the ARN, SCN and ME. In the 
latter two hypothalamic areas GnRH was restricted to fibres alone (Witkin et al, 
1982; Shivers etal, 1983a; Palkovits et al, 1984). The GnRH fibres reach to the 
ME by more than one route (Merchanthaler et al, 1984; Silverman and Witkin, 
1994). The major septo-preoptico-infundibular pathway begins as a midline 
bundle of GnRH which processes anteriorly neai- the level of the diagonal band of 
Broca(Silverman etal, 1994). This bundle bifurcates neai- the preoptic recess of 
the third ventricle. They both travel close the midline, one along the dorsal and the 
other along the ventral surface of the optic chiasm. The ventral bundle tends to run 
close to the surface of the brain, being covered only by the pia (Merchanthaler et al,
1984). Axons of the GnRH neurons in the more caudal and lateral aspects of the 
preoptic area and hypothalamus travel in or near the medial forebrain bundle and 
then turn medially near the level of the ME. These axons also project to the limbic 
system and circumventricular organs other than the ME, such as the organum 
vasculosum of the lamina terminalis (OVLT).
In addition to their major projections to the ME, GnRH neurons also project to 
several extrahypothalamic stmctures such as the midbrain, the hippocampus, the 
amygdala and other olfactory structures (Silverman et al, 1994). Coordination 
between both populations of GnRH neurons is achieved by intercellulai’ 
communications through numerous collateral synaptic contacts between GnRH- 
producing neurons and putative GnRH receptors (Wetsel et al, 1992). Indeed, 
during the pre ovulatory LH surge, all GnRH neurons have been shown to 
synchronise to initiate synthesis of this neuropeptide (Silverman and Witkin, 
1994). This simultaneous firing of many, if not all, GnRH neurons is required for 
the pulsatile discharge of GnRH.
Hypothalamic GnRH binds to specific receptors on the adenohypophyseal 
gonadotroph and stimulates the synthesis and secretion of the gonadotrophins 
(Conne et al, 1982). This secretory activity occurs intermittently in apparent 
synchrony with, and in response to, the pulsatile discharge of GnRH from tire
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Figure 1.5. Schematic representation of the organisation of the neural circuitry 
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1984.
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hypothalamus. GnRH receptor numbers on the gonadotroph increase over two­
fold during dioestrus to reach a peak during the morning of pro-oestms. This is 
followed by a rapid fall during the late afternoon of pro-oestrus to reach a nadir by 
oestrus (Childs et al, 1994). Experimental data indicate that E2 increases pituitaiy 
responsiveness to the GnRH signal at the time of the pre-ovulatory LH surge. 
This is achieved by increasing GnRH receptor numbers, at least partially, by 
increasing the number of GnRH-receptive cells (Lloyd and Childs, 1988). In 
addition, the hypothalamic hormone itself may prime the gonadotrophs to increase 
their response to subsequent GnRH pulses (Mitchell et al, 1988).
Under the influence of gonadal steroids, a rapid increase in the hypothalamic 
GnRH content has been reported during the critical period on the afternoon of pro- 
oestms (Kalra, 1986). GnRH levels in portal blood have been measured and well- 
coiTelated to the LH surge in anaesthetised (Sarkar et al, 1976) and conscious rats 
(Levine and Ramirez, 1982). These experiments clearly demonstrate that GnRH 
release is elevated on the afternoon of pro-oestms and that this rise precedes the 
pre-ovulatory LH surge.
Existence of a "GnRH pulse generator" in the central nervous system has now been 
commonly accepted, since the pulsatile release of LH well corresponds with the 
episodic nature of GnRH (Clarke and Cummins, 1982; Kalra and Kalra, 1985; 
Leonhardt et al, 1991). The pulse generator appears to be contained within the 
hypothalamus (Karsch, 1990). This is in line with the recent evidence that 
multiunit activity of the GnRH neurons in the MBH increases in association with 
the LH surge (Kimura and Sano, 1995). Various neurotransmitter systems and 
the gonadal steroids, which convey information both from the external and internal 
environment, seem to be involved in modulating activity of the GnRH pulse 
generator. However, not much is yet known about how it operates.
As mentioned earlier, release of both FSH and LH is stimulated by the 
hypothalamic decapeptide, GnRH (Wise et al, 1979). Administration of antiserum 
to GnRH or sodium pentobarbitone abolish LH release, but have no effect upon 
FSH secretion (Culler and Negro-Vilar, 1987; Kovacs et al, 1993). In addition, 
their hormone profiles throughout the oestrous cycle are known to be dissociated. 
LH release seems to be completely dependent upon GnRH secretion, but GnRH is 
not the sole regulator of FSH release. It has been suggested by McCann and his 
colleagues that there may be a separate FSH-releasing hormone (FSH-RH) which
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is produced in the paraventricular nucleus, anterior hypothalamic area and 
surrounding the ARN and ME to selectively regulate FSH release. However, this 
suggestion is controversial. Although there is some evidence for its existence 
(Mizunuma cr a/, 1983; Lumpkin et al, 1984), the proposed FSH releaser has not 
yet been identified.
NEUROTRANSMITTER SYSTEMS MODULATING GnRH  
RELEASE
It has recently become evident that GnRH neurons contain neither E2  (Shivers et al, 
1983b) nor P (Fox et al, 1990) receptors, and therefore the influence of the gonadal 
steroids on GnRH release must be indirect. There is now a growing evidence that 
a complex network of neuronal systems, which elaborate messenger molecules, 
regulate the release of GnRH from the hypothalamus (see Figure 1.5.). These 
neurotransmitter systems are also believed to mediate the feedback effects of the 
steroid hormones on GnRH release. This new theory is contrary to the eailier 
belief that the GnRH neurons initiate their own release (Estes et al, 1982).
The neuromodulatoiy systems in the central regulation of GnRH and hence LH 
release may be classified as 1) monoaminergic neurotransmitters, 2 ) amino acid 
neurotransmitters and 3) neuropeptides. However, most recently a gaseous 
neurotransmitter nitric oxide (NO) has emerged as a possible regulator as well.
Synthesis, storage, release and deactivation of neurotransmitters
Neurotransmitters aie continually being synthesised, stored, released and 
deactivated. The amount of neurotransmitter stored in secretory vesicles can 
regulate its own rate of synthesis by a negative feedback loop. The concentration 
of transmitters recaptured by presynaptic reuptake mechanism also regulates 
formation of new neurotransmitters. This is accomplished by altering the levels of 
the enzymes necessary for their biosynthesis. Neural signals from other 
neurotransmitter systems can modulate each others synthesis as well.
Monoamines
In the first step of catecholamine synthesis, the amino acid, tyrosine, is converted 
to dopa in the nerve cell through the action of tyrosine hydroxylase (Figure 1.6.). 
Dopa is then converted to dopamine (DA) in the cell body by dopa decarboxylase,
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and DA is transported to the nerve terminals in vesicles. In a dopaminergic 
neuron, biosynthesis does not proceed further. However, at a noradrenergic nerve 
terminal, DA is converted to noradrenaline (NA) in the synaptic vesicles by the 
action of dopamine-beta-hydroxylase. At an adrenergic nerve terminal, NA is 
converted to adrenaline (ADR) by a specific enzyme, phenylethanol amine N- 
methyltransferase (PNMT).
Serotonin or 5-hydroxytryptamine (5-HT) is synthesised from tryptophan, which 
is converted to 5-hy droxy tryptophan (5-HTP) by the action of tryptophan 
hydroxylase. 5-HTP is then converted to 5-HT in the cytoplasm by tryptophan 
decarboxylase (see Figure 1.14.).
Acetylcholine (ACh) is derived from choline and acetyl coenzyme A through the 
action of choline acetyltransferase in the cholinergic nerve terminals (See Cooper et 
al, 1991).
Amino acid transmitters
Glutamate and aspartate are synthesised from glucose and other precursors in 
neurons and glial cells. G ABA is formed from its precursor, glutamic acid, by the 
enzyme glutamic acid decarboxylase in the nerve terminals (Figure I.7.).
Neuropeptides
Precursors for the neuropeptides are prepropeptides, which are synthesised in the 
endoplasmic reticulum of the cell body and packaged into secretory vesicles in the 
Golgi apparatus. Endogenous opioids, for example, are derived from three 
different precursors; proenkephalin, prodynorphin and proopiomelanocortin 
(POMC) (Akil et al, 1984). Synthesis of peptide neurotransmitters is completed in 
the synaptic vesicles, which are transported down to the nerve terminal for storage 
and release of the neuropeptides.
Release
Following postsynaptic stimulation by neurotransmitters, the neuron fires and 
releases its transmitters presynaptically into the next synaptic area. There, these 
neurotransmitters bind and stimulate their postsynaptic receptors. They cause ion 
channels to open and the nerve membrane is depolarised, i.e. sodium ions (Na+) 
flow in and potassium ions (K+) move out of the cell. This depolarisation causes 
a measurable change in the electrical activity of the cell, called an action potential
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which travels along the axon until the nerve terminal. When depolarisation of the 
nerve terminal occurs, the secretory vesicles fuse with the cell membrane, and 
under the influence of calcium ions (Ca+) release their transmitters into the synaptic 
area. After these pre- and postsynaptic events, the cell returns to its resting 
potential until stimulated by another neurotransmitter to fire again. The release of 
these messenger molecules involves a number of complex biochemical actions 
which are explained in detail elsewhere (Rang and Dale, 1991). A schematic 
diagram of neurotransmitter release is shown in Figure 1.8.
Deactivation
After the neurotransmitter has stimulated its postsynaptic receptor, it is deactivated 
by two degradation mechanisms. The first is reuptake (endocytosis) by receptors 
on the presynaptic cell which take the neurotransmitter into vesicles where it is 
reused or deactivated. Up to 80% of the monoamines released into synapse are 
degraded in this way. The amino acid neurotransmitters are also deactivated by 
presynaptic reuptake. ACh is rapidly broken down by acetylcholine esterase. 
The two degradation products, acetic acid and cholin may then be picked up by the 
presynaptic neuron and used to synthesise new transmitter molecules.
The second way of degradation is catabolism of the neurotransmitters by specific 
enzymes within the synapse. The monoamines are deactivated by two different 
enzymes, catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) 
(Figures 1.9. and 1.10.). Peptidergic transmitters are deactivated by peptidase 
enzymes (McKelvy, 1986).
1) Monoaminergic Neurotransmitters
Noradrenaline
Considerable amount of literature suggests that NA may be the major 
neurotransmitter in initiation of the LH pre-ovulatory surge which directly 
stimulates the GnRH neurons (See Ramirez et al, 1984; Barraclough, 1994). The 
neurotransmitter role of NA in mediating this process may be complicated due to its 
interactions with the other neurotransmitter systems and its diffuse pathways.
There are two major noradrenergic pathways within the central nervous system 
(CNS) which project to the hypothalamus. The cell bodies of the noradrenergic
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Figure 1 . 8 . The main processes involved in synthesis, storage and release of 
aminergic transmitters (including NA, DA, 5-HT and ACh): 1) Uptake of transmitter 
precursors by nerve terminals, 2) Synthesis of transmitter in nerve terminals, 3) 
Storage of transmitter in releasable form, 4) Degradation of surplus transmitter within 
nerve terminals, 5) Depolarisation of nerve terminal by propagated action potential, 6 ) 
Influx of Ca++ in response to depolarisation, 7) Release of transmitter in quantal 
packets, 8 ) Diffusion of transmitter to post-synaptic receptors, 9) Interaction with 
receptors and production of post-synaptic effect, 10) Inactivation of tiunsmitter within 
synaptic cleft. T: Transmitter or neurotransmitter. Adapted from Rang and Dale, 1991.
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neurons are found exclusively in the pons and medulla. The locus coeruleus (LC) 
appears to contain the most prominent cluster of NA neurons whose axons pass 
through the cerebral cortex, limbic system, the hypothalamus, the cerebellum and 
the spinal cord. The major projection of LC axons ascends in a dorsal 
noradrenergic bundle (DNAB) transversing the midbrain tegmentum which 
innervates the MPOA and ME of the hypothalamus, the cortex, the hippocampus 
and the cerebellum (Jones and Moore, 1977). At the caudal diencephalon the LC 
axons descend to enter the ventral noradrenergic bundle (VNAB) which provides a 
diffuse innervation of the hypothalamus including the MPOA, SCN, MB and 
ARN, and the hippocampus and the other parts of the forebrain (See Figure 1.11. 
for NA pathways).
NA nerve terminals and GnRH neurons aie found in close proximity in the MPOA 
and to a lesser extent in the ME and ARN (McNeill and Sladek, 1978). 
Furthermore, catecholamine neurons have been shown to innervate GnRH 
perikarya in the MPOA (Watanabe and Nakai, 1987; Leranth et al, 1988a) and 
other hypothalamic ai'eas (Chen et al, 1989). Thus, these neuroanatomical sites 
provide evidence for direct functional connections between the two systems.
Based on the relative affinities of adrenergic agonists and antagonists, adrenergic 
receptors are divided into two main classes; a - and p-adrenoreceptors. These aie 
further subdivided into a^- and a 2~ and |3p and P2" adrenoreceptors on the same 
criteria. All four adrenoreceptor types and subtypes have been visualised in the 
hypothalamus (Leibowitz et al, 1982). The a-adrenoreceptors have been found in 
highest concentrations in the MPOA, ME and ARN with p-adrenoreceptors 
(predominantly P2) being most common in the MPOA.
It has been recognised that blockade of NA adrenoreceptors or suppression of NA 
synthesis or release disrupts spontaneous pre-ovulatory LH surges while 
intracerebroventricular (icv) infusion of this neurotransmitter stimulates GnRH 
secretion in cyclic rats (Barraclough and Wise, 1982; Ramirez et at, 1984; Al- 
Hamood et al, 1985). During the E2-induced LH surge in ovx rats, increased NA 
turnover rate in the MPOA, SCN, ME and ARN occurs concomitant with a rise in 
circulating levels of LH (Wise etal, 1981). Conversely, suppression of increased 
NA turnover by administration of phénobarbital or lesion of the LC in the 
brainstem results in failure of the pre-ovulatory LH surge on pro-oestrus (Kalra 
and Simpkins, 1981; Ranee and Barraclough, 1981; Franci and Rodrigues, 1985).
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There is evidence for a relationship between the noradrenergic activity of the 
hypothalamus and the oestrous cycle of the rat. During the oestrous cycle, NA 
turnover follows a cyclic fluctuation that reaches its highest level during the 
afternoon of pro-oestrus. This is intimately correlated with GnRH and the pre­
ovulatory LH discharge (Ranee and Barraclough, 1981). A decrease in the 
hypothalamic activity of MAO during the afternoon of pro-oestms has also been 
reported (Honma and Wuttke, 1980).
Tyrosine hydroxylase (TH) is the rate-limiting enzyme for the synthesis of 
catecholamines (see Figure 1.6). One index of increased activity within the 
noradrenergic neurons is a rise in TH mRNA levels. Noradrenergic neiwe 
terminals in the vicinity of GnRH neurons are known to originate almost 
exclusively from the Al and A2 noradrenergic cell groups located in the brainstem. 
There is an increase in the TH activity of the NA neurons from the Al and A2 
region (Liaw et al, 1992) as well as of the NA terminals in the MPOA (Herbison et 
al, 1990) at the time of the afternoon LH surges. This increased TH activity is 
accompanied by a rise in hypothalamic NA release, c-fos is an immediate early 
gene (Sagar et al, 1988). Immunocytochemical detection of its protein product, 
Fos, has now been used extensively as a marker for neuronal activation (for review 
see Hoffman et al, 1993). Jeunes et al (1992) has shown a significant increase in 
the Fos immunoreactivity of the Al and A2 noradrenergic neurons on the afternoon 
of pro-oestms compared with that at dioestrus. These biochemical studies indicate 
that an increased neuronal activity within these cells occurs at a time when 
hypothalamic NA release and turnover rates increase and plasma LH levels begin to 
rise.
Inhibitory effects of NA on pulsatile LH release have also been reported. Infusion 
of NA directly into the MPOA (Leipheimer and Gallo, 1985) or into the third 
ventricle and electrical stimulation of the ascending noradrenergic tiacts (Bergen 
and Leung, 1987) or LC (Dotti and Taleisnik, 1984) inhibit LH secretion. This 
inhibition is predominantly through a reduction in LH pulse frequency. It should 
be noted that the rat models employed in these studies were mainly ovx and not 
steroid-primed. However, ventricular administration of NA, p- (isoproterenol) or 
a-adrenoreceptor agonists (phenylephrine and methoxamine) have been found to 
be effective in disrupting the P-induced GnRH release in ovx rats (Bergen and 
Leung, 1988). It thus appears that NA exerts a dual action on GnRH release
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Figure 1 .11. Schematic illustration of a saggital section through the rat brain 
showing the noradrenergic projections to the hypothalamus. The main groups of 
perikarya and fibre tracts are shown in black. Grey areas represent the location of axon 
terminals. Adapted from Rang and Dale, 1991.
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Figure 1.12.  Schematic illustration of a saggital section through the rat brain 
showing the dopaminergic projections to the hypothalamus. The main groups of 
perikarya and fibre tracts are shown in black. Grey areas represent the kxration of axon 
terminals. Adapted from Rang and Dale, 1991.
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depending upon the steroidal milieu so that NA is stimulatory in the presence of E2 
but inhibitory in its absence (Ramirez et al, 1984; Dyer et al, 1985).
These stimulatory effects of NA are mediated by a-adrenoreceptors (Gallo and 
Kalra, 1983) particularly by a^-receptor subtypes in the anterior hypothalamic- 
preoptic area and MBH (Ramirez et al, 1984). NA acting via |3-adrenoreceptors 
modulates the transmission of inhibitory impulses originating in the LC (Dotti and 
Taleisnik, 1984), on LH release in ovx E2-primed rats. The p2-adrenergic
receptor sites may become de-activated on the late afternoon of pro-oestrus, since 
only the stimulation of P2"adrenoreceptors in the afternoon with a high dose of 
fenoterol (a selective p2~r®ceptor agonist) is effective in inducing ovulation along 
with the well-documented a-adrenergic stimulatory components (Al-Hamood et al, 
1985); this could mask the possible inhibitory action of the p^-adrenergic system.
Moreover, it has also been shown that electrical stimulation of the LC or of the 
medullary Al noradrenergic cell group in E2-primed ovx animals markedly
amplifies the surge release of LH in the MPOA, and this amplifying action can be 
blocked by a - (predominantly a^-) but not p-adrenoreceptor antagonists (Gitler 
and Barraclough, 1988). On the other hand, a-adrenergic mechanisms have been 
implicated the inhibitory action of NA on pulsatile GnRH release (Bergen and 
Leung, 1988).
a-adrenoreceptors have been visualised on GnRH neurons in the MPOA and ME. 
These neurons show high affinity for NA (Al-Damluji et al, 1993). It may thus 
indicate that NA released within brain regions could directly affect GnRH neuronal 
activity. Moreover, NA can stimulate GnRH release from ME fragments in vitro 
(Negro-Vilar er a/, 1980).
In addition to direct modulatory effects of NA on GnRH neurons in inducing LH 
secretion, and thereby ovulation, indirect effects of NA have also been reported via 
putative interneurons interposed between NA and GnRH neurons (Jeunes et al, 
1982; Barraclough, 1994). Noradrenergic terminals within the hypothalamus 
possess a mixed population of opioid receptors. There is a variety of evidence 
indicating that the EOPs can modulate the activity of NA neurons acting at pre­
synaptic nerve terminals (Van Vugt et al, 1982; Bicknell, 1985). Ovarian steroids 
may reactivate NA neurons by removing the tonic inhibitory effect of the opioid 
peptides (Crowley, 1988). The modulatory effects of opioids on GnRH and LH 
release will be reviewed later in this chapter.
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A good candidate for neurons which could alter the responsiveness of GnRH 
neurons aie GAB A interneurons. GnRH cells receive GABAergic innervation 
(Leranth et al, 1988b) and GAB A receptor agonists suppress LH surges in steroid- 
primed ovx rat (Adler and Crowley, 1986). A pre-synaptic modulatoiy role of 
G ABA on the NA nerve terminals has been shown (Demling et al, 1985). Perhaps 
this inhibitory transmitter may affect the activity of the GnRH neurons both via its 
direct synaptic connections and indirectly by modulating the presynaptic release of 
NA. It could also modulate GnRH neuronal responsiveness to NA (Barraclough, 
1994). Conversely, NA can influence GAB A release in the hypothalamus whose 
excitatory action is mediated by a-adrenoreceptors (Herbison et al, 1990) and 
particularly a^-subtypes (Kim etal, 1991). Thus, these indirect effects provide a 
simple explanation for the inhibitory action of NA on both basal and surge release 
of LH (Adler and Crowley, 1986) depending upon the steroid environment 
(Herbison er fl/, 1989).
A serotonergic involvement has also been suggested to affect NA concentrations, at 
least in the DNAB. This belief is based on the inhibitory effect of electiical 
stimulation of the DNAB on steroid-induced LH secretion. Indeed, in the 
midbrain, NA neurons have been found close to serotonergic neurons (Morello and 
Taleisnik, 1985).
Gonadal steroids aie known to influence catecholamine transmission in the brain 
(Barraclough and Wise, 1982). The catecholaminergic neurons have been shown 
to possess Ei receptors (Sar, 1984; Lehman and Karsch, 1993). The steroid 
hormones may thus exert their feedback effects on the GnRH neurons through the 
brain noradrenergic system. It is believed that the role of NA in the operation of 
the GnRH surge generator is dependent on priming effects of Ej or Eg plus P . 
These hormones may determine whether the noradrenergic input is excitatory or 
inhibitoiy on the LH surge (Ramirez et al, 1984). All these findings provide 
further evidence for the cmcial role of the ovarian steroids, particulaily Ej, in the 
mediation of GnRH release. They not only elevate the releasable pool size of 
GnRH in the ME, but they are also essential for the increased release of NA during 
the early afternoon of pro-oestrus.
In view of all these reports, there can be little doubt of the influence of NA on 
GnRH secretion. It is generally believed that NA is an essential component of the
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GnRH pulse generator and may be the triggering neural stimulus for the pre­
ovulatory LH surge.
Dopamine
There is a large body of evidence implicating central dopaminergic mechanisms in 
the neuroendocrine regulation of GnRH release and the LH surge (Ramirez et al, 
1984; McKenzie etal, 1988).
There have been conflicting reports on the modulatory role of the dopaminergic 
system on GnRH release suggesting both stimulatory (McKenzie et al, 1988; 
Sanghera et al, 1991a) and inhibitoiy (Tasaka et al, 1985; Kerdelhue et al, 1989) 
actions of DA in rats (For review see Ramirez et al, 1984). Dopaminergic 
neurons exert an important stimulatoiy effect on the pulsatile release of LH, since 
administration of DA antagonists such as pimozide or haloperidol, reduces the LH 
surge and ovulation when given to pro-oestrous rats (MacKenzie et al, 1988), 
Infusion of DA or dopaminergic receptor agonists into the zona incerta (ZI) elevates 
plasma LH levels and advances the LH surge in the intact or ovx and steroid- 
primed rats (McKenzie et al, 1984; James et al, 1987). Lesions of the medial ZI 
have disrupted the LH surge (Sanghera et al, 1991a). Moreover, there is a temporal 
relationship between the onset of LH pulses and increases in DA concentrations in 
the ME of ovx rats (Negro-Vilar et al, 1982). However, infusion of DA receptor 
agonists such as apomoiphine into the third ventricle has also been reported to 
cause a marked inhibition of the episodic LH release (Drouva and Gallo, 1977).
These dual effects of DA on GnRH release could be due, at least in part, to a 
complex network of dopaminergic neurons in the hypothalamus where DA may 
have both direct and indirect actions. Four distinct groups of DA-containing cell 
bodies, which were originally designated as A ll through A14 (Bjorklund et al, 
1975), appear to innervate the hypothalamus (See Figure 1.12. for DA pathways). 
Neurons of the tuberoinfundibular dopaminergic tract (TIDA or A 12) originate in 
the ARN and PeVN and project to both the external and the internal layers of the 
ME (Lindvall and Bjorklund, 1982), where they are found to be in close apposition 
to the GnRH terminals (Jeunes et al, 1983). The TIDA appeal's to exert an 
inhibitory effect upon GnRH release (Rose and Weick, 1986). Furthermore, DA 
turnover rates were found to be significantly lower in the ME compared to the other 
stages of the oestrous cycle (Ranee and Banaclough, 1981). Indeed, a decrease in
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the TIDA dopaminergic activity has been associated with the pre-ovulatory LH 
surge (Hiemke et al, 1985).
The incertohypothalamic dopaminergic tract consists of cell bodies in the thalamus 
(A ll) which run to the ZI, where another dopaminergic cell group (A13) projects 
terminals to the PVN and anterior hypothalamus. A third group of 
incertohypothalamic dopaminergic cells in the PeVN (A14) sends terminals to the 
preoptic area (Bjorklund et al, 1975; Chan-Palay, 1984). Synaptic contacts 
between dopaminergic and GnRH neurons in the MPOA have been demonstrated 
(Leranth et al, 1988a). Several studies have suggested that DA may have 
stimulatory effects in the control of LH secretion in these brain areas (Kawakami et 
al, 1975; MacKenzie etal, 1988).
Receptors for DA have been characterised and divided into two main subtypes, 
DAj and DAg, based on their ability to stimulate adenylate cyclase activity 
(Dumbrille-Ross etal, 1985). ADAg receptor subtype has also been identified in 
the midbrain; however, its function in controlling GnRH release is unknown. 
Dopaminergic receptors have been visualised in the hypothalamus (Leibowitz et al, 
1982). The ME and ARN appear' to contain a moderate density of these receptors, 
while the SCN and MPOA are sparsely populated. It has been found that DAj 
receptors stimulate (Stoof and Kebabian, 1984) whereas DA2 receptors inhibit
(Onali et al, 1985) adenylate cyclase activity. Indeed, the stimulatory effect of DA 
on GnRH release in the ZI has been observed to be exerted via DA| but not DA2
post-synaptic receptors (James et al, 1987). More recent evidence has emerged to 
favour this view that DA directly stimulates GnRH release via DAi receptors in 
vitro (Escalara et al, 1992). Hence, the nature of the receptor subtype involved 
may be another factor to explain the diverse actions of DA in the central control of 
LH release.
TH-containing immunoreactive cells are known to concentrate P (Fox et al, 1990) 
and E2 (Sar, 1984) receptors in the hypothalamus, while neither E2 (Shivers et al,
1983b) nor P (Fox et al, 1990) are found on the GnRH-immunoreactive neurons in 
the rat brain. E2 and P can affect the quantity and enzymatic activity of TH in 
neurons of the ME (Wang and Porter, 1986). Furthermore, E2+P treatment has a
positive feedback effect on the TH neurons (Sanghera et al, 1991b), and the DA- 
producing neurons of the TIDA region are found to be targets for E2 and P (Morrell
et al, 1989). Thus, it appears that raising DA activity in the hypothalamus can
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either stimulate or inhibit LH secretion depending on the endocrine state of animal. 
In the presence of steroids DA is excitatory (Vijayan, 1985) whilst being inhibitory 
in their absence (Sarkar and Fink, 1981) on GnRH release. However, opposite 
findings have also been reported. E2 treatment may elevate the contents and
turnover rates of DA in the hypothalamus, which in turn inhibits pulsatile GnRH 
release (Tadokoro et al, 1986).
There are also reports of interactions between the dopaminergic system and other 
modulatory systems in the control of LH release, p-endorphin axon terminals 
have been visualised to make contact with DA cell bodies and dendrites throughout 
the hypothalamus and lateral part of the ZI, suggesting that the dopaminergic 
system may mediate, at least in part, the inhibitory effects of opioids on 
gonadotrophin secretion (Horwarth et al, 1992a). Increased opioid peptidergic 
activity before the critical period of pro-oestrus is concomitant with enhanced 
hypothalamic DA release (Leadem and Kalra, 1985) that suppresses the pre­
ovulatory LH surge and ovulation (Kalra and Kalra, 1985). Conversely, 
morphine, a p-opioid receptor agonist, has been found to stimulate DA turnover in 
the hypothalamus (Gopalan et al, 1989a). Furthermore, activity of the TIDA 
dopaminergic neurons is increased following the activation of 6 -opioid receptors 
(Manzanares et al, 1993). However, there are opposite findings in the literature as 
well indicating that activation of both p- and K-opioid receptors inhibits DA release 
from the MBH slices and p-endorphin decreases the turnover rate of hypothalamic 
DA in the TIDA tract (Wilkes and Yen, 1980; van Loon et al, 1980; Heijna et al, 
1991). DA neurons have also been shown to impinge on GABAergic neurons 
(Leranth etal, 1988b) which may operate as interneurons in the control of GnRH 
secretion. These reports thus provide evidence for an indirect action of DA in LH 
release.
Dopaminergic activity in the hypothalamus varies during the oestrous cycle 
(Honma and Wuttke, 1980; Osterberg et al, 1987). DA may be stimulatory in the 
MPOA and SCN (Kawakami et al, 1975) and the ZI (MacKenzie et al, 1988) but 
inhibitory in the ARN and ME (He et al, 1994) to GnRH release. It would appear 
that both a decrease in inhibitoiy dopaminergic activity and an increase in its 
stimulatory activity contribute to the stimulation of the LH release. However, the 
central dopaminergic transmission is probably not the crucial neural signal in 
initiation of the pre-ovulatory LH surge under physiological conditions.
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Serotonin
The hypothalamus is extensively innervated by serotonergic projections from the 
midbrain raphe nuclei (Steinbusch, 1984). Serotonergic fibres have been 
visualised in the MPOA, MBH, SON, PVN, and all layers of the ME (Sawchenko 
et al, 1983; Steinbusch, 1984). Their anatomical distribution overlaps with GnRH 
perikarya and processes in the MPOA, MBH, OVLT and septo-preoptic region 
(Jennes et al, 1982; Kiss and Halasz, 1985). This spatial correlation between 
5-HT and GnRH fibres also exists in the ME (See Figures 1.13. and 1.14. for 
serotonergic pathways and biosynthesis, respectively).
Serotonergic receptors are divided into two major classes; 5-HT^ and 5 -HT2 . 
Additional receptor subtypes for 5-HT and further subdivisions have been 
documented based on binding affinity of selective agonists and antagonists (Frazer 
et al, 1990). Populations of 5-HT receptors have been demonstrated in the 
MPOA, ARN and ME in addition to several other hypothalamic areas (Biegon et al, 
1982; Yillar et al, 1984).
Both a stimulatory and inhibitory role for 5-HT in the regulation of GnRH and LH 
release have been reported (For review see Vitale and Chiocchio, 1993; Kordon et 
al, 1994). lev infusion of 5-HT into female rats inhibits GnRH release (Schneider 
and McCann, 1970). Activation of the medial raphe nucleus (MRN) blocks the 
LH surge and ovulation (Morello and Taleisnik, 1985). On the other hand, there 
is a bulk of evidence suggesting that 5-HT is excitatory to GnRH release (Walker, 
1983; James et al, 1989; Dow et al, 1994). Administration of a 5-HT agonist 
(quipazine) stimulates LH secretion. Accordingly, depletion of hypothalamic 
5-HT content or impainnent of the serotonergic transmission abolishes the LH 
surge (Walker, 1980). In vitro, 5-HT stimulates GnRH release from the ME 
fragments (Vitale et al, 1986). The hypothalamic serotonergic content fluctuates 
during the oestrous cycle (Honma and Wuttke, 1980) and an increase in its activity 
occurs in association with the pre-ovulatory LH surge on pro-oestrus (Vitale et al, 
1987; Kerdelhue etal, 1989). Furthermore, 5-HT binding sites increase in the 
hypothalamus on the day of pro-oestrus; the increases appear to be modulated by 
E2  (Williams and Uphouse, 1989).
This dual effect of the serotonergic system on the release of GnRH could 
correspond to different distribution and action of the two raphe nuclei. The dorsal
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raphe nucleus (DRN) sends terminals to the PeVN, ARN and ME, whereas fibres 
from the MRN teiminate in the MPOA and lateral hypothalamic area. Injection of 
a 5-HT agonist into tlie MRN blocks the LH surge and lesions of the DRN in the 
rat result in a decreased pro-oestrous LH surge and blockade of ovulation (Morello 
and Taleisnik, 1985; Morello et al, 1992). These experimental data thus suggest 
that DRN-ME 5-HT projections may exert a facilitatory influence while MRN is 
inhibitory to the LH surge.
Administration of steroids can alter 5-HT synthesis, turnover and release (Johnson 
and Crowley, 1986). This may provide explanation for the different effects of 
5-HT in the regulation of LH release. Steroid treatment increases 5-HT synthesis 
in the MPOA (King et al, 1986). In ovx rats, 5-HT has a negative influence on 
LH release, which is converted to a stimulatoiy effect by pre-treatment of the 
animals with Eg. Electrical stimulation of the DRN in ovx rats inhibits LH release, 
however, the same stimulus elevates plasma LH levels in the presence of Eg (Kitts 
and Johnson, 1986). In vitro, P enhancement of the Eg-induced LH surge in ovx 
rats can be blocked by 5-HT antagonists indicating that their excitatory action on 
the GnRH neurons is expressed by 5-HT (King and Kang, 1988). Thus, it would 
appear that 5-HT facilitates the LH surge in the presence of the gonadal steroids.
Another important aspect of steroid modulated-serotonergic neurotransmission is 
the density of brain 5-HT receptors. The positive feedback effect of the ovaiian 
steroids on the serotonergic system appears to involve 5-HTg, not 5-HTi receptors
(Johnson and Kitts, 1991). Stimulatoiy actions of 5-HT on GnRH release have 
been attributed to the activation of 5-HTg receptor subtypes (Lenahan et al, 1987;
Tanaka et al, 1993; Dow et al, 1994). Hormone-induced alterations of 5-HT 
binding sites may be one of the factors that modulate the final effect of 5-HT on the 
LH secretory mechanism.
5-HT metabolism may also influence other neurotransmitter systems which aie 
known to participate in the neuroendocrine regulation of LH secretion. 
Serotonergic innervation of the TIDA dopaminergic neurons in the ZI and ARN has 
been reported (Bosler et al, 1984; Willoughby and Blessing, 1987). The 
serotonergic mediation of LH secretion may depend, at least partly, upon 
noradrenergic transmission (Gopalan et al, 1989b). Effects of opioid peptidergic 
system on the pre-ovulatory LH surge may also involve an interaction with the 
serotonergic system (Gopalan et al, 1989b). Recent evidence has suggested that in
36
cortex hippocampus
caudate nucleus
thalamus
medial forebrain bundle
cerebellum
hypothalamus
rostral 
serotonin nuclei
caudal 
serotonin nuclei
projection 
to spinal cord
Figure 1 .13. Schematic illustration of a saggilal section through the rat brain 
showing the serotonergic projections to the hypothalamus. The main groups of 5-HT 
cell bodies and fibre tracts me shown in black. Grey areas represent the kxtation ol' 
axon terminals. Adapted from Rang and Dale, 1991.
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the DRN, EOPs may pre-synaptically inhibit 5-HT release (Pinnock, 1992). 
Inhibitory effects of 5-HT on LH release have been reported to be mediated by 
GABAergic neurons (Morello et al, 1989). It thus appears that effects of 5-HT 
may be either direct or indirect on GnRH release.
The existence of anatomically separate excitatory and inhibitoiy serotonergic 
systems (Morello etal, 1992), temporal factors (Walker 1983), steroid hoimone 
milieu (Johnson and Crowley, 1986) and interactions with other modulatory 
systems may all contribute to deteiiuining the direction of 5-HT influence on LH 
release.
Adrenaline
Involvement of ADR as a neurotransmitter in the central regulation of LH release 
has been proposed. lev administration of exogenous ADR stimulates GnRH and 
LH release (Swartz and Moberg, 1986). Inhibitors of PNMT have been shown to 
suppress the pre-ovulatory or the steroid-induced LH surge in ovx and pro- 
oestrous rats (Crowley and Terry, 1981; Coen and Gallo, 1986). Moreover, a 
decrease in the hypothalamic ADR content was observed concomitantly with the 
abolition of the LH surge in the same animals. An increase in the hypothalamic 
ADR turnover on the afternoon of pro-oestrus has been reported (Coen et al,
1985). ADR has also been described as the most potent catecholamine in 
stimulating the LH release (Rubinstein and Sawyer, 1970). Thus, these findings 
would indicate an essential excitatory neurotransmitter role for ADR in the central 
control of LH release (Kalra and Kalra, 1985).
The presence of adrenergic nerve terminals in the hypothalamus has been 
demonstrated (Hokfelt et al, 1977). These projections are of extrahypothalamic 
origin and arise from adrenergic cell bodies in the brainstem. Reportedly, the 
hypothalamus contains the highest content of ADR in the brain (Hokfelt et al, 
1984). However, the existence of ADR as a classical neurotransmitter in the rat 
brain has been questioned. It has been claimed that nerve terminals containing all 
the enzymes required for ADR biosynthesis aie not necessarily adrenergic (Sved, 
1989). ADR may be synthesised by other cells in the hypothalamus and then 
taken up into catecholamine nerve terminals. Indeed, there is evidence to favour 
the view that this catecholamine may be a co-neurotransmitter with NA in the 
noradrenergic nerve tenuinals or a postsynaptic metabolite of NA catabolism
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(Mefford, 1987). Therefore, the effects of adrenergic agonists and antagonists on 
GnRH release could be a result of activating the adrenoreceptors on the 
noradrenergic system or by altering the NA metabolism itself.
Histamine
Histamine (HA) has been suggested as a neurotransmitter in the mammalian CNS 
(Schwartz et al, 1991). The brain histaminergic system has been implicated in the 
neuroendocrine regulation of LH secretion (Knigge and Warberg, 1991). The 
modulatoiy actions of HA are mediated through phannacologically well- 
characterised Hi and H2 receptors and H3 autoreceptors.
HA is found in high concentrations in the hypothalamus with the highest levels 
observed in tire preoptic region, SCN, ME and ARN. HA-containing nerve 
terminals have also been visualised in close proximity to GnRH-producing cells or 
nerve teiininals (Panula et al, 1989). Increases in plasma LH levels have been 
reported following icv administration of HA to ovx, steroid-primed (Libertun and 
McCann, 1976) and pro-oestrous rats (Donoso, 1978). HA stimulates GnRH 
release from the steroid-treated rat MBH in vitro (Jorgenson et al, 1989). 
Furthermore, the histaminergic system is involved in elevation of LH release in 
response to ovarian steroids (Moguilevsky et al, 1989). Conversely, E2 activates 
the release of both HA and NA, which results in the amplification of GnRH 
secretion. However, the HA action appears to be independent from that of NA 
(Ohtsuka et al, 1989). The pharmacological evidence outlined above seems to 
indicate that HA may have a facilitatory role in the induction of LH release. 
However, the modulatory role of HA in the physiological regulation of the LH 
surge is still unclear and awaits further investigations for a convincing argument to 
be made.
Acetylcholine
ACh receptors are divided into two main classes; muscarinic and nicotinic. The 
population of ACh muscarinic receptors fluctuates in the MPOA throughout the 
oestrous cycle, being highest at pro-oestrus when sexual behaviour normally 
occurs, and rats mate (Olsen et al, 1988). Administration of a cholinergic 
muscarine agonist, bethanechol, increases the apparent number of E2 binding sites 
in a dose-dependent manner in the whole hypothalamus of the female rat, but not in
39
the male (Lauber and Whalen, 1988). Furthermore, in an in vitro study P has 
been found to inhibit hypothalamic and pituitary muscarinic receptors, but 
oestrogenic compounds do not (Klangkalya and Chan, 1988). Thus, the 
muscarinic receptors may be involved in the induction of receptors in the 
hypothalamus.
The existence of ACh nicotinic receptors in the brain has been shown. Exposure 
of dioestrous rats to acute intermittent nicotine results in a dose- and time- 
dependent lowering of plasma LH levels (Anderson et al, 1988). However, very 
little is known about the neuroendocrine function of the nicotinic receptors.
The hypothalamus receives cholinergic projections from cell bodies located in the 
other brain areas (Hokfelt et al, 1977; Hokfelt et al, 1984). An important 
mechanism of cholinergic system in regulating GnRH secretion has been 
suggested. Administration of atropine (a muscarinic receptor antagonist) blocks 
GnRH-induced LH release (Casanueva et al, 1986). However, a modulatory 
function of ACh on the GnRH system has not yet been established. Sexual 
behaviour in female rats is influenced by an E2-mediated cholinergic mechanism in 
which the MPOA and VMH appear' to be involved in ACh regulation of lordosis 
(Dohanich and Clemens, 1981). Thus although ACh may be an important 
neurotransmitter in control of oestrous behaviour, but it may have little or no 
involvement in the central control of the pre-ovulatory LH surge.
2) Amino acid neurotransmitters
y-Aminobiityric Acid
G ABA has been known to act on the CNS to influence GnRH/LH release (Kordon 
etal, 1994).
GAB A and the rate-limiting enzyme for its synthesis, glutamate decarboxylase 
(GAD), are found in high concentrations in the hypothalamus (Vincent et al, 1982). 
GABAergic neurons are extensively distributed throughout the hypothalamo- 
pituitaiy system (Sakaue et al, 1988). A dense plexus of GAD-containing nerve 
teiminals in the external layer of the ME has been shown (Vincent et al, 1982). 
Direct connections have been visualised in the MPOA between GABA- 
immunoreactive axons and GnRH-containing neurons (Leranth et al, 1988b).
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Furthermore, the hypothalamic GABAergic neurons have been found to contain E2 
receptors (Flugge et al, 1986). The rich GABAergic innervation of tlie 
hypothalamus is consistent with the belief that GABA may be involved in the 
neural circuitry which controls LH secretion.
Receptors for GABA are divided into two subtypes; GABA^ and GABAb 
receptors, which mediate both pre- and post-synaptic actions of GABA in the CNS 
(Akema and Kimura, 1993).
Central GABAergic neurotransmission exerts an inhibitory influence on the GnRH 
neurons which in turn results in the suppression of LH release (Kordon et al, 
1994). Phannacologically-induced increase of endogenous GABA levels in the 
hypothalamus inhibits LH release in ovx rats (Donoso, 1988). Infusion of either 
GABA or the GABAa receptor agonist, muscimol, in regions containing GnRH 
neurons suppresses the pulsatile release of LH in ovx rats (Fuchs et al, 1984; 
Herbison and Dyer, 1991). Similarly, muscimol and the GABAb agonist, 
baclofen, have been shown to block the surge release of LH in ovx and steroid- 
primed rats (Donoso, 1988; Adler and Crowley, 1986). Activation of GABAa but 
not GABAb receptors has been seen to cause a rapid decrease in GnRH gene 
expression in the preoptic and anterior hypothalamic area concomitant with the 
inhibition of LH secretion (Leonhardt et al, 1995). Furthermore, release rates of 
GABA in the preoptic-anterior hypothalamic area are markedly reduced prior to the 
E2-induced LH surge in ovx rats (Jaixy et al, 1988). Thus, this spontaneous 
decrease in hypothalamic GABAergic activity may transiently relieve tire GnRH 
neurons from a strong inhibitory action of GABA and may lead to pulsatile release 
of GnRH. Indeed, decreased GABA activity in the MPOA, MBH and LC have 
been found to precede an E2-induced LH surge in ovx rats (Seltzer and Donoso, 
1992).
In addition to tire direct effects of GABA on GnRH release, central GABAergic 
neurons may interact with the other neuromodulator systems. Stimulation of Al 
noradrenergic input projecting to the MPOA results in GABA release in ovx rats 
when E2 levels are relatively low, but not when they are high (Herbison et al,
1989). E2 has a determining role on this interaction via E2 receptors on the GABA 
neurons (Flugge et al, 1986). Thus, it appears that GABAergic neurons in the 
MPOA may function as inhibitory interneurons between noradrenergic terminals 
and GnRH neurons. Furthermore, expression of the triggering neural signal of
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NA for the pre-ovulatory LH discharge has been attributed to a reduction in tlie 
hypothalamic GABAergic activity (Jairy et al, 1991). GABAergic modulation of 
the noradrenergic system has also been shown (Diez-Guerra et al, 1987; Horwarth 
et al, 1992b). Activation of GABA neurons with muscimol and baclofen causes a 
fall in NA turnover in the MPOA and MBH in association with a sustained decrease 
in serum LH levels (Fuchs et al, 1984; Demling et al, 1985; Adler and Crowley, 
1986). Microinjection of the GABA transaminase inhibitor into the LC and MPOA 
decreases plasma LH levels, suggesting that GABA may affect the noradrenergic 
function in discrete brain areas (Donoso, 1988). Furthermore, GABA may 
modulate GnRH neuronal responsiveness to NA and its withdrawal at the time of 
the LH surge would allow a greater pre-synaptic release of NA (Barraclough, 
1994).
An interaction between GABA and DA systems in the hypothalamus has also been 
reported. In the ZI, GABA suppresses the stimulatory action of the 
incertohypothalamic DA tract upon GnRH neurons, which in turn inhibits LH 
secretion (Wilson et al, 1990). Icv infusion of muscimol decreases the DA 
turnover in the MPOA, MBH and anterior hypothalamic ai'ea (Fuchs et al, 1984). 
Surprisingly, a stimulatory neurotransmitter role has been attributed to GABA on 
GnRH release both in vivo (Kalra and Kalra, 1985; Masotto and Negro-Vilar,
1986) and in vitro (Hales et al, 1994). GABA may have a stimulatory effect on 
GnRH release in the ARN and ME (Masotto and Negro-Vilar, 1986). This is 
believed to be a consequence of its negative modulatory action on the activity of the 
inhibitoiy dopaminergic system in these hypothalamic regions (Nikolarakis et al, 
1988). Furthermore, GABAergic inhibition of the p-endoiphin neurons in the 
MPOA may contribute to its stimulatory action by eliminating the opioidergic 
suppression of GnRH release (Horwath et al, 1992b). Interactions between 
GABA action and the serotonergic system has also been reported to influence LH 
release (Morello et al, 1989).
These inhibitory effects of GABA on the steroid-induced LH surge aie exerted via 
GABAa and GABAb receptors (Wilson et al, 1990; Akema and Kimura, 1993). 
GABAb receptors aie further implicated in the neural suppression of the 
responsiveness of the GnRH system to NA (Hartman et al, 1990). On the other 
hand, stimulatoiy GABA action, if any, is mediated only by GAB A A receptor types 
(Nikolarakis ef a/, 1988).
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In summary, GABA is generally believed to be an inhibitory neurotransmitter in the 
CNS acting either directly or indirectly on GnRH neurons.
Excitatory Amino Acids
Recently, excitatory amino acid (EAA) neurotransmission has been suggested as an 
essential component of the neuroendocrine regulation of the LH release from the 
anterior pituitaiy (Bourguignon et al, 1989; Brann and Mahesh, 1994). The 
mediation of EAAs neurotransmission in the CNS is achieved primarily by 
glutamate and aspartate. However, cysteic and quinolinic acid may also function 
as excitatory neurotransmitters. Glutamate, aspartate and cysteic acid have been 
shown to increase LH secretion following icv or systemic administiation (Ondo et 
al, 1976; Scheibel et al, 1980), respectively. Quinolinic acid has also been 
suggested to stimulate LH release through a 5-HT-dependent mechanism (Johnson 
and Crowley, 1986). The postulated stimulatory role of the EAAs on LH release 
has recently been reinforced by in vitro studies (Brann and Mahesh, 1991).
The site of action of the EAAs in regulating gonadotropin secretion resides at a 
suprapituitary level (Arslan et al, 1988). Immunocytochemical studies have 
revealed the presence of the EAAs, such as glutamate and aspartate, in large 
concentrations in several hypothalamic nuclei, including the MPOA, ME, ARN and 
SCN (van den Pol et al, 1990). Furtheimore, glutamate-immunoreactive terminals 
have been shown to form synapses with GnRH neurons in the lamina terminaJis 
and the ARN.
Receptors for EAAs are classified in two major classes; NMDA and non-NMDA 
receptors (Brann and Mahesh, 1991), and the latter is further subdivided into 
kainate and quisqualate receptors (Watkins and Olverman, 1987). These receptors 
types have been identified in various hypothalamic regions (Cotman et al, 1987).
Infusion of a specific agonist, NMDA into the MPOA stimulates LH release (Ondo 
etal, 1988; Pohl et al, 1989). Accordingly, NMDA receptor antagonists prevent 
the steroid-induced LH surge in ovx rats (Urbanski and Ojeda, 1990). In addition 
to the NMDA, kainate receptor agonists have also been demonstrated to enhance 
the release of LH in steroid-treated ovx rats (Brann and Mahesh, 1991). NMDA, 
kainate and glutamate have also been reported to elicit GnRH release from 
hypothalamic fragments incubated in vitro (Bourguignon et al, 1989; Lopez et al,
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1992). This stimulation of GnRH secretion is enhanced by the E^+P pre-treatment 
of ovx rats (Carbone et al, 1992) which indicates that ovarian steroids potentiate the 
GnRH response to NMDA. Indeed, the stimulatory influence of the EAAs on 
both GnRH and LH release appear to be dependent on the steroid milieu, since 
NMDA inhibited the LH release in ovx animals while it potently enhanced the LH 
secretion in pro-oestrous rats (Brann and Mahesh, 1991).
The major site of NMDA action on GnRH release appears to be the MPOA where 
the GnRH cell bodies reside whereas glutamate and kainate act primarily at the 
ARN-ME which are tlie sites of the GnRH nerve terminals (Brann and Mahesh,
1994). Interestingly, NMDA has been found to facilitate sexual receptivity 
through stimulating GnRH release (Hsu et al, 1993).
In addition to the direct effects of the EAAs, there may be interactions with the 
other neuromodulator systems as well. The EAAs act upon the noradrenergic 
neurons in the brainstem to influence hypothalamic GnRH release (Blandina et al, 
1992). Conversely, noradrenergic modulation of the amino acid neurotransmission 
in GnRH and LH release has also been shown (Barraclough and Wise, 1982). 
Recent work by Rettori et al (1993) has suggested that NO is an important mediator 
of glutamate stimulation in GnRH release in vitro.
Although EAAs neurotransmission in the CNS has been suggested as an important 
stimulatoiy component in the regulation of GnRH release and the pre-ovulatory LH 
surge, their involvement in this mechanism has not yet been fully assessed.
3) Neuropeptides 
Endogenous Opioid Peptides
A large number of studies have indicated a neuromodulator role for opioid 
peptidergic mechanisms in the central control of gonadotrophin release.
The opium alkaloid, moiphine, was first isolated from the poppy, Papaver 
somnifermn, by Serturner in 1803 and has long been known to have widespread 
effects on many physiological systems (Bernard, 1864). There had long been 
convincing evidence that the administration of morphine during the critical period 
on the day of pro-oestrus could block the pre-ovulatory LH surge and ovulation in
44
rats (Baixaclough and Sawyer, 1955). However, it was not until 1971 that a 
stereospecific binding site for moiphine in the brain was identified (Goldstein et al, 
1971). Two years later opioid receptors in the CNS were discovered (Pert and 
Snyder, 1973). The existence of an endogenous substance in the brain, acting as 
an agonist at opioid receptor sites, was then described (Hughes et al, 1975). The 
isolation and characterisation of the first EOPs, the leu- and met-enkephalins was 
reported by Hughes et al (1975). EOPs have since been extensively studied. 
Three major classes of EOPs have now been defined; the endorphins, enkephalins 
and dynoiphin/neo-endorphins. These opioid peptides are derived from three 
different precursors; POMC, pro-enkephalin A and pro-enkephalin B or pro- 
dynorphin, respectively (Hollt, 1983). The major opioid product of POMC 
processing is p-endorphin. Several other less common EOPs have been identified 
in the brain (for review see Palkovits, 1988; Bonavera et al, 1994).
There have been numerous investigations into the opioid receptors and their 
widespread distribution throughout the brain (see Table 1.1.). Activation of these 
receptors generally results in an inhibition of ceilulai' activity and a corresponding 
decrease in neurotransmitter release (Schoffelmeer et al, 1992). Three major 
types o f opioid receptors, mu (|Li), kappa (k) and delta (5) have been 
pharmacologically chaiacterised by radioligand binding and functional analyses 
(Leslie, 1987; Mansour et al, 1988). Recent cloning studies have confirmed the 
presence of these three receptor subtypes, which are stmcturally homologous but 
encoded by separate genes (Chen et al, 1993; Yasuda et al, 1993). Two other 
opioid receptor subtypes, sigma (a) and epsilon (e), have also been postulated 
(Hollt, 1983; Su et al, 1986; Holtzman, 1989). There is also further support for 
additional subdivisions of the p.- and K-opioid receptor classes (Dougall, 1988) on 
the basis of the ability of various p.- and K-agonists and antagonists to bind with 
high affinity to these receptors.
The p.-opioid receptors are characterised as having high affinity for morphine-like 
drugs and for several EOPs, especially p-endoiphin (Leslie, 1987). The p,-opioid 
receptors are widely distributed in the brain and high numbers of the p. receptor 
sites have been visualised in the hypothalamus, including the MPOA, SCN, ME, 
AHA and ARN (Loughlin et al, 1995). Several raphe nuclei, the midbrain 
dopaminergic cells and the LC noradrenergic neurons have also been shown to 
contain moderate levels of p-opioid receptor subtypes (Thompson et al, 1993; 
Loughlin et al, 1995). The K-opioid receptors are characterised as those sites
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which have high affinity for benzomoiphan drugs such as U-50488H and U-69593 
(Vonvoigtlander et al, 1983) and for certain endogenous opioids, particulaily 
dynorphin A (1-17). High numbers of K sites have been found in many 
hypothalamic regions, including the ME, lateral hypothalamic area, MPOA, DMN, 
PeVN, ARN and SCN and some also in the raphe nuclei, the brainstem and several 
midbrain structures (Hoffman et al, 1989; Loughlin et al, 1995). The 0-opioid 
receptors are characterised as having high affinity for the endogenous opioid 
peptide, enkephalin (Leslie, 1987) and enkephalin analogues like DPDPE 
(Mosberg et al, 1983). The 8 -opioid receptors have a more restricted distribution 
than those of p- and K-opioid receptors. The density of 8 -opioid binding has 
usually been described as being low to moderate throughout the rat hypothalamus 
and the highest concentrations of these receptors aie located in the SCN, ARN and 
MPOA (Mansour etal, 1988; Desjardins et al, 1990). Dense numbers of 8 -opioid 
receptors have been found in several other brain areas including the brain stem and 
the midbrain. The distribution of the 8 -opioid receptors correlates well with that of 
enkephalin-containing axon tenninals (Desjaidins et al, 1990).
The a-receptor subtype was originally defined by Maitin et al (1976), based on the 
unique effects of SKF 10,047, the prototypical agonist for the a-receptors. 
However, the opioid nature of these receptor subtypes has been brought into 
question as cocaine and pharmacologically-related compounds also display 
affinities for the a-opioid subtypes (Sharkey et al, 1988). Furthermore, a non­
opioid a-receptor has been found in the guinea-pig myenteric plexus (Roman et al,
1988). However, more recent evidence has shown that the a-receptor exists and 
is distinct from the non-opioid a-receptor (Holtzman, 1989), These a-opioid 
receptors have been visualised by autoradiographic localisation studies in high 
density in the hypothalamus (Largent et al, 1986). Although they have been 
originally classified as a subtype of opioid receptors, many in vivo effects of SKF 
10,047 are not blocked by the opioid antagonists, naloxone and naltrexone (Katz et 
al, 1985).
EOPs are widely distributed throughout the CNS, particularly in the limbic system. 
There are at least three separate opioid neuronal networks in the brain; an 
enkephalin family, a p-endoiphin family and a dynoiphin family (Watson et al,
1982). High concentrations of p-endorphin and leu- and met-enkephalin have 
been demonstrated in the ME, SCN, MPOA, ARN and PVN as well as in many 
other hypothalamic regions and extrahypothalamic sites. In the SCN and MPOA,
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the enkephalins have been found to be contained in the perikaiya of opioid 
peptidergic neurons (Hokfelt etal, 1977). In the ME, the enkephalins (Watson et 
al, 1982; Williams and Dockray, 1983) and p-endoiphin (Mezey et al, 1985) are 
present only in fibres. Enkephalin-containing perikarya and fibres (Hokfelt et al, 
1977; Watson et al, 1982; Williams and Dockray, 1983) and P-endoiphin- 
containing cells (Mezey etal, 1985; Jirikowski etal, 1986) have been visualised in 
the ARN. Dense concentrations of dynorphin cells and fibres are present in the 
ARN and corresponding projections innervate the ME (Fallon and Leslie, 1986; 
Loughlin et al, 1995). Dynorphin-containing cells and fibres are also found in the 
lateral hypothalamic area, preoptic area, SCN, PeVN, DMN, VMN along with 
some other hypothalamic and extrahypothalamic areas, including the raphe nuclei, 
dopaminergic midbrain stmctures and the brainstem (Hokfelt et al, 1977; Loughlin 
et al, 1995). In addition to these well known EOPs, some other less common 
EOPs have also been demonstrated in several parts of the hypothalamus (for review 
see Palkovits, 1988). Furthermore, there is also evidence for the co-existence of 
two or more endogenous peptides within the same neuronal perikarya or even in 
the same secretory granule (Chan-Palay et al, 1984; Griffond et al, 1993). Indeed, 
P-endoiphin, ACTH and a-MSH have been shown to be all present in the same 
population of ARN neurons (Mezey et al, 1985).
Opioid peptides depress spontaneous neuronal activity and hence neuronal 
transmission by direct action on the neuron and the underlying basis for this effect 
is a naloxone-reversible hyperpolarisation of the cell membrane (Henderson,
1983). For ligands of p,-, k- and 0-opioid receptors, the inhibitoiy 
hypeipolarisation results from activation of a calcium-sensitive potassium 
conductance (Williams et al, 1982; Grudt and Williams, 1995; Lagrange et al,
1995). This inhibitory opioid influence appears to involve activation of potassium 
conductance, a decrease in calcium conductance and inhibition of adenylyl cyclase 
activity (Grudt and Williams, 1995). The reduction of both spontaneous electrical 
activity and the amount of neurotransmitter released is a common feature of opioid 
action (Grossman and Dyer, 1989).
P-endorphin is one of the most important and biologically active endogenous 
peptides in the CNS. It has an important role in the control of the anterior pituitary 
function, particularly in the stimulation of prolactin and the inhibition of LH release 
(Van Vugt et al, 1982; Genazzani et al, 1990). p-endoiphin inhibits GnRH 
secretion by preventing its release from the ME (Bicknell, 1985; Bonavera et al,
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Î994). It is generally agreed that P-endorphin, as well as other EOPs, act at the 
hypothalamic level and have no direct effect at the pituitary level, on LH secretion 
(Parnet et al, 1990). Indeed, the anterior pituitary has been reported to be 
relatively poor in opioid receptors (Khachaturian et al, 1985). It is therefore most 
likely that the endogenous opioid control of LH release is caused by actions and/or 
interactions within the brain; in particular, by modulating the secretion of GnRH 
into the hypophyseal portal system.
EOPs have a profound inhibitory influence on GnRH and LH release (Kalra, 1993; 
Barraclough, 1994; Kordon et al, 1994). There is considerable overlap in the 
distribution of EOPs and GnRH innervation in the preoptic-tuberal pathway 
(Witkin et al, 1982) and direct synaptic connections between opioid peptidergic and 
GnRH neurons in the MPOA have been shown (Leranth et al, 1988a). Acute and 
chronic administration of morphine suppresses the release of GnRH and therefore 
blocks ovulation (Baixaclough and Sawyer, 1955; Mehmanesh et al, 1988). 
Similarly, both moiphine and p-endorphin can block the pre-ovulatory LH surge 
and hence ovulation when administered on the day of pro-oestrus (Leadem and 
Kalra, 1985). Infusion of antisera to p-endorphin or to dynoiphin into the third 
ventricle elevates plasma LH levels (Schultz et al, 1981). Studies by several 
groups have indicated that naloxone is able to overcome the suppressive 
opioidergic influence on GnRH secretion and its administration is associated with 
GnRH release in rats (Piva et al, 1985; Allen and Kalra, 1986; Brown et al, 1994). 
Furthermore, chronic moiphine treatment brings about a supersensitivity to 
naloxone (Cicero etal, 1983). The administration of naloxone on the morning of 
pro-oestrus advances the LH surge by restraining the inhibitoiy opioid action 
(Allen and Kalra, 1986). In view of these results it seems that a decrease in the 
hypothalamic opioid peptidergic tone before the critical period on the day of pro- 
oestms may be the neural stimulus to initiate the pre-ovulatory LH surge.
p-endorphin concentrations in tlie hypophyseal portal blood vary during different 
stages of the oestrous cycle (Sarkar and Yen, 1985). In the hypothalamus largest 
variations in the concentration of p-endoiphin occurs in the ME, and fluctuations 
are also evident in the MPOA and ARN. The plasma levels of P-endorphin have 
been found to be minimal on the morning and afternoon of pro-oestrus (Parnet et 
al, 1990). However, it has also been suggested that P-endoiphin levels are high 
on the morning whereas the lowest concentration is seen on the late afternoon of
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the pro-oestrus (Sarkar and Yen, 1985). Furthermore, the hypothalamic 
P-endorphin content fluctuates with a diurnal rhythm, showing a significant 
nocturnal increase that is abolished by the suppression of the dark phase of the day- 
night cycle (Genazzani et al, 1987). The circadian changes in the hypothalamic 
p-endoiphin content are dependent upon the steroid hormone status of animals, 
since they are elevated by gonadectomy and restored following chronic Eg 
replacement (Genazzani et al, 1990). Thus the ovarian steroids appear to exert a 
priming effect on this endogenous neuronal rhythm.
There is ample evidence to show that ovarian steroids are potentially important in 
modulating the output of the EOPs (Kalra, 1993). A considerable number of 
p-endoiphin, enkephalin and dynoiphin-immunoreactive neurons in the 
hypothalamus have been demonstrated to contain Eg and P receptors (Jirikowski et 
al, 1986; Fox et al, 1990). Specific implantation of Eg in the MPOA of dioestrous 
rats increases P-endorphin levels in the ARN-ME axis (Sturzebecher et al, 1988). 
During chronic exposure to opioids. Eg administration causes an exaggerated pro- 
oestrous-like LH surge in Eg plus P-treated ovx rats (Gabriel et al, 1986). Eg has a 
time-specific inhibition on p-endorphin levels on the afternoon of pro-oestrus 
(Lustig et al, 1988). Indeed, the hypothalamic opioidergic tone decreases in 
response to increased circulating Eg levels on the afternoon of pro-oestrus. These 
modulatory effects of steroids on p-endoiphin release may be dependent on the 
amount and the duration of exposure to the steroids rather than on their simple 
presence or absence. Moreover, steroid hormones may activate LH release by 
reducing the responsiveness of the LH secretory mechanism to the tonic inhibitory 
influence of EOPs (Berglund et al, 1988). More recent studies have indicated that 
POMC gene expression changes significantly during the oestrous cycle as well. 
Increased POMC mRNA levels are sustained until lO.OOh on pro-oestrus, 
thereafter a steady decrease occurs, reaching nadir levels by IS.OOh (Wise et al,
1990). The regulation of the POMC gene expression is steroid-dependent because 
ovariectomy abolishes and Eg plus P treatment reconstitutes the diminution in 
mRNA levels (Wise et al, 1990; Bohler et al, 1991). Ovarian steroids also up- 
regulate pro-enkephalin and pro-dynoiphin gene expression and immunoreactivity 
(Langub and Watson, 1992). Thus, it would appear that opioid peptidergic 
neurons are targets for steroid hormones.
The effects of EOPs on GnRH and LH release have been extensively investigated 
by using selective opioid agonists and antagonists in order to reveal the nature of
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opioid receptor subtypes involvement in the control of the pre-ovulatory LH surge 
and ovulation. Activation of fx-opioid subtypes inhibits GnRH neuronal activity 
and thereby its release in vitro (Lagrange et al, 1995). Administration of a long- 
acting p-opioid agonist, Duromorph, suppresses the LH surge (Brown et al, 
1994). Both K- and p -  receptor agonists tonically inhibit LH secretion in a dose- 
related manner following cential infusion (Pfeiffer et al, 1987). The latter effect 
can, however, be blocked by a highly specific p-receptor antagonist 
p-funaltrexamine, which suggests that opioid suppression of LH release is 
predominantly mediated via p-receptor s. The number of opioid receptors within 
the brain is not constant throughout the oestrous cycle. In the whole brain of 
cycling rats the density of p-opioid receptors significantly increases on the morning 
of pro-oestrus (Limonta et al, 1989). This is followed by a progressive decline in 
the number of p-receptors on the afternoon of the same day. Furthermore, the 
decrease in the p-binding sites observed on the afternoon of pro-oestrus coincides 
with the beginning of the LH surge and may be linked to the increase in serum Eg 
andP levels (Maggi etal, 1993). These observations thus provide an explanation 
why p-opioid receptor antagonists, naloxone and P-funaltrexamine have failed to 
elevate LH secretion in long term ovx rats owing to the lack of a steroid milieu 
(Pfeiffer er a/, 1987).
There is also evidence for the involvement of K-opioid receptors in the opioid 
control of LH secretion. The highly specific K-agonist, tifluadom is as effective as 
morphine in reducing plasma LH concentrations on the eaily afternoon of pro­
oestrus (Gopalan et al, 1989a; Brown et al, 1994). In agreement with these 
observations, K-agonists have also been seen to inhibit GnRH release in vitro 
(Leposavic et al, 1991). There are contradictory reports for the paiticipation of 
a- and 5-opioid receptors in the regulation of LH secretion. Only high doses of 
the a-receptor agonist, N-allynormetazocine hydrochloride, have been found to 
induce a fall in serum LH levels (Brown et al, 1994). However, the significance 
of a-opioid receptors in LH release is poorly understood because of the lack of 
specific ligands for these receptors and awaits further investigations. Selective 
5-opioid receptor agonists have been shown to suppress GnRH and LH secretion 
on the day of pro-oestrus (Leadem and Yagenova, 1987). However, their 
involvement in this process has also been questioned since a specific 5-opioid 
antagonist fails to elevate plasma LH levels (Leposavic et al, 1991). Hence, it 
appears that multiple opioid receptors may be involved in regulating LH release 
(Pechnick ef 1985).
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Although EOPs may directly inhibit GnRH release by a presynaptic inhibitory 
action, there is a lai'ge volume of evidence indicating that EOPs may have indirect 
effects on GnRH secretion by interfering with the other neuromodulator systems 
(For review see Kalra, 1993; Barraclough, 1994). The modulatory actions of 
EOPs on GnRH and LH release appear to involve central monoaminergic 
transmission (Leadam et al, 1985; Nishihara et al, 1991). Immunocytochemical 
studies have illustrated a degree of overlap in the distribution of opioid peptidergic 
perikarya and NA neurons and terminals (Kordon et al, 1994). Moreover, 
noradrenergic terminals within the hypothalamus possess a mixed population of 
opioid receptors. Naloxone-induced LH secretion can be prevented by prior 
administration of a-adrenoreceptor antagonists (Van Vugt et al, 1981; Kalra and 
Simpkins, 1981; Al-Hamood etal, 1985) and dopamine-p-hydroxylase inhibitors 
(Kalra and Crowley, 1982). Naloxone has been shown to stimulate NA release 
within the hypothalamus (Nishihara et al, 1991). Furthermore, icv administration 
of a-adrenoreceptor agonists can enhance LH release in morphine-treated rats 
(Kalra and Gallo, 1983). lonophoretically applied naloxone elevates the response 
of GnRH neurons in the MPOA to stimulation of the VNAB (Dyer et al, 1988). 
Activation of p.- and 5-opioid receptor subtypes inhibit NA release from slices of 
the MPOA (Diez-Guena et al, 1987). Thus, it would appear that NA axon 
terminals in discrete hypothalamic areas may be presynaptically inhibited by EOPs 
and this interaction may be of importance in the regulation of the LH release.
Many of the central catecholamine cell groups have been shown to contain one or 
more peptides (Hokfelt et al, 1984). Coexistence of TH and met-enkephalin in a 
considerable proportion of the Al NA cell group has also been reported (Ceccatelli 
et al, 1989). Therefore, these observations would point to the possibility that 
EOPs may exist as co-transmitters in the NA nerve terminals.
Pharmacological evidence has implicated a role for ADR in mediating the opioid 
peptidergic influence on GnRH and LH release since central administration of ADR 
synthesis inhibitors suppress naloxone-induced LH secretion (Kalra and Crowley, 
1982).
In addition to the interaction between the NA and EOP systems, there is also 
evidence that the EOPs can alter the modulatory effects of the dopaminergic system 
on GnRH release. Systemic administration of morphine reduces the rate of 
synthesis and turnover of DA in the ME by inhibiting activity of the TIDA neurons
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(Alper et al, 1980). Similarly, morphine reduces the DA content in the 
hypophyseal portal blood (Reymond et al, 1983). The TIDA neurons aie tonically 
inhibited in diestrous rats by K -, but not by a p.-opioid receptor mechanism 
(Manzai’anes et al, 1992). In vitro, the stimulation of both k -  and |Lt-opioid 
receptors with their respective agonists results in an inhibition of evoked DA 
release from the MBH (Heijna et al, 1991). Furthermore, activation of oCg- 
adrenoreceptors inhibits DA release indirectly by elevating the release of EOPs 
which in turn reduce the evoked DA release via K-opioid receptors (Werling et al, 
1988; Schofelmeer ef al, 1988). Naloxone by itself has been shown to stimulate 
DA and 3,4-dihydroxyphenylacetic acid (DOPAC) efflux from the TIDA 
dopaminergic neurons within the hypothalamus (Wilkes and Yen, 1980). The 
dopaminergic TIDA neurons are also believed to be responsible, at least in part, for 
the regulation of prolactin release. Inhibition of the TIDA DA turnover and release 
into the hypophyseal portal system results in a decrease in plasma LH levels (Van 
hoon etal, 1980). These effects also account for the prolactin-stimulating action 
of opioid peptides since a decrease in portal blood DA concentrations coixelates 
well with moiphine-induced prolactin secretion (Arita and Porter, 1984).
On the contraiy, stimulatory actions of EOPs on the dopaminergic system have also 
been documented. Administration of morphine activates the incertohypothalamic 
dopaminergic neurons and increases the DA turnover (Gopalan et al, 1989a) and 
concentrations of DOPAC (Alper et al, 1980; Lookingland and Moore, 1985) 
concomitant with the inhibition of the LH release. These effects of morphine may 
be reversed by the opioid antagonists, naloxone and naltrexone. Furthermore, 
recent evidence has shown that morphine enhances DA neuronal activity within the 
incertohypothalamic DA neurons by increasing TH mRNA levels without affecting 
plasma LH levels (He et al, 1994; Barraclough, 1994). Moiphine-induced 
increases in DA release and activity in the incertohypothalamic system seem 
somehow surprising since this pathway has been suggested to be stimulatory to 
GnRH and LH release as explained eaidier in this chapter. It is evident from the 
above studies that EOPs differentially affect activity of various DA-containing 
neurons and pathways in the brain, particularly in the hypothalamus.
High numbers of the various opioid receptors have been detected in the raphe 
nucleus (Mansour et al, 1988). In the DRN, activation of K -, but not (i-opioid 
receptors decreases the response of 5-HT-sensitive neurons to electrical stimulation 
(Pinnock, 1992). Thus, EOPs may have an inhibitory effect at the pre-synaptic
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5-HT nerve terminals in this brain region. In addition, moiphine has been shown 
to stimulate LH release in the presence of exogenous 5-HT while having inhibitory 
influence in its absence (Lenahan et al, 1987). There may be an important 
interaction between the opioid and serotonergic systems in controlling LH 
secretion.
Thus, it would appear that the inhibitory effects of EOPs on GnRH secretion may 
be mediated in a large pait by the central noradrenergic, but to some extent also by 
the dopaminergic and serotonergic systems.
On the other hand, both the serotonergic and the dopaminergic (George and 
Keitesz, 1986) systems may modulate the activity of the hypothalamic pro­
enkephalin neurons. Activation of the a-adrenergic system stimulates the 
accumulation of met-enkephalin in the ME (George et al, 1990). Long term DA 
agonist treatment of male rats reduces P-endoiphin immunoreactivity in the MBH 
and ME, two brain ai'eas where P-endoiphin perikarya and terminals, respectively, 
aie located (Locatelli et al, 1983). However, DA agonists increase P-endoiphin 
concentrations in the hypothalamus of females rats. What becomes obvious from 
these studies is that there may be a reciprocal interactions between catecholamine, 
indolamine and EOP systems in the hypothalamus.
Recently, intermodulatoiy actions of opioid peptidergic systems both on EAAs 
(Bonavera et al, 1993) and neuropeptide Y (NPY) (Xu et al, 1993) in the central 
regulation of LH release have also been reported. Corticotropin releasing factor 
(CRF) has been implicated in the modulation of the inhibitoiy effects of EOPs. 
CRF-induced inhibition of LH secretion may be mediated by opioid peptidergic 
mechanisms since opioid antagonists eliminate this inhibitory influence of CRF 
(Akema et al, 1996). Hence, in addition to the monoaminergic mediation, some 
amino acid and peptidergic neurotransmitters may also mediate the effects of EOPs 
in the GnRH neurosecretory mechanisms.
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CNS Region F K ÔTelencephalon
Frontal cortex +++ 4 4 4
Pirifoim cortex 4-4- 4 4 4 4Entorhinal cortex 4-4- 4 4 4 4Amygdala 
Central nucleus 0 0 4 4Medial nucleus 4-4—X 4—(- 4 4Lateral nucleus {-4—h 4 4 4 4 4 4Hippocampal formation 
Hippocampus 4-4-4- 4 4 4Dentate gyrus 4-4-4- 4 4Olfactory tubercle 4- 4 4 4 4 4 4Nucleus accumbens -t-4—t—t- 4 4 4 4 4 4 4Caudate-putamen ■44—1-4- 4 4 4 —h 4 4 4Globus pallidus 4 4 4Medial septum 4 4 4 4 4Bed nucleus stria terminalis 4 4 4 4 4 4 4Preoptic area 4 4 4 4 4 —hDiencephalon
Hypothalamus 
Supraoptic nucleus 0 0 4 4Paraventricular nucleus 0 0 4 4Ar cuate nucleus 0 0 4 4Ventromedial nucleus 0 4 4—h 4Dorsomedial nucleus + 0 4 4 4Lateral hypothalamic area + 0 4 4Thalamus 
Periventricular area 0 0 4 4 4Central-medial nucleus 4 4 4 4 4 4 4Reuniens nucleus 4 4 4 4 4 4 4Medial habenula 4 4 4 + 4 4 4M esengpcephalon
Inteipeduncular nucleus 4—1—1—h + + + 4 4 4Substantia nigra 
Par s compacta 4 4 4 0 0Par s reticulata 4—h 4 4Ventr al tegmental area 4 4 0 4Periaqueductal grey 4 0 4 4Superior/Inerior collicuH 4 4 4 4 + 4 4Dorsal raphe nucleus 4 4 0 4 4Pons/m edulla
Parabrachial nucleus 4 4 4 0 -1—1_Nucleus raphe magnus 4 4 0 4Nuc. retie, gigantocellularis 4 0 4Nucleus tractus solitarius 4 4 4 4 + 4 4 4Lateral reticular nucleus 4 0 4Spinal trigeminal nucleus 4—1—H 0 4 4Spinal Cord
Substantia gelatinosa 4 4 4 4 -1—
Table 1.1. Regional distribution of opioid receptors in the rat brain (very dense: 
++++; dense: +++; moderate: ++; low: +; undetectable; 0). From: Mansour et al, 
1988).
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Neuropeptide Y
Neuromodulator actions of NPY in the central control of LH release have been 
extensively studied (for review see Kalra, 1993; Kordon etal, 1994).
NPY-containing neurons show an extensive distribution pattern in the rat brain. 
NPY cells and nerve terminals have been found in the MBH, ARN, SCN and the 
preoptic ai'ea along with the other hypothalamic regions (Plorwath et al, 1992b). 
Synaptic contacts between the NPY perikarya and GnRH neurons in the lateral 
aspect and internal zone of the ME have also been visualised (McDonald et al,
1989).
NPY exerts both stimulatory and inhibitory effect on pulsatile discharge of LH in 
ovx rats depending upon the steroid honnone milieu. Infusion of NPY into the 
third ventricle in ovx hormonally-untreated rats produces a dramatic and sustained 
inhibition of LH secretion, while it tiansiently increases plasma LH levels and 
advances the LH surge in steroid-primed ovx rats (Crowley et al, 1987; McDonald 
et al, 1989). NPY may mediate the positive feedback effects of the ovarian 
steroids since NPY-producing neurons have been shown to possess E2 receptors 
(Sar et al, 1990). In vitro, NPY stimulates the release of GnRH from the MBH of 
steroid-primed ovx and pro-oestrous rats (Crowley and Kalra, 1987; Besecke and 
Levine, 1994). Accordingly, icv tieatment with antiserum to NPY prevents the 
LH surge in steroid-treated rats (Wehrenberg et al, 1989). Thus, NPY would 
appeal* to have an important role in the stimulation of the episodic LH surge on the 
day of pro-oestms. Indeed, its levels in the ME reach a peak nearly one hour prior 
to anticipation of the impending LH surge (Sahu et al, 1989). Furthermore, NPY 
gene expression is increased in the MPOA and MBH during the pre-ovulatory LH 
surge (Bauer-Dantoin et al, 1992; Sahu etal, 1995).
The gonadal steroid-dependent effects of NPY on GnRH release are remarkably 
similar to those of NA (Kalra, 1993). There is a variety of evidence suggesting 
that NPY and NA or ADR coexist intraneuronally in the brainstem and also in tire 
diencephalon (Lundberg et al, 1982; Hokfelt et al, 1984). It has further been 
reported that NPY may act on the GnRH neurons as a co-transmitter with NA 
(Everitt aZ, 1984). Thus, NPY and the adrenergic system in the hypothalamus 
may play a concerted role in evoking the LH surge (Allen et al, 1987).
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There may also be interplay between NPY and the hypothalamic dopaminergic 
systems since NPY has been shown to increase genetic expression of TH in the 
TIDA neurons in the rat (Hong et al, 1995). Immunopositive NPY nerve 
terminals synapse on the ^-endorphin-containing cells in the ARN (Horwath et al, 
1992b). This anatomical relationship may imply that NPY modulates secretion of 
P-endoiphin in the hypothalamus.
In addition to a neurotransmitter/neuromodulator role in the hypothalamus, NPY 
may also function as a neurohumoral signal to amplify LH release from the anterior 
pituitary. NPY potentiates the GnRH-induced LH response from dispersed 
pituitary cell cultures (Crowley and Kalra, 1987). A similar potentiation of LH to 
GnRH by NPY has also been observed in vivo (Bauer-Dantoin et al, 1992).
In view of the evidence outlined above, one would conclude tliat NPY plays an 
important role in the regulation of LH release in the rat either independently or in 
concert with the adrenergic system.
Neurotensin
Neurotensin-containing cell bodies are found in the anterior periventiiculai* system, 
PVN, preoptic area, SCN and the ARN along with other some other brain areas 
(Jeunes et al, 1982). The majority of the neurotensin-positive cells in the ARN 
terminate in the ME (Merchenthaler and Lennard, 1991),
The major nonreproductive endocrine functions of neurotensin are stimulation of 
insulin secretion, inhibition of glucagon secretion and modulation of 
gastrointestinal motility (see Kordon et al, 1994).
High concentrations of neurotensin and its abundant binding sites in the 
hypothalamus (Moyse et al, 1987) are suggestive of this neuropeptide's 
participation in the pre-ovulatory discharge of LH. Neurotensin has been reported 
to suppress LH levels in long term ovx rats (Vijayan and McCann, 1979). 
However, it has also been claimed that neurotensin stimulates LH release when 
infused directly into the MPOA (Ferris et al, 1984). In agreement with the latter 
report, infusion of neurotensin antiserum directly into tlie diagonal band of the 
broca, MPOA and lateral preoptic area significantly decrease the steroid-induced 
LH surge (Alexander et al, 1989). Neurotensin immunopositive cells have been
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demonstrated to be E% receptive (Herbison and Dyer, 1991) and, therefore, 
upregulation of neurotensin secretion by the ovarian steroids may account for the 
dual actions of this neuropeptide on the LH release.
Neurotensin-containing neurons show an overlapping distribution with 
catecholamines in the hypothalamus (Hokfelt et al, 1984). This neuropeptide 
stimulates DA and NA release within the hypothalamus (Gudelsky et al, 1989). 
Furthermore, neurotensin-induced LH surge can be blocked by dopaminergic and 
a-adrenergic receptor antagonists (Akema and Kimura, 1989). It is therefore 
possible that catecholamines mediate the excitatoiy effects of neurotensin on LH 
release.
Galanin
Galanin is widely distributed in the brain and its immunoreactive perikaiya are 
abundant in the MPOA, SCN, PeVN, PVN, ME and ARN (Melander et al, 
1986a). Moreover, galanin has been visualised to co-localise with several other 
neuropeptides such as GnRH, neurotensin as well as G ABA and TH (Melander et 
al, 1986b; Merchenthaler ef a/, 1990). Immunocytochemical and autoradiographic 
studies have demonstrated that a large population of galanin-immunopositive cells 
in the hypothalamus concentrate Eg (see Kalra, 1993). Galanin may thus mediate 
the positive feedback effects of steroidal milieu on the GnRH secretory systems.
Current evidence suggest a role for galanin in initiation of the pre-ovulatory LH 
surge. Administration of galanin stimulates LH release in a dose-dependent manner 
in steroid treated ovx rats (Sahu et al, 1987). Intraventricular infusion of a galanin 
antagonist, galantide, blocks the steroid-induced LH surge in ovx rats (Xu and 
Sahu, 1993). A marked increase in the ME-ARN concentrations of galanin has 
been reported to occur after treatment with E^ concomitant with the LH surge 
(Gabriel et al, 1990). Furthermore, galanin has been shown to stimulate GnRH 
release from ME-ARN fragments in vitro (Lopez et al, 1991).
Although these studies appear to indicate a stimulatory influence of galanin in the 
regulation of the LH secretion, the significance of its involvement in this process 
has yet to be determined.
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Substance P
Neurons containing substance P (SP) are widely distributed throughout the 
hypothalamus, especially in the MPOA, ARN and ME (Makai’a et al, 1986; Tsuruo 
etal, 1991).
It has been suggested that SP acts as a neuromediator in the control of LH release, 
at least in part, at the level of the MPOA (Picanco-Diniz et al, 1990). SP- 
containing projections make synaptic contact with GnRH neurons in the septo- 
preoptic area of the rat (Tsuruo et al, 1991). It has been shown that extrinsic SP 
stimulates LH secretion by affecting the hypothalamic GnRH neurons (Jarry et al, 
1988). Endogenous SP exerts a tonic stimulatory effect on GnRH release 
(Arisawa et al, 1990). In addition, it elevates GnRH secretion from the MBH in 
vitro and this stimulatory LH response appears to be E2-dependent (Ohtsuka et al,
1987). Consistent with the latter observation, levels of SP have been found to 
fluctuate in discrete hypothalamic areas throughout the oestrous cycle of the rat 
(Jarry etal, 1988). Central administration of SP exerts little effect on LH release 
in unprimed and ovarian steroid-primed ovx rats (Kalra, 1993). On the other 
hand, inhibitory effects of SP have also been reported, icv (Kerdelhue et al, 1982) 
or peripheral (Battmann et al, 1991) administration of SP inhibits cyclical GnRH 
release in rats on the day of pro-oestrus. These results are contradictory since 
Kerdelhue and co-workers have also shown that SP concentrations are the highest 
in the MPOA, ME and ARN during the entire course of the pre-ovulatoiy LH surge 
compared to the other stages of the oestrous cycle (Parnet et al, 1990). Hence, 
these results would point to an excitatory influence of the hypothalamic SP on 
GnRH and LH release.
In addition to its neuromodulatory effects at the hypothalamic level, SP also exists 
in the anterior pituitary and its concentrations and binding sites vary depending 
upon the ovarian steroidal milieu (Mikkelsen et al, 1989). Recently, it has been 
shown that SP stimulates LH release in vitro from anterior pituitary cells obtained 
from female rats (Shamgochian and Leeman, 1992). These findings would thus 
suggest a paracrine/autocrine role for SP in the regulation of LH release.
In view of the data reported so far, it could be inferred that SP may have only a 
minor involvement in the central control of LH release.
58
Vasoactive Intestinal Peptide
The existence of vasoactive intestinal peptide (VIP) in the hypothalamus has been 
reported, specifically in neurons located in the SCN and PVN (Mezey and Kiss, 
1985; Koves etal, 1991). VIP-containing cell bodies located in the PVN project 
to the ME, whereas those of the SCN send nerve terminals to the preoptic area 
(Mezey and Kiss, 1985). In the SCN, VIP-containing fibres have been observed 
in apposition to a substantial proportion of the GnRH neurons suggesting a direct 
functional role for VIP in the circadian control of LH secretion (van der Beek et al, 
1994),
A single class of VIP receptors has been described and its distribution in several 
brain areas has been shown (Kordon et al, 1994),
Infusion of VIP into the third ventricle considerably attenuates the magnitude of the 
steroid-induced LH surge in ovx rats (Weick and Stobie, 1992). This inhibitory 
action appears to be exerted within the hypothalamus. Accordingly, administration 
of VIP into the MPOA has also inhibited the anticipated LH surge in the ovx and 
steroid-primed rat (Kimura et al, 1987). The effects of VIP on the LH surge 
appear to be independent of the inhibitory influence of the endogenous opioids 
since administration of naloxone does not prevent the inhibiton of pulsatile LH 
secretion by VIP (Kimura et al, 1987). However, VIP has also been suggested to 
stimulate GnRH release in vitro from the ME synaptosomes and the perifused 
MBH (Samson et al, 1981 ; Ohtsuka et al, 1988), respectively. Furthermore, it has 
been reported that the VIP content of the SCN, ME and PVN does not change 
during the LH surge (Watanobe et al, 1991). Thus, it is possible that the 
stimulatory and inhibitory effects of VIP may be expressed through different 
hypothalamic sites.
In summary, this neuropeptide may act to suppress GnRH secretion during the LH 
surge. However, its significance in the regulation of GnRH release has not yet 
been fully established.
Pituitary Adenylate Cyclase-Activating Polypeptide
Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates LH release 
both in the rat anterior pituitary cell culture, in vitro (Schomerus et al, 1994) and
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from the anterior pituitary, in vivo (Sawangjaroen and Curlewis, 1994), This 
polypeptide is also able to interact synergistically with GnRH in producing this 
effect (Culler and Paschall, 1991).
Immunohistochemical studies have demonstrated the presence of PACAP 
immunoreactive nerve terminals in the rat ME (Koves et al, 1991). These fibres 
are in close contact with the hypophyseal portal capillaries. High-affinity specific 
binding sites for PACAP have also been demonstrated in the rat hypothalamus and 
anterior pituitary (Koves et al, 1991).
Taken the above findings suggest that PACAP may function both as a 
hypophysiotropic factor and as a neurotransmitter within the hypothalamus. 
However, more work has yet to be carried out to elucidate the involvement of this 
neuropeptide in the regulation of LH secretion.
Nitric Oxide
NO is a novel messenger molecule and enzymatically formed from L-arginine by 
nitric oxide synthase (NOS) in the presence of oxygen (Palmer et al, 1987). It is a 
short-lived free radical which rapidly diffuses in all directions in the tissue. 
Recently, Bredt et al (1990) have isolated the enzyme (NOS) and shown by 
immunocytochemistry its wide distribution in the brain. A large population of 
NOS-containing neurons, teimed NOergic neurons, has also been found in the 
hypothalamus.
NO has recently been implicated in the regulation of several neuroendocrine 
functions including that of GnRH release (for review see McCann and Rettori,
1996). Intraventricular infusion of a NOS inhibitor, N^-monoethyl-L-arginine, 
cause a cessation of LH but not FSH pulses, indicating that NO is required for 
pulsatile GnRH secretion (Rettori etal, 1993). NO stimulates GnRH release from 
ARN-ME fragments in vitro (Moretto et al, 1993). Furthermore, it has been 
suggested that NO is involved in ovulatory mechanisms since administration of 
NOS inhibitors significantly reduce the rate of ovulation in rats both in vivo and in 
vitro (B onéilo et al, 1996).
Intermodulatory actions of NO have also been reported. Inhibition of NOS activity 
suppresses the excitatory amino acid stimulation of GnRH release in vivo
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(Bonavera e? a/, 1993) indicating that NO may modulate the stimulatory effects of 
EAAs on LH release. Similarly, NO may also mediate the stimulatory effects of 
NA on LH release. Furthermore, in vitro studies have shown that NO may control 
G ABA release since inhibitory effects of GAB A on GnRH secretion can be 
prevented by NOS inhibitor (Seilicovich et al, 1995; McCann and Rettori, 1996). 
Therefore, it appears that NO may not only be involved in the stimulation, but also 
in the inhibition of GnRH release.
Although the evidence presented so far would point to a neuromodulatoiy role for 
NO, its participation in the regulation of GnRH and LH release has not yet been 
well established.
Summary
In view of the review presented so far, it is clear that the secretion of LH, including 
the pre-ovulatory LH surge, is regulated by a complex neural circuitiy involving 
several classes of neurotransmitters/neuromodulators. These neuromessengers 
modulate the LH release by altering the activity of the GnRH pulse generator within 
the hypothalamus.
The neurotransmitters which appear to be of paramount significance in this neural 
network aie NA, EOPs, DA, 5-HT, G ABA and NPY. There is a complex 
interaction between these neurons with the effects of some being mediated by 
others (see Figure 1.5).
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AIMS
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The present study was designed to examine:
(i) the involvement of \i~, k -  and 0 -opioid receptors in the central regulation of the 
LH surge in the rat. To date, there have been relatively few attempts to study the 
significance of the 5-opioid subtypes in the control of LH release.
(ii) role of monoamines, paiticularly NA, in the generation of the pre-ovulatory LH 
surge.
(iii) the inter-relationship between the opioid peptidergic and aminergic systems in 
the control of LH release.
(iv) neurochemical changes in the preoptic-tuberal pathway, where GnRH cell 
bodies (MPOA) and nerve terminals (SCN, ARN and ME) are found, at the time of 
the LH surge.
To achieve these aims, specific opioid receptor agonists and antagonists were 
utilised. Their effects on plasma LH levels and on the aminergic content and/or 
turnover within selected hypothalamic regions were investigated in the urethane- 
anaesthetised rat on the late afternoon of pro-oestrus.
When the initial findings indicated that the urethane anaesthesia totally abolished the 
anticipated pre-ovulatory LH surge, a modified method for blood sampling from 
freely-moving conscious animals was employed in the second set of experiments.
In order to further elucidate the interactions between the opioids and aminergic 
neurotransmitters in the regulation of the LH surge, p.-, k- and 5-opioid agonists 
and antagonists were administered and co-administered intracerebroventricularly to 
ovariectomised and steroid-primed rats.
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MATERIALS AND METHODS
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Animals
Adult female Sprague-Dawley rats were purchased from Hai'lan UK Ltd, (Oxen, 
England). Upon their anival in the Animal Unit, they were numbered by eai* 
mai’king under light halothane anaesthesia and maintained in groups of three in 
transparent polycarbonate cages. The animals were housed under controlled 
temperature (21±1 ®C) and light conditions (lights on from 07.00h to 19.00h). 
Food (standard pellet diet) and water were supplied ad libitum.
Two different types of animal models were employed during the course of this 
study. In Experiments I and II, intact female rats and, in Experiment III, ovx and 
steroid-primed rats were used.
1. Intact Female Rats
Vaginal smearing was performed between 08.30h-10.30h eaeh morning and the 
smears examined under the X I0 objective of a light microscope. The morphology 
of the cells sloughed from the vagina were used to identify the four different stages 
of the oestrous cycle of each rat.
Stage of cycle
Dioestrus I
Vaginal Smear
Some nucleated epithelial cells and 
many poly-moiphonuclear leucocytes 
with some keratinised squamous 
epithelial cells.
Dioestms II Nucleated epithelial cells and many 
leucocytes.
Pro-oestrus Predominantly nucleated epithelial 
cells.
Oestrus Keratinised (cornified) squamous 
cells only.
Table 2.1. Assessment of oestrous cyclicity by vaginal cytology.
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Only those animals (weighing 220-300g) which had exhibited at least three 
consecutive four-day oestrous cycles were selected for experimentation on the 
morning of pro-oestrus.
2. Ovariectomised and Steroid-Primed Rats
Ovariectomy:
Adult female Sprague-Dawley rats were arbitrarily selected from the colony and 
bilaterally ovx under halothane anaesthesia.
While under deep anaesthesia, the rats were secured to a dissecting board in a 
dorso-ventral position. The upper abdominal skin was neatly trimmed and 
swabbed with absolute alcohol. A small incision was made in the skin, and the 
exposed subcutaneous fat was deflected to reveal the abdominal muscle coat. The 
muscle layer was then cut. The ovaries were very gently withdrawn, and a 
haemostatic ligature (silk thread) was made around the uteri before the removal. 
The tied ends were returned to the abdominal cavity and the muscle layer was 
sutured with surgical silk. The skin was closed using Michel clips. Polybactrin 
spray (The Wellcome Foundation Ltd., London, UK) was applied to the area to 
prevent any post-operative infection.
After the surgery, the animals were allowed to recover in individual cages for a 
period of ten days to three weeks before use. They were subcutaneously injected 
with p-oestradiol 3-benzoate (5pg/0.2ml olive oil, Sigma Chemicals Co., St. 
Louis, USA) 48h before and P (0.5mg/0.2ml olive oil. Sigma Chemicals Co., St. 
Louis, USA) 4h prior to experimentation.
On the day of the anticipated LH surge, the animals were anaesthetised with Vetalai* 
(Ketamine hydrochloride lOOmg/ml; Parke-Davis Veterinary Com. Pontypool, 
Gwent, UK). The surgical anaesthesia (complete cessation of the hind limb flexor 
withdrawal reflex) was maintained by periodic intramuscular (i.m.) injections of 
Vetalar (0.5-0.7ml) until the end of the experiment i.e. at 19.00h. A heparinised 
(sodium heparin, 10 units/ml; Leo Laboratories Ltd., Bucks, UK) cannula was 
inserted into the right femoral aitery and the animals mounted on a stereotaxic 
frame to perform icv infusions. These procedures will be explained in detail later 
in this chapter.
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Drugs
The properties of the drugs used as tools in this study are summarised in Table 2.2. 
Their chemical names are given in the 'List of Abbreviations'.
Morphine is a highly specific jx-agonist and displays very little activity at other 
opioid receptor types. In this study a rapid-acting preparation of morphine 
(diamorphine hydrochloride) was used which exhibits potent analgesic effects 
(Kruk and Pycock, 1993).
Drug Receptor Properties
Naloxone opioid antagonist
Diamorphine |x-agonist
U-50488H K-agonist
U-69593 K-agonist
MR2266 K-antagonist
MR1452 K-antagonist
DPDPE 5-agonist
ICI 174,864 5-antagonist
ICI 154,129 5-antagonist
Table 2.2. Drugs used in the present study and their receptor properties.
Naloxone is a specific opioid antagonist which has greatest affinity for the 
p.-receptor but also possesses substantial affinity for both k- and 5-receptors (Kruk 
and Pycock, 1993).
U-50488H and U-69593 are both highly selective K-opioid agonists, being more 
potent at the K-receptor than at any other opioid receptor (Vonvoigtlander et al, 
1983; Lahti etal, 1985). These two K-agonists do not show any affinity towards 
jX-opioid subtypes.
MR2266 and MR 1452 are two selective K-opioid receptor antagonists 
(Vonvoigtlander ef a/, 1983; Ciœïo et al, 1988). MR2266 shows some affinity
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towards jX-opioid receptor subtypes (Vonvoigtlander et al, 1983). Affinities of 
MR1452 towards the other opioid receptor subtypes are at present unknown.
DPDPE, an enkephalin analogue (peptide) is a highly selective 0-opioid receptor 
agonist (Mosberg etal, 1983; Crook etal, 1992).
ICI 174,864 and ICI 154,129 are two selective 5-opioid receptor antagonists 
(Cowan and Gmerek, 1982; Crook et al, 1992). These peptide ligands prevent 
actions of DPDPE at 5-receptors, .and do not have affinities towards p.-opioid 
receptors (Cowan and Gmerek, 1982; Crook et al, 1992).
I would like to thank to the following institutions for the gifts of the drugs 
employed in the experiments: Boehringer Ingelheim Ltd. (Ingelheim am Rhein, 
Germany) for the gifts of MR2266 and MR1452, the Upjohn Company 
(Kalamazoo, Michigan, USA) for U-50488H and U-69593, the National Institute 
on Dmg Abuse (Rockville, Maryland, USA) for DPDPE.
Naloxone was purchased from Sigma Chemicals Corporation (Poole, Dorset, 
UK), diamoiphine from Napp Laboratories Ltd. (Cambridge UK), ICI 174,864 
and ICI 154,129 from Cambridge Research Biochemicals Ltd. (Cheshire, UK).
Femoral Artery Canimlation
Surgical anaesthesia was induced under halothane anaesthesia as described in 
Experiments II and III. A plastic cannula (Portex, outside diameter 0.63mm) 
combined with vinyl tubing (internal diameter 0.55mm) was inserted into the right 
femoral artery. With the aid of a stainless steel guide cannula, the vinyl tubing 
was fed under the dorsal skin to emerge at the back of the neck where it was 
loosely stitched to the skin. This procedure took no longer than 20-25 minutes.
The animals were allowed to recover for around two hours prior to the blood 
sampling commencing at 13.00h. Blood samples (200pl) were withdrawn 
through the heparinised cannula at hourly intervals from freely-moving conscious 
animals throughout the afternoon and early evening of pro-oestms. A small 
volume (20-30jxl) of warmed, heparinised physiological saline was injected after
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each blood sample collection to maintain the cannula open. The animals were kept 
warm throughout the experiment by the use of a heating lamp.
Only one or two rats were operated upon on tlie same day. All dmg
administrations were canied out under light halothane anaesthesia.
The animals were killed by decapitation just after the final blood collection at 
19.00h. The blood samples were centrifuged at 4°C for 5 mins at 3000 rpm. The 
plasma was transferred into fresh tubes and stored at -20°C until assayed for LH 
determination by radioimmunassay (RIA) at St. George’s Hospital Medical School 
in London.
Carotid Artery Cannulation
On the day of pro-oestms at around 12 noon, the right carotid aitery was 
cannulated (Portex, outside diameter 0.63mm) under urethane anaesthesia (ethyl 
carbamate, Ig/kg; Sigma Chemical Co., St. Louis, USA) as described in 
Experiment I. The surgical anaesthesia was maintained by periodic intraperitoneal 
(IP) injections of urethane. Tmnk blood (200jxl) was collected via the heparinised 
cannula at hourly intervals commencing at 13.00h. After centrifugation and 
sepaiation of the plasma, the red blood cells were reconstituted with lOOjxl of 
warmed, heparinised saline ( 1 0  units/ml) and reinjected through the cannula to 
maintain a constant plasma volume.
The animals were kept warm throughout the experiment by the use of a heating 
lamp. Decapitation of the rats and centrifugation of the blood samples procedure 
were carried out as explained above.
Removal of the Brain
Following the decapitation, the rat's head was placed on crushed dry ice. The skin 
lying over the skull was removed and the occipital muscles cut to reveal the 
foramen magnum. One blade of the scissors was cautiously introduced into the 
foramen. Cuts were made through the bone by keeping the blade pai’allel to the 
inner wall of the skull and as close to it as possible to avoid damaging the brain. 
These cuts were extended as rostrally as far as bregma. After two parallel cuts had 
been made, the skull was lifted forward and its rostral point of attachment separated
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Figure 2.1. Removal of the brain. *Bregma.
Figure 2.2. Plaœment of the brain on the mounting stage of the microtome.
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(Figure 2.1.). The closed scissors were then slipped under the frontal lobe and the 
brain lifted upwards. The optic and trigeminal nerves were cut, and the whole 
brain was coaxed gently out of the skull. The entire procedure was carried out 
within 60 seconds and the brains were frozen on dry ice to prevent post mortem 
degradation of the brain aminergic neurotransmitters prior to their analysis.
Brain Microdissection and Micropunch
Brain microdissection and micropunch procedures were always canied out on the 
same day that the experiments were undertaken. The MPOA, SCN, ME and ARN 
of the hypothalamus were surgically isolated by a modification of the Palkovits 
Technique (Palkovits and Brownstein, 1983). The frozen brains were allowed to 
partially thaw to promote adherence to the mounting platform of a freezing 
microtome. The hind brain and the anterior portion of the forebrain were removed 
by coronal cuts. The dorsal cut surface of the brain was placed on the mounting 
stage of the microtome (-SO^C; Leitz-Wetzler, Germany) and the tissue was held 
firmly in place by encasement of the base in Cryo-Gel (BDH Lab. Supplies, Poole, 
England) (Figure 2.2.).
There are several landmarks in various parts of the brain which are of guidance 
during microdissection. 1 0 0 |im coronal brain slices were cut until the fusion of 
the corpus callosum and thereafter the anterior commissure could be seen. 
Subsequently, serial 500pm sections were taken in the frontal plane, numbered 
0-10 and put on cooled microscope slides resting upon dry ice. There were no 
punches made from tlie first section (0); it was merely cut to ensure the coiTect 
plane of the sectioning. The remainder of the brain following removal of the 11 
sections was discarded.
The slides, section numbers 1-8 (excepting number 4) which contained the 
hypothalamic areas of interest were then placed on a petri dish containing dry ice 
and viewed under a binocular dissection microscope (XI6  magnification). 
Bilateral homologous tissue samples of the MPOA, SCN, ME and ARN were 
micropunched from the sections using modified stainless steel hypodermic needles 
(0.7 and 0 .3 mm internal diameter). The locations of discrete brain regions were 
identified by reference to the Stereotaxic Atlas of the Rat Brain (Paxinos and 
Watson, 1986) in conjunction with section number and standard neuroanatomical 
landmarks such as the third ventricle and midbrain (Figure 2.3.). A different
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Figure 2.3. Coronal section (number 3) through the rat bmin showing the location of 
the medial preoptic area (MPOA) to be isolated by micropunch. (Adapted from Paxinos 
and Watson, 1986).
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Figure 2.4. Isolation of the specific hypothalamic regions by micropunch technique.
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needle was used for each area and the needles were rinsed in absolute alcohol 
between samples and always kept cold on dry ice before use.
The punch needle was held at an angle of 45® and brought to the surface of the 
section. When the tip of the needle was in the appropriate location, it was placed 
in a vertical position and gently pressed on to the slice. The punch was then 
rotated to free the surrounding tissue and withdrawn (Figure 2,4.). After a tissue 
sample was successfully withdrawn a shaip edged hole remained in the section, 
and the tissue disc is contained within in the needle. The ME was isolated by 
punches of half the needle cross-sectional area. Finally, the tissue discs were 
pushed out of the dissecting needle by its stylet. The isolated hypothalamic 
regions were immediately transferred into separate, cooled Eppendorf tubes and 
frozen in liquid nitrogen. They were stored at -80®C and processed (on the 
following day) for the measurement of their biogenic amine content.
As the hypothalamic ai'eas were isolated by multiple micropunches, it was possible 
that a fraction of each area (particulaiiy in the case of the SCN) may have been 
missed. A record of the success of the punches was therefore kept.
Intracerebroventricular Infusion
lev infusion of the drugs to the ovx and steroid-primed rat model took place only in 
Experiment 111.
Stereotaxic Apparatus
All infusions were performed using a lOp.1 graduated Hamilton Syringe (Hamilton 
Company, Reno Nevada, USA) mounted upon David Kopf stereotaxic equipment 
(Tujunga, California, USA). Three dimensional constmction of the frame of this 
instrument allows the fixation of the rat’s head at three different points. The eai' 
bars were fixed in the external auditory meatus on either side and the nose was 
adjusted to a position in which the upper incisor bar firmly supported the upper jaw 
at the gingival margin behind the incisor teeth and a clamp was lowered on to tlie 
nasal region. The interaural rostro-caudal fixation maintained a recognised 
position of the head during infusion. Thus the infusion apparatus could be moved 
anteriorly and posteriorly along the long axis of the skull and the underlying brain.
74
LOo
CL
o
Û-D)
CÛ
N
EX
CO
N
ClCL
O
75
Figure 2 .6  .a. Fixation of rat in the stereotaxic apparatus for intracerebroventricular 
infusion of sterile saline, opioid agonists and antagonists.
Figure 2 .6 .b . Stereotaxic apparatus showing the intracerebroventricular infusion 
technique.
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The placement of the Hamilton syringe needle into the lateral ventricle was assessed 
with the aid of the De Groot Rat Brain Atlas (1972) using bregma as the reference 
point. Bregma is where the frontal and paiietal bones meet in the midline. The 
position of bregma according to the De Groot atlas was found to be approximately 
5.9mm anterior to the vertical zero plane (A5.7 to A6.1) and 6.3mm above the 
horizontal zero plane (H +6.1 to H 6 .6 ) (Figure 2.5.).
On the afternoon of the anticipated LH surge, following the femoral artery 
cannulation, the Vetalai-anaesthetised rat was mounted on the stereotaxic 
apparatus. The dorsal skin of the skull was trimmed and swabbed with alcohol. 
A midline incision was made in the scalp, the skin deflected and the membraneous 
connective tissue scraped from the superior aspect of the skull (Figure 2.6 .a). 
This revealed the bregma. The position of the bregma was marked and the 
vertical, lateral and anterio-posterior co-ordinates noted. A hole was drilled in the 
appropriate location (detei*mined by reference to the De Groot Atlas) of the skull, 
using a 5mm dental burr, to expose the superior sagittal sinus. Caie was taken not 
to injure the surface of the brain. The Hamilton syringe was filled with lOjal of a 
freshly-made solution containing the drug under investigation, or the vehicle 
(sterile saline) alone. The infusion apparatus was placed on the stereotaxic frame 
and the needle tip lowered on to the brain surface and then advanced deeply to the 
pre-determined position (Figure 2.6.b). The solution was infused gently over a 
period of 60 seconds into the right lateral ventricle. The syringe was then raised 
and the animal carefully removed from the stereotaxic apparatus.
Once the icv infusion had been completed, the anaesthetised animal was kept warm 
by using a heating lamp. Blood samples (200|xl) were collected from the 
indwelling cannula at hourly intervals throughout the afternoon and early evening 
as explained earlier.
H istological Verification
In order to assess the effectiveness of icv infusion, the position of the syringe 
needle was histologically verified in two separate rats. The Hamilton syringe was 
filled with 5jal of a marker, Indian ink, which was subsequently infused into the 
right lateral ventricle. No hypothalamic samples were, collected from these mai'ker- 
infused rat brains. The brains were fixed and kept in formol saline. The frontal 
lobes and the hind brain were cuts, and the dorsal portion of the brain was mounted
77
on the specimen holder of a cryostat (Jung Frigocut 2800E, -25“C). 50p.m
sections were cut and arranged on a slide in series. They were then examined 
under a dissection microscope (2 X 1 0  magnification).
Because of the fact that the brains had to be frozen following their removal and the 
hypothalamic regions had to be micropunched from the microdissected brain slices, 
a slightly different method was adapted to verify the position of the syringe. 
During the brain microdissection and micropunch, the location of the syringe 
needle was examined under a dissection microscope (XI6  magnification). The 
infusions were considered to be intraventiiculai" if the tract of the needle was 
observed in the lateral ventricle or if drops of blood were seen within its swollen 
cavity. Only those brain samples, which fulfilled one of these criteria, were 
included in the results.
Chromatography
To identify and quantify monoamines such as NA, ADR, DA, 5-HT and aminergic 
metabolites in the brain samples, this study employed reversed-phase high 
performance liquid chromatography with electrochemical detection (HPLC-ECD), 
because of its high sensitivity and specificity.
HPLC involves the physical sepai*ation of components in a mixture which aie 
distributed between a mobile phase and a stationary phase under high pressure. 
The separation occurs by differential migration and depends on the relative 
affinities of the various solute molecules for the mobile and stationary phases. The 
sepai’ated compounds are then quantitatively measured by an electiochemical 
detector (Jussofie et al, 1993). A schematic diagram of the main constituents 
which comprise the HPLC-ECD set-up utilised for this study is shown in Figure 
2.7.
i) Analytical column; The column (S5ODS2-250A, 4.6mm i.d.x25cm, 
HICHROM) was packed with octadecyl silane (ODS) hypersil (5|im) non-polar 
packing material comprised of silica particles bonded to a Cig moiety. This forms 
a column environment suitable for reversed-phase chromatography. The solid 
phase thus enables separation according to the size, structure and polai’ity of the 
analyte, and determines the time talcen for elution from the column. The more
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polar a compound, the faster it is eluted, as there is little attraction between it and 
the non-polar packing gel.
ii) Mobile phase (solvent reservoir): HPLC grade reagents were used in the 
preparation of the solvent. The aqueous medium used consisted of 6.74g citric 
acid, 4.81 g sodium citrate, 47mg ethylenediamine tetra-acetic acid (EDTA), 200mg 
heptasulphonic acid, 1.15ml glacial acetic acid, 3ml tetrahydrofuran and 25ml 
methanol. It was made up to 1 litre with deionised water and then brought to pH 
4.9 using lOM NaOH to ensure complete ionisation of tlie biogenic amine 
molecules. The solvent was then degassed with helium for 10 minutes in order to 
eliminate the presence of oxygen, which increase baseline noise. The mobile phase 
was renewed every two to three weeks depending on the degree of use.
iii) Pump: A computer-controlled HPLC pump (Gilson 302) fitted with a 
manometric module (Gilson 802) capable of producing high pressure (up to 6000 
psi) was used. The mobile phase was drawn into and delivered from the pump 
head (Gilson lO.WSC) through the inflow and outflow check valves. The flow 
rate was set at Iml/min during analysis. The system was set to a low flow rate of 
0 .2 ml/min when not in use.
iv) Sample loading: The supernatant sample or composite mixture was 
introduced into the column through an injection valve (Rheodyne 7125). The 
valve was turned from ‘load’ position to ‘inject’ position simultaneously with 'start 
command’ on the computer. The mobile phase was then delivered through the 
loop to carry the sample on to the analytical column. The injection port was 
always flushed with HPLC grade methanol prior to and after each sample injection.
v) Detector: An electrochemical detector (Model 141, Gilson) was used to 
quantitatively measure the sepaiated compounds. The ECD consisted of a carbon 
working electrode (BAS ME-1000), a platinum wire auxiliaiy electrode (BAS MF- 
2020) and a silver/silver chloride reference electrode (BAS RE-1 Ag/AgCl), which 
was immersed in a 3M solution of NaCl.
The cell consists of a Plexiglass block divided in half by a 0.2mm polytetra 
fluoroethylene (teflon) gasket. A flow cell with a volume of <lml, containing the 
glassy carbon working electrode, is formed by a slit (1.6X0.5cm) cut in the gasket.
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Figure 2 .7 , A schematic representation of the HPLC-ECD experimental set-up. The 
flow of the mobile phase is depicted by arrows. The supernatant sample is introduced 
to the system through the injection port. The mobile phase is delivered by the pump to 
carry the sample injected on to the analytical column. The separated compounds are 
then quantitatively detected by the ECD. Chromatograms are analysed and displayed 
by an integrating computer.
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Figure 2.8. a. Chromatogram of a composite mixture containing some of the major 
neurotransmitters and their metabolites (Ing/lOpl). b . A typical chromatogram ol a 
sample obtained from the ARN ol the rat hypothalamus.
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Electrochemical detection is based on the principle that compounds capable of 
oxidation or reduction in an electrical field result in the passage of current. The 
magnitude of this current is a measure of the quantity of compound oxidised or 
reduced. Each chemical reaction has a threshold voltage related to its Redox 
Potential and the potentiostat, a foim of feedback voltage control, allows this 
voltage to be set for the particular compound to be determined. This introduces 
some measure of selectivity into the system. For the catechol and indoleamines 
under investigation, a potential of +0.70V was used.
vi) Chromatogram; As oxidisable bands of each compound pass through the 
detector, the current (and resultant voltage) rises and falls, as a function of time, to 
yield a liquid-chromatography, electrochemical chromatogram (Figure 2.8. a, b). 
The first peak on the chromatogram is called the solvent front which has the 
shortest retention time and leaves the analytical column first. This is followed by 
DHPG, NA, ADR, DHBA, DA, 5-HIAA and finally 5-HT. As 5-HT remains in 
the column longest, it is susceptible to band broadening and the peak is short and 
broad compared to the rest. Therefore, compounds aie separated in order of 
decreasing polarity and increasing time. Chromatograms were analysed by an 
integrating computer (Hyundai HCM-428 Super VGA, with Gilson 712 HPLC 
application software) and quantified using the peak area ratio of DHBA to analyte 
method (Table 2.3.).
Specific hypothalamic regions were collected and kept at -80°C until assayed. At a 
later date (maximum two days later), lOOjxl of O.IM HCl was added to each 
sample, along with 50r1 of 3,4-dihydroxybenzylamine (DHBA: Ing). DHBA 
was used as an internal standard because it does not react with any of the biogenic 
amines in the samples and is veiy stable. Since it is added in known 
concentrations, peak area of DHBA can be used to calculate the concentrations of 
unknown amines. Samples were centrifuged at 3000rpm at 4°C for 10 mins in a 
Denley BR401 refrigerated centrifuge to ensure all the tissue was sedimented at the 
bottom of the tube. The samples were homogenised using a vortex mixer for 30 
seconds and then re-centrifuged (as above). The supernatants were transferred 
into fresh tubes and the remaining protein pellets were stored at -80°C until the 
protein assay was carried out.
82
10|il aliquots of supernatant were drawn off and injected on to the HPLC column. 
The concentrations of DHPG, NA, ADR, DA, 5-HIAA and 5-HT were 
simultaneously measured by the BCD. All samples were measured in duplicate.
The response of the HPLC system was checked by running composite mixtures of 
the amines under investigation in known concentrations each morning. Stock 
solutions of NA, DHPG, ADR, DA, 5-HIAA and 5-HT were made up in O.IM 
HCl to a final concentration of lng/10|il. They were kept at 4°C and renewed 
every two weeks. The amines in the samples were identified by the coincidence of 
their retention times with the known amines in the composite mixture. The ratio of 
the amine peak areas to the peak area of DHBA in the standard mixture indicates the 
percentage recovery at the detector. This ratio is known as the response factor. 
Addition of internal standard (Ing) to the samples thus allows the integrating 
computer to calculate the content of the amines in the samples by taking the ratio of 
the peak areas with the internal standard and incorporating the response factor. 
The mean amine concentration of each sample was calculated and is shown in Table 
2.3. The minimum detectable quantity of each of the biogenic amines was
4-5pg/10|il of supernatant, dependent on the noise level of the system.
Peak area of DHBA in composite mixtureResponse Factor (RF): ---------------------------------------------------
Peak area of amine in composite mixture
Peak ar ea of unknown in sample
Peak Concentration:   x RF x "*"DF
Peak ai’ea of DHBA in sample
Peak concentration
Final Amine Calculation:   (pg amine/|Lig protein)
Weight of protein
*DF: Dilution Factor i.e. 150/10 =15
Table 2.3. HPLC amine concentration calculations.
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Protein Estimation
The amount of brain tissue in the homogenate was estimated by its protein content. 
The protein content of the brain is fairly stable, and therefore the amount of protein 
in a sample is proportional to its brain tissue content. The tissue pellets remaining 
in the Eppendorf tubes after centrifugation were stored at -SO^C for protein 
determination by a modified method of Lowiy et al (1951).
A standard curve of protein concentrations versus absorbance at 595nm after 
reaction with Coomassie Blue G250 (Pierce, Life Science Laboratories Ltd., 
Luton, U.K.) was first obtained (Figure 2.9.). Known weights of bovine serum 
albumin (BSA) were prepared in a range of 0-200p,g by using O.IM sodium 
hydroxide (NaOH) and incubated overnight at 4°C. On the following morning, 
the BSA (100|il) was diluted to 0.9ml with distilled water. Then, 1ml of 
Coomassie Blue G250 was added and the absorbance at 595nm read immediately 
on an LKB Biochrom Ultrospec 4050 spectrophotometer. The blank solution 
consisted of 200pl of O.IM NaOH plus 1800jil of distilled water. The absorbance 
of each tube was read in duplicate and the mean used for the calculation.
The protein pellet remaining after the preparation of the supernatant for injection on 
to the HPLC column was dispersed in 210jxl O.IM NaOH by a vortex mixer (Hook 
& Tucker Instmments Ltd.) for 30-50 seconds and incubated overnight at 4^0. 
On the following day, duplicate 100|il samples were transferred to two separate 
tubes and each treated as described above for the standard BSA curve. The protein 
concentration in each tube was calculated by substitution of the absorbance into the 
regression equation of the standai'd curve. The protein content of the duplicate 
tubes were added together to give the total protein content of the original sample.
If the sample tissue content lay below two standard deviations of the mean and no 
tissue had been lost in the micropunch procedure itself, then it was assumed that 
the protein had been lost during the course of storage/assay/transfer of the samples 
and was replaced by the mean protein content of the aiea for the calculation of the 
amine concentrations.
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Amine Concentration Calculation
The total content of the individual amines in each sample was divided by the total 
protein content of the sample, or the mean protein concentration for the particular 
area, to give the concentration of each amine in the original tissue in pg amine/|Xg 
protein.
LH Radioimmunassay
The immunoreactivity of LH was used to determine its relative abundance in each 
of the serum samples using a homologous double antibody. The samples were 
assayed in duplicate and the standard curve in triplicate. The latter involved an 
eight point curve representing concentrations which ranged from 6.25pg/10|il to 
800pg/10p.l which was provided by a stock solution of LH (lOOng/ml). Three 
further sets of tirbes were set up as (1) total counts, (2) blank and (3) zero reference 
(Table 2.4.).
Reagents:
1) Merthiolated phosphate buffer; 8 .8 g NaCl (0,15M) and lOOmg Thiomersal were 
mixed well in 1 litre of distilled water on a stirrer, and the pH was adjusted to 7.0 
using IM sodium hydroxide (NaOH). Then, 20ml was discarded and 7.8ml 
NaH2PÛ4  (0.5M) and 12.2ml Na^HPO^ (0.5M) were added. Once made up, the 
solution was stored at 4°C.
2) 1% Egg white; this was prepared by dissolving Ig of egg albumin in 100ml 
merthiolated phosphate buffer (this had to be stirred very fast for a long period) and 
then filtering through acetone-washed glass wool. The pH was adjusted to 7.0 
using IM NaOH when necessary. This solution was stored at 4°C and made up 
freshly each week as required.
3) Serum diluent; 0.05M EDTA (disodium salt) was prepared with merthiolated 
phosphate buffer i.e. 1.86g EDTA in 60-80ml of merthiolated phosphate buffer. 
The volume was made up to 100ml with merthiolated phosphate buffer and pH was 
ensured to be at 7.0. This solution too was stored at 4°C. On the day of assay, 
2 % normal rabbit serum was added.
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4) LH standard; NIH - rLH - RP3 was used. 984ml of egg white-meithiolated 
phosphate buffer was added to 16|il aliquot of standard (lOOng/ml) which then 
gave a 160ng/ml (1600pg/10jxl) solution. This was then double diluted in egg 
white/merthiolated phosphate buffer to give the curve.
5) Antibody; NIH - rLH SIO was diluted to 1:60,000 with serum diluent so that on 
adding 50|il to each tube, a final diluent 1:180,000 was achieved.
6 ) Precipitating antibody; Donkey-anti-rabbit antibody (Guldhay Antisera Ltd.) was 
diluted to 1:24 with egg white-EDTA.
Protocol:
Day L
A  20|l i 1 sample was taken from each of the collected plasma which were then 
maintained in the tubes at similar' volumes with egg white/merthiolated phosphate 
buffer. Serum diluent was added to the blank (tube 2). This was composed of 
normal rabbit serum at a dilution of 1:400, and 0.5M EDTA in merthiolated 
phosphate buffer a pH of 7.0. 50|xl of the anti-serum (NIH-rLH-SlO) was added 
to all the tubes (except tube 1 and 2). The tubes were incubated at 4°C for 24 
hours.
Day 2.
Radiolabelled LH with total counts/min, of between 15-20,000/50|il was then 
added. Egg white/merthiolated phosphate buffer was used to achieve the cori'ect 
dilution and again the tubes were incubated at 4°C for a further 24 hours.
Day 3.
The precipitating serum, donkey-anti-rabbit immunoglobulin G, was used with 
0.1% NaNH] at a dilution of 1:24 in merthiolated phosphate buffer/EDTA.
Day 4.
500|il of egg white/merthiolated phosphate buffer was added to all the tubes 
(except tubel) which were then centrifuged at 4000rpm for one hour at 4°C. The 
supernatant was then drained and the sedimented pellets allowed to dry overnight. 
The totals were neither spun nor counted.
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Day 5.
The pellets were measured for LH radioactivity using an LKB rack gamma counter. 
The sensitivity of the assay was 10 pg/tube (Ing/ml) and the inter- and intra-assay 
co-efficients of variation were 8.0% and 9.5% respectively.
Tube No. No Sample
(Fl)
EW/MPS
(FD
SD
(fd
A/S
(Fl)
*LH
(Fl)
PPS
(Fl)
EW/MPS
(Fl)
1. Total 3 - - - - 50 - -
2. Blank 3 - 1 1 0 50 - 50 50 500
3. Zero 3 - 1 1 0 - 50 50 50 500
4-11. Curve I 3 1 0 1 0 0 - 50 50 50 500
12-n. Sample 2 2 0 1 0 0 - 50 50 50 500
Curve n 2 1 0 1 0 0 - 50 50 50 500
Table 2.4.  The schedule and reagents used for the assay. EW/MPS = egg 
white/merthiolated phosphate buffer; SD = serum diluent; A/S = anti-LH antibody 
in serum diluent; '"LH = *^ I^-LH; PPS = precipitating serum.
LH radioimmunassay reagents were obtained from the National Hormone and 
Pituitary Program (Baltimore, Maryland, USA).
Statistics
Tukey’s one-way analysis of vaiiance (MINITAB for Windows, 10) was 
performed on the hypothalamic monoamine results. When the F-test was 
significant, it was followed by the Kiuskal-Wallis non-parametric test in groups 
where standard deviations were lai'ge between means. The Mann-Whitney U test 
was utilised to analyse the 5-HT and 5-HIAA results obtained from the urethane- 
anaesthetised animals (Experiment I), because in some cases the levels of these 
amines were undetectable; these were entered into the data sheet as zero.
Turnover estimation
Concentrations of each neurotransmitter and metabolite were first worked out in pg 
amine/jLig protein as explained previously. The ratios of DHPG to NA and
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Figure 2.9. Standard curve of absorbance at 595nm after reaction with 
Coomassie Blue G250 versus concentration of bovine serum albumin (BSA).
5-HIAA to 5-HT were then calculated from the individual values obtained. The 
statistical analysis carried out on the results was as explained above.
Analysis o f  hormone results
In most cases, statistical analysis could not be performed on the LH results because 
of the lack of variables in the groups. In Experiment I, plasma LH levels were 
always below the limit of detection. In Experiment II, plasma LH levels were 
mostly undetectable in the drag-treated groups. Also, at some sampling intervals 
blood samples could not be obtained due to the spontaneous blockage of the 
cannula (see Tables 4.5. to 4.11.). ANOVA and Kraskal-Wallis non-parametric 
test were utilised to analyse the changes in plasma LH levels between the saline and 
diamorphine-treated groups in Experiment II. In these cases, individual values at 
all sampling intervals (between 15.00h and 19.00h) were used for comparisons. 
In Experiment III, plasma LH levels were mostly undetectable even in some of the 
control group animals (Tables 5.5 to 5.13).
EXPERIMENT I
Effects of various opioid agonists and antagonists on the 
hypothalamic monoamine concentrations during the p re­
ovulatory LH surge in the urethane-anaesthetised rat
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The GnRH pulse generator involves a complex neural circuitry and feedback 
effects of the gonadal steroids. EOPs have been reported to exert a profound 
inhibitory influence on LH release. Although direct connections have been 
demonstrated between the opioid peptidergic and GnRH neurons in the 
hypothalamus, effects of opioids on LH secretion appears to be indirect. It has 
been suggested that opioid inhibition of the pre-ovulatory LH surge involves 
alterations in the central monoaminergic neurotransmission.
This experiment was designed to investigate the effects of various selective opioid 
receptor agonists and antagonists, administered just before the critical period on the 
day of pro-oestrus, on hypothalamic monoamine concentrations and plasma LH 
levels in the intact female rat.
Any relationship between the opioid peptidergic system and the aminergic 
neurotransmitters in the MPOA, SCN, ME and ARN in the central regulation of 
LH secretion was also investigated. These specific hypothalamic regions were 
studied to establish the effective site of action of the opioids on the amine content 
and LH release.
This method was chosen such that it would allow us to serially collect blood 
samples throughout the afternoon of pro-oestrus for LH determination by RIA and 
to obtain specific regions of the hypothalamus by micropunch at the end of the LH 
surge.
Materials and Methods
Pro-oestrous rats were selected for experimentation in the morning. Following 
anaesthesia with urethane at around 1 2  noon, a heparinised cannula was inserted 
into the right carotid artery. The animals were injected IP with either diamorphine 
(3mg/kg), U-50488H (lOmg/kg), DPDPE (Img/kg), U-50488H plus MR2266 
(5mg/kg) or DPDPE plus ICI 174,864 (Img/kg) at 13.00h. Controls received 
physiological saline (1 ml/kg) IP alone.
Subsequently, tmnk blood (200p-l) was collected via the indwelling cannula at 
hourly intervals throughout the afternoon of pro-oestrus. The red blood cells were 
reconstituted with lOOql of warmed, heparinised saline (10 units/ml) and re­
injected through the cannula to maintain a constant plasma volume. The surgical
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anaesthesia was maintained by periodic IP injections of urethane. The animals 
were kept warm throughout the experiment by the use of a heating lamp and were 
killed by decapitation just after the final blood collection at 19.00h. The 
experimental design is explained in details in the Materials and Methods. The 
number of animals in each group is shown in the Tables and Figures.
Results
The monoamine results are summarised in Tables 3.1 to 3.4. and Figures 3.1 to 
3.14.
a) Noradrenaline
Control values found for NA concentrations (Mean ± SEM) in the MPOA, SCN, 
ME and ARN of the urethane-anaesthetised rats at 19.00h on pro-oestrus were
13.1 ± 1.2, 12.1 ±2.1, 13.6 ± 2.4 and 16.7 ±1 .5  pg/flg protein respectively.
(i) Diamorphine
Diamorphine did not significantly alter NA concentrations in the MPOA, SCN and 
ME, however, it significantly reduced the amine levels in the ARN compared to 
those seen in the control animals.
(ii) U-50488H
Similarly, this K-opioid agonist also significantly lowered NA concentrations in the 
ARN compared to the control group values, but it did not have any significant 
effect in the MPOA, SCN and ME.
(iii) U-50488H + MR2266
This treatment significantly increased NA levels in the SCN and ARN compared to 
the group which received U-50488H alone. The NA levels were not significantly 
changed in the MPOA and ME.
(iv) DPDPE
Administration of this ô-opioid agonist resulted in significant decreases in NA 
concentrations in the MPOA, SCN and ARN compared to the saline-treated 
animals, but it had no significant effect in the ME.
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(v) DPDPE + ICI 174,864
When DPDPE was co-administered with ICI 174,864, NA concentrations were 
significantly raised only in the SCN compared to the group receiving DPDPE 
alone. This treatment did not significantly alter the amine levels in the other 
hypothalamic regions examined.
b) 3,4-Dihydroxyphenylglycol
DHPG concentrations (Mean ± SEM) in the MPOA, SCN, ME and ARN of the 
urethane-anaesthetised control animals at 19.00h on pro-oestrus were 13.2 ± 2.3,
11.1 + 2.1, 15.0 ±3.1 and 11.0 ± 1.4 pg/pg protein respectively.
(i) Diamoiphine
DHPG concentrations were significantly reduced by the p-opioid agonist in the 
MPOA and ARN in comparison to the control values. Diamoiphine had no 
significant effect in the SCN and ME.
(ii) U-50488H
Administration of U-50488H brought about significant decreases in DHPG 
concentrations in the MPOA, ME and ARN compared to the saline-treated animals, 
but not in the SCN.
(iii) U-50488H + MR2266
Treatment with the K-opioid agonist and antagonist significantly increased DHPG 
levels only in the MPOA compared to the group which received U-50488H alone. 
The levels of this NA metabolite were not significantly altered in the SCN, ME and 
ARN.
(iv) DPDPE
DPDPE significantly lowered DHPG concentrations in all the hypothalamic regions 
examined compared to the values seen in the control animals.
(v) DPDPE + ICI 174,864
When DPDPE was co-administered with the Ô-opioid antagonist, DHPG levels 
were significantly elevated in the SCN and ARN compared to the group receiving 
DPDPE alone. However, this treatment had no significant effect in the MPOA and 
ME.
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c) Dopamine
Control values for DA concentrations (Mean ± SEM) in the MPOA, SCN, ME and 
ARN of the urethane-anaesthetised animals at 19.00h on pro-oestrus were 3.4 ± 
0.7, 4.2 ± 1.2, 9.3 ± 3.3 and 5.0 ± 0.9 pg/|lg protein respectively.
(i) Diamoiphine
DA levels were significantly decreased by diamorphine only in the ARN compared 
to the saline-treated animals. The amine levels were unaffected in the MPOA, 
SCN and ME in this group.
(ii) U-50488H
The K-opioid agonist significantly reduced DA concentrations only in the MPOA, 
but not in the SCN, ME and ARN, in comparison to the control values.
(iii) U-50488H + MR2266
Co-administration of U-50488H with MR2266 significantly reversed the inhibitory 
effects of U-50488H on DA concentrations in the MPOA. However, the amine 
levels were not significantly altered in the SCN, ME and ARN of this group.
(iv) DPDPE
Administiation of DPDPE produced significantly lower concentrations of DA in the 
MPOA, SCN and ARN compaied to the control group values. This 5-opioid 
agonist had no significant effect in the ME.
(v) DPDPE + ICI 174,864
This treatment did not significantly alter DA levels in any of the hypotlialamic 
regions examined.
d) 5-Hydroxyindoleacetic Acid
Concentrations (Mean ± SEM) of 5-HIAA in the MPOA, SCN, ME and ARN of 
the urethane-anaesthetised control animals at 19.00h on pro-oestrus were 1.1 ± 
0.8, 4.2 ± 3.5, 1.6 ± 0.6, 1.5 ± 0.7 pg/j-lg protein respectively.
(i) Diamorphine
(ii) U-50488H
(iii) U-50488H + MR2266
(iv) DPDPE
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(v) DPDPE + ICI 174,864
None of the above drug regimes did significantly affect 5-HIAA concentrations in 
any of the four hypothalamic areas studied.
e) Serotonin
Control values obtained for 5-HT in the MPOA, SCN, ME and ARN of the 
urethane-anaesthetised rats at 19.00h on pro-oestrus were 2.3 ± 1.0, 1.8 ± 0.8, 
2.6 ± 0.9 and 4.3 ±1.3 pg/|lg protein ± SEM respectively.
(i) Diamorphine
5-HT concentrations were not significantly changed by diamorphine in any of the 
hypothalamic regions examined.
(ii) U-50488H
The K-opioid agonist significantly reduced 5-HT levels in the MPOA and ARN 
compared to the saline-treated animals, but had no significant effect in the SCN and 
ME.
(iii) U-50488H + MR2266
When U-50488H was co-administered with MR2266, 5-HT concentrations were 
significantly raised in the MPOA and ME compared to the group receiving 
U-50488H alone. This treatment did not significantly change the indoleamine 
levels in the SCN and ARN.
(iv) DPDPE
Administration of the ô-opioid agonist caused significant reductions of 5-HT 
concentrations compared to those seen in the control animals in the ME and ARN, 
but had no significant effect in the MPOA and SCN.
(v) DPDPE + ICI 174,864
This treatment produced significantly higher concentrations of 5-HT only in the ME 
compared to the DPDPE-treated animals. However, the 5-HT levels were not 
significantly changed in the MPOA, SCN and ARN.
f) Ratio of DHPG/NA
Control group values for the ratio of DHPG/NA in tlie MPOA, SCN, ME and 
ARN of the urethane-anaesthetised animals at 19.00h on pro-oestrus were 1.001 ±
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0.119, 0.969 ± 0.171, 1.094 ± 0.100 and 0.678 ± 0.091 respectively (results 
expressed as Mean ± SEM).
(i) Diamoiphine
The |x-opioid agonist did not significantly alter the ratio of DHPG to NA in any of 
the hypothalamic region examined.
(ii) U-50488H
U-50488H significantly lowered the ration of DHPG/NA in the MPOA and ME 
compared to the control group values, but had no significant effect in the SCN and 
ARN.
(iii) U-50488H + MR2266
Co-administration of the K-agonist with the K-antagonist significantly increased the 
ratio of DHPG/NA only in the SCN compared to the group which received U- 
50488H alone. The ratio was unaffected in the MPOA, ME and ARN.
(iv) DPDPE
DPDPE significantly reduced the ratio of DHPG/NA compared to those seen in the 
saline-treated animals in the ME and ARN, but not in the MPOA and SCN.
(v) DPDPE + ICI 174,864
This treatment did not produce significant alterations in the ratio of DHPG/NA in 
any of the hypothalamic regions examined.
g) Ratio of 5-HIAA/5-HT
The ratio of 5-HIAA/5-HT in the MPOA, SCN, ME and ARN of the urethane- 
anaesthetised control group at 19.00h on pro-oestrus were 0.323 ± 0.144, 1.217 ± 
0.918, 0.712 ± 0.211 and 0.310 ± 0.129 respectively (results expressed as Mean 
± SEM).
(i) Diamoiphine
(ii) U-50488H
(iii) U-50488H + MR2266
(iv) DPDPE
(v) DPDPE + ICI 174,864
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None of these drag regimes significantly changed the ratio of 5-HIAA/5-HT in any 
of the four hypothalamic areas studied.
h) Luteinising Hormone
In none of the groups plasma LH levels were detectable (including the controls). 
When the opioid agonists were administered alone or co-adminstered with their 
respective antagonists, again no detectable changes in LH levels were found.
Discussion
Luteinising Hormone
In the present study, the expected pre-ovulatoiy LH surge was completely 
abolished for seven hours on the afternoon of pro-oestrus in the urethane- 
anaesthetised and saline-treated rats.
It has been reported that activation of both p- and K-opioid subtypes by specific 
agonists brings about an inhibition of LH surge (Dyer et al, 1988). However, 
administration of p-opioid agonists at low doses have been found to be stimulatory 
to LH release (Pang et al, 1977; Brown et al, 1994). Compared to work canied 
out p- and K-opioid subtypes, there have been less attempts to study the 
involvement of Ô-opioid subtypes in the central control of LH secretion. Only 
moderate doses of opioid agonists were employed in the present study. Plasma 
LH levels were found to be undetectable at all sampling intervals following the 
administration of diamorphine, U-50488H or DPDPE on the afternoon of pro­
oestrus. Moreover, co-administration of U-50488H with the specific K-opioid 
antagonist or of DPDPE with a selective ô-opioid antagonist did not bring about 
any detectable changes in LH levels either. Therefore, it is difficult to interpret 
these findings and draw any conclusions regarding which opioid receptor subtypes 
may be involved in opioid inhibition of the LH surge.
These results have led us to hypothesise that it was the urethane anaesthesia which 
inhibited the pre-ovulatory LH surge in even the control animals. Previously 
reported doses of urethane were used to induce surgical anaesthesia. Our attempt 
in employing urethane as an anaesthetic in neuroendocrine experiments was based 
on the reports of de Greef et al (1987), who claimed that the urethane
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administration did not prevent the LH surge. The clear discrepancies between 
these studies may be a result of the use of different strains of rats; the de Greef 
group used a hybrid strain, bred at their own institution. In addition, the rats were 
ovx and steroid-primed. It is possible that the ovx hybrid strain may be more 
susceptible to anaesthesia, or their neural circuitiy involved in the LH surge more 
resistant to pharmacological suppression, than the intact pro-oestrous Sprague- 
Dawley rats used in the present study.
However, the mechanisms by which urethane inhibits the LH surge are unknown. 
It could be either by reducing the responsiveness of the gonadotrophs to the 
hypothalamic GnRH or by altering the GnRH neuronal activity. Since urethane is 
a centrally-acting anaesthetic, it seems likely that its site of action would be within 
the brain. Indeed, it has recently been reported that urethane anaesthesia decreases 
neuronal activity by promoting expression of Fos protein in the rat CNS 
(Takayama et al, 1994). It appears that urethane anaesthesia may suppress the 
neural stimulus necessary for LH release. This therefore suggests that 13.00h, the 
time around which the animals were anaesthetised, is still within the critical period 
for the initiation of the pre-ovulatory LH surge on the early afternoon of pro- 
oestrus. It has previously been shown that drugs may abolish the LH surge and 
ovulation if administered during a paitieular time period on pro-oestrus (Everett et 
al, 1949). After this time, the LH surge has been found to be resistant to 
pharmacological blockade.
There have been many reports in the literature regarding the use of anaesthetics in 
neuroendocrine experiments and several anaesthetics are suspected to influence LH 
release in the female rat (Sherwood et al, 1980; Dyer and Mansfield, 1984; de 
Greef gf nZ, 1987; Hartman era/, 1989; Stratton and Coen, 1996). However, the 
results are conflicting. Kimura and Sano (1995) have suggested that separate 
GnRH pulse and surge generators exist in the brain. They demonstrated that 
pentobarbitone administered in the afternoon to ovx-steroid-primed rats inhibited 
the ensuing LH surge, while it had no effect on pulsatile LH release when given in 
the morning of the same day. Urethane may be similar since we have shown that 
it abolishes the LH surge, while others have found it did not prevent the occuixence 
of LH pulses although it reduced their amplitude (de Greef et al, 1987; Matzen et 
al, 1987). It is possible that urethane arrested the GnRH surge generator by 
decreasing the stimulatory noradienergic input, since it significantly reduced NA 
levels in all areas investigated. In a similar study, Hartman et al (1989) showed
that amplified LH release occurred in urethane-anaesthetised rats following icv 
infusion of exogenous NA. Even greater increases were found in plasma LH 
levels after electrochemical stimulation of the MPOA in conjunction with icv NA 
administration to these rats (Hartman et al, 1989). It seems therefore that the 
exogenous NA infusion may have replaced the loss in NA concentrations brought 
about by the urethane anaesthesia. Pentobarbitone and chloral hydrate have also 
been found to reduce NA turnover and release respectively, concomitant with their 
inhibition of the LH surge (Ranee and Barraclough, 1981).
Recently, it has been suggested that primary cause of LH pulse suppression in the 
anaesthetised animals may be hypothermia (Strutton and Coen, 1996). 
Administration of pentobarbitone at the standard laboratoiy temperature of 21®C 
induced hypothermia and a concunent inhibition of plasma LH levels in the female 
Wistar rats. However, when the same experiment was performed at an ambient 
temperature of 35°C, which precludes the induction of hyperthermia, the 
suppressive effects of pentobarbitone were no longer observed. This suggests that 
hypothermia may disrupt LH pulses. These findings would therefore point to the 
importance of ambient temperature during such experiments. In this study, the 
surgical anaesthesia and the experiments were performed at standard ambient 
temperature (21±1°C). The animals were kept warm by the use of a heating lamb 
throughout the experiment, however, the body temperature was not monitored. In 
a different study, pentobarbital has been shown to inhibit LH release by a non­
specific mechanism, inducing hypothermia in ovx rats (Simpkins and Katovich, 
1987). Since pentobarbitone decreases the hypothalamic NA activity (Ranee and 
Barraclough, 1981), it is possible that a reduction in the core temperature may 
reduce the noradrenergic input to the GnRH pulse generator. Interestingly, the 
same treatment had no inhibitory effects on LH secretion when the ovx rats were 
pre-treated with Eg and P. These observations thus demonstrate that the response 
of the GnRH neurons is dependent on the steroidal state of the animal (Simpkins 
and Katovich, 1987). It is thought that occurrence of a hypothermia in the present 
experiment was unlikely. Unrecognised hypothermic effects of the treatments may 
also have been the cause of the pulse suppression.
It is concluded from the present experiment that care should always be taken when 
using general anaesthetics in neuroendocrine studies. Ambient temperature may 
have crucial effects on the drag treatments.
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Hypothalamic Aminergic Activity
Monoamine content of the MPOA, SCN, ME and ARN was measured by the 
HPLC-ECD at 19.00h on the afternoon of pro-oestrus. Of the amines 
investigated, DHPG and 5-HIAA were the only metabolites which appeared within 
the detectable range of the HPLC-ECD system employed. When increased 
concentrations of NA were detected, raised levels of DHPG were almost always 
observed. This indicates that when the release of the neurotransmitter is elevated, 
its synthesis is also stimulated by an autoregulation mechanism (For review see 
Kruk and Pycock, 1993). Sui-prisingly, such a close relationship was not seen 
between the concentrations of 5-HT and 5-HIAA in most instances. Their levels 
were generally low and in some of the hypothalamic samples below the limit of 
detection. None of the DA metabolites could be detected in the present study. 
Therefore, the conclusions regarding the central dopaminergic transmission, if any, 
to be made from this experiment will solely be based on the neurotransmitter levels 
found. These premises will be reviewed in more detail in the General Discussion.
Opioid-induced decrease in the hypothalamic NA content and turnover has been 
reported (Dyer etal, 1988). It has also been demonstrated that moiphine inhibits 
electrically stimulated NA release from slices of MPOA in vitro (Diez-Guerra et al, 
1987). In the present study, DPDPE was the only drug which significantly 
reduced NA concentrations compaied to control group values in the MPOA. 
However, DHPG levels were significantly lowered by all three opioid receptor 
agonists investigated in this hypothalamic aiea. Moreover, the falls in the NA 
metabolite's concentrations were prevented by the selective K- and 6-opioid 
receptor antagonists following their co-administration with U-50488H and 
DPDPE, respectively. It has been shown that the noradrenergic nerve terminals 
contain a mixed population of the opioid receptors in the MPOA as well as in the 
several other hypothalamic areas. It is possible that although limited to some 
extent, the opioid peptides may have modulatory effects on the noradrenergic 
neurotransmission in this hypothalamic area. Since no detectable changes were 
observed in plasma LH levels in these animals, no coixelation can be made between 
the changes in the hypothalamic NA or DHPG concentrations and the GnRH 
secretory system.
Neither diamorphine nor U-50488H caused any significant changes in the NA 
levels in the SCN and ME. However, they both reduced NA levels in the ARN.
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It seems that both the opioid agonists have area-dependent inhibitory effects on the 
NA release. Surprisingly, the Ô-opioid agonist reduced the NA concentrations in 
the SCN and ARN, but was ineffective in the ME. Its effects were reversed by 
ICI 174,864 only in the SCN, indicating a specific ô-opioid modulation in this 
area. Indeed, the highest density of Ô-opioid binding has been visualised in the 
SCN (Desjardins et al, 1990). DHPG concentrations were selectively reduced by 
DPDPE in the SCN, ME and ARN, by U-50488H in the ME and ARN, by 
diamorphine only in the ARN. Administration of moiphine lowers the NA 
turnover in tlie hypothalamus (Kalra et al, 1989), but dual effects of K-opioid 
agonists have been reported (Brown et al, 1994). These results seem to favour a 
modulatory role for the jd- and K-opioid receptors on the noradrenergic 
neurotransmission in the ARN, however, it is difficult to compromise the findings 
from the other hypothalamic areas examined. Prevention of the decreases in the 
DHPG levels by the selective ô-antagonist would point to a specific ô-opioid action 
in the SCN and ARN.
It has been postulated that the opioid peptides have both stimulatoiy and inhibitory 
effects on the dopaminergic system. Administiation of morphine reduces DA 
synthesis and turnover in the ME by inhibiting activity of the TIDA neurons (Alper 
etal, 1980; Akabori and Barraclough, 1986). In vitro, the stimulation of both k -  
and [x-opioid receptors with their respective agonists decreases DA release from the 
MBH (Heijna etal, 1991). On the contrary, morphine has been shown to activate 
the incertohypothalamic dopaminergic neurons and increase the DA turnover 
(Gopalan etal, 1989a). In the present study, none of the dmg treatments had any 
significant effect on the dopaminergic activity in the SCN and ME. However, DA 
levels were selectively lowered by DPDPE in the MPOA and ARN and by 
diamoiphine only in the ARN. The only significant effect of the K-opioid agonist 
and antagonist on the DA levels was observed in the MPOA. This suggests a 
specific modulatory action of K-opioid receptors in this area. However, these 
results seem to be inconclusive regarding inhibition of the dopaminergic activity in 
discrete hypothalamic regions via specific opioid receptor subtypes.
An inhibitory action of opioid peptides on the serotonergic system in the brain has 
been suggested. Activation of K -, but not |.i-opioid receptors has been shown to 
decrease the response of 5-HT-sensitive neurons to electrical stimulation in the 
raphe nucleus (Pinnock, 1992). The presence of high numbers of various opioid 
receptors has been shown in this brain region (Mansour et al, 1988). Increased
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turnover of 5-HT has been observed in the SCN and AHA following 
administration of K-and a-, but not jx-opioid agonists (Gopalan et al, 1989b). 
However, the same treatments did not have any effect in the MPOA, ME and ARN. 
In the present study, none of the drug regimes employed significantly altered 
5-HIAA concentrations in any of the hypothalamic areas examined. The |x-agonist, 
diamorphine, was ineffective in causing any significant changes in hypothalamic 
5-HT levels. There were isolated area-dependent effects in the rats treated with the 
K- and 5-agonists. U-50488H reduced 5-HT levels in the MPOA and ARN; 
however, its effects were reversed by the K-antagonist in only the MPOA. 
DPDPE also lowered the 5-HT content in the ME and ARN and its inhibitory 
effects were prevented by the 5-opioid antagonist in only the ME. It is suggested 
that the serotonergic transmission may be selectively mediated by opioid receptors 
other than those of the |X-subtype. The nature of intermodulatory action between 
the opioidergic and serotonergic systems still remains to be investigated.
In general, the monoamine levels obtained from the urethane-anaesthetised animals 
have been found to be lower than those values seen in the conscious rats as 
reported in the next chapter. Since urethane anaesthesia has been observed to 
reduce neuronal activity in the CNS (Takayama et al, 1994), it is possible that 
urethane itself may have interfered with the monoaminergic systems. However, 
the mechanisms underlying these postulated effects are at present unknown.
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EXPERIMENT II
Effects of various opioid agonists and antagonists on the 
hypothalamic monoamine concentrations during the pre­
ovulatory LH surge in the freely moving conscious rat
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As explained in detail in the Introduction, release of the pre-ovulatory LH surge is 
regulated by a series of complex neuroendocrine mechanisms. It has been 
reported that monoaminergic neurotransmitters, particularly NA, play an important 
role in the generation of the LH surge. These neurotransmitters may mediate the 
inhibitory effects of the EOPs on LH secretion. Indeed, morphine-induced 
inhibition of the LH surge has been attributed to a reduction in NA levels in the 
preoptic-tuberal pathway of the hypothalamus. Furthermore, naloxone-induced 
LH stimulation can be prevented by prior administration of a-adrenergic blockers.
In the previous experiment, while we were attempting to study the effects of 
various opioid drugs on the hypothalamic monoamine concentrations and plasma 
LH levels in the anaesthetised rats on the afternoon of pro-oestrus, it became cleai* 
that urethane anaesthesia totally inhibited the expected pre-ovulatory LH surge. 
These initial findings then led us to use a modified method for blood sampling 
employing conscious animals.
The same objectives in the Experiment I were adopted in this experiment. Because 
of the unexpected interference by the urethane in Experiment I, no conclusions 
could be made regarding the opioid modulation of the hypothalamic monoamines in 
the control of the pre-ovulatory LH surge.
In the present experiment, the inter-relationship between the opioid and aminergic 
systems in the control of GnRH activity has been further investigated and the 
modulating effects of specific p.-, K- and 5-opioid receptor agonists and antagonists 
on hypothalamic monoaminergic content and LH release have been noted 
simultaneously. The investigation has been confined to the modulation of the pre­
ovulatory LH surge in conscious female rats on the day of pro-oestrus.
It was hoped that this modified method would allow us to avoid interference by the 
urethane-anaesthesia to the hypothalamo-pituitary axis while serially collecting 
blood samples throughout the afternoon of pro-oestrus for LH determination.
Materials and Methods
On the morning of pro-oestrus, rats were selected for experimentation. The right 
femoral artery was cannulated under halothane anaesthesia. The animals were 
allowed to recover and then early in the afternoon, just before the onset of the pre-
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ovulatoiy LH surge, were IP injected with either DPDPE (1 mg/kg), diamorphine 
(3mg/kg), U-50488H (lOmg/kg), DPDPE plus naloxone (lOmg/kg), diamorphine 
plus naloxone (15mg/kg) or U-50488H plus MR2266 (lOmg/kg). Controls 
received physiological saline (1 ml/kg) IP alone. The number of observation in 
each group is given in the Tables and Figures.
Blood samples (200pl) were withdrawn through the indwelling cannula at hourly 
intervals from freely-moving conscious animals throughout the afternoon and early 
evening of pro-oestrus. Only a small volume (20-30pl) of warmed, heparinised 
physiological saline was injected after each blood sample collection to maintain the 
cannula open. The animals were kept warm throughout the experiment by the use 
of a heating lamp and were killed by decapitation just after the final blood collection 
at 19.00h to obtain specific regions of the hypothalamus by micropunch. Only 
one or two rats were operated upon on the same day. All drug administrations 
were carried out under light halothane anaesthesia. More details on the 
methodology of this experiment are given in the Materials and Methods.
Results
The monoamine results of this experiment are summarised in the Tables 4,1 to 4.4 
and Figures 4.1 to 4.14.
a) Noradrenaline
Control group values for NA concentrations (Mean ± SEM) in the MPOA, SCN, 
ME and ARN of the conscious rats at 19,00h were 34.5 ± 1.5, 35.1 ± 2.5, 33.2 ± 
1.7 and 32.5 ± 1.6 pg/pg protein respectively.
(i) Diamorphine
This p-opioid agonist significantly decreased NA concentrations in all the 
hypothalamic regions examined compared to the control group values.
(ii) Diamorphine + Naloxone
Co-administration of diamorphine with naloxone significantly increased NA levels 
in all the hypothalamic regions examined compared to the diamorphine-treated 
animals. In this group, the NA concentrations were even higher than the control 
group values.
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(iii) U-50488H
NA concenti'ations were significantly lowered by U-50488H in the four 
hypothalamic regions examined compared to the saline-treated animals.
(iv) U-50488H + MR2266
When the K-opioid agonist was co-administered with MR2266, NA concentrations 
were significantly elevated in the SCN, ME and ARN compared to the group which 
received U-50488H alone. This treatment had no significant effect on the NA 
levels in the MPOA.
(v) DPDPE
DPDPE significantly reduced NA concentrations in all the hypothalamic regions 
examined compared to the control animals.
(vi) DPDPE + Naloxone
Treatment with DPDPE and naloxone caused significant increases of NA levels in 
the four hypothalamic areas studied in comparison to the DPDPE-treated group.
b) 3,4-Dihydroxyphenylglycol
DHPG concentrations (Mean ± SEM) in the MPOA, SCN, ME and ARN of the 
conscious control animals at 19.00h were 15.8 ± 1.9, 20.0 ± 1.5, 14.4 ± 1.6 and 
16.0 ± 2.0 pg/pg protein respectively.
(i) Diamorphine
Diamorphine administration brought about significant decreases of DHPG 
concentrations in all the hypothalamic regions examined compaied to those seen in 
the control animals.
(ii) Diamorphine + Naloxone
Naloxone significantly reversed the inhibitoiy effects of the p-opioid agonist on the 
DHPG concentrations in the MPOA, SCN, ME and ARN following its co­
administration with diamorphine.
(iii) U-50488H
The K-agonist significantly reduced concentrations of DHPG in all the 
hypothalamic regions examined compared to the saline-treated animals.
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(iv) U-50488H + MR2266
This treatment significantly raised DHPG levels in all four hypothalamic areas 
compared to the group which received U-50488H alone.
(v) DPDPE
The 0-opioid agonist significantly decreased DHPG concentrations in all the 
hypothalamic regions studied compared to those seen in the saline-treated animals.
(vi) DPDPE + Naloxone
DHPG levels were significantly elevated following co-administration of DPDPE 
with naloxone in the hypothalamus compared to those receiving DPDPE alone.
c) Dopamine
Control values for DA concentrations (Mean ± SEM) in the MPOA, SCN, ME and 
ARN of the conscious animals at 19.00h were 6.1 ± 0.8, 6.2 ± 1.1, 19.1 ± 1.6 
and 6.2 ±1.0 pg/pg protein respectively.
(i) Diamoiphine
DA levels were significantly reduced by the p-opioid agonist only in the MPOA 
compared to the control group values. They were unaffected in the SCN, ME and 
ARN of this group.
(ii) Diamoiphine + Naloxone
When naloxone was co-administered with diamoiphine, DA levels were 
significantly increased in all the hypothalamic regions examined compared to tire 
group which received diamoiphine alone.
(iii) U-50488H
The K-opioid agonist had no significant modulatory effects on DA concentrations in 
any of the hypothalamic areas examined.
(iv) U-50488H + MR2266
This treatment significantly raised DA concentrations only in the ME compared to 
the U-50488H-treated animals, but not in the MPOA, SCN and ARN of this 
group.
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(v) DPDPE
DPDPE significantly lowered DA levels in the MPOA, ME and ARN compared to 
those seen in the control group. However, DA levels were not significantly altered 
in the SCN.
(vi) DPDPE + Naloxone
DA concentrations were significantly increased following co-administration of 
DPDPE with naloxone in the MPOA, ME and ARN compared to those receiving 
DPDPE alone. There was no significant alteration of the DA levels in the SCN of 
this group.
d) 5-HydroxyindoIeacetic Acid
Concentrations (Mean ± SEM) of 5-HIAA in the MPOA, SCN, ME and ARN of 
the saline-treated conscious animals at 19.00h were 7.2 ± 0.9, 7.3± 1.3, 7.8 ± 
1.1, 6.7 ± 1.1 pg/pg protein respectively.
(i) Diamorphine
Diamoiphine significantly decreased 5-HIAA levels in the MPOA and ME 
compaied to the control group values. However, the 5-HIAA levels were 
unaffected in the SCN and ARN.
(ii) Diamoiphine + Naloxone
Treatment with naloxone plus diamoiphine significantly elevated concentrations of 
5-HIAA in the respective hypothalamic regions (MPOA and ME) compared to the 
group which received diamoiphine alone. Again, there was no alteration of the 
5-HIAA concentrations in the SCN and ARN.
(iii) U-50488H
The K-opioid agonist reduced 5-HIAA levels only in the ME compared to the 
saline-treated animals, but not in the MPOA, SCN and ARN.
(iv) U-50488H + MR2266
This tieatment significantly increased 5-HIAA concentrations only in the ARN 
compared to the U-50488H-treated animals, but it did not significantly affect those 
of the MPOA, SCN and ME in this group.
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(v) DPDPE
5-HIAA levels were significantly lowered following administration of DPDPE in 
the MPOA, ME and ARN compared to those values seen in the saline-treated 
animals. But they were not significantly altered in the SCN.
(vi) DPDPE + Naloxone
When DPDPE was co-administered with naloxone, 5-HIAA concentrations were 
significantly increased in all the hypothalamic regions examined compared to the 
group which received DPDPE alone.
e) Serotonin
Control values found for 5-HT in the MPOA, SCN, ME and ARN of the conscious 
rats at 19.00h were 8.7 ± 1.3, 6.2 ± 0.7, 7.7 ± 0.6 and 5.9 ± 0.6 pg/pg protein ± 
SEM respectively.
(i) Diamoiphine
5-HT concentrations were not significantly changed by diamorphine in any of the 
hypothalamic areas examined compared to those values seen in the controls.
(ii) Diamorphine + Naloxone
Co-administration of diamoiphine with naloxone had no significant effect of
5-HT levels in the MPOA, ME and ARN, but it significantly increased the 
indoleamine levels only in the SCN compaied to those receiving diamoiphine 
alone.
(iii) U-50488H
The K-opioid agonist did not significantly alter 5-HT concentrations in any of the 
hypothalamic ai*eas studied compared to the controls.
(iv) U-50488H + MR2266
5-HT levels were significantly elevated in the SCN and ARN, but significantly 
reduced in the MPOA following co-administration of the K-agonist with MR2266 
compared to the group which received U-50488H alone. This treatment had no 
significant effect in the ME of this group.
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(V) DPDPE
DPDPE significantly reduced 5-HT levels in the four hypothalamic areas compar ed 
to the control group values.
(vi) DPDPE + Naloxone
When DPDPE was co-administered with naloxone, 5-HT concentrations were 
significantly raised in all the hypothalamic regions examined compared to the 
DPDPE-treated animals.
e) Ratio of DHPG/NA
Control group values for the ratio of DHPG/NA in the MPOA, SCN, ME and 
ARN of the conscious animals at 19.00h were 0,452 ± 0.047, 0.589 ± 0.041, 
0.432 ± 0.039 and 0.498 ± 0.061 respectively (results expressed as Mean+SEM).
(i) Diamorphine
The p-opioid agonist significantly lowered the ratio of DHPG/NA in the MPOA, 
SCN, ARN and ME compared to the control group.
(ii) Diamorphine + Naloxone
Co-administration of diamorphine with naloxone increased the ratio of DHPG to 
NA in the MPOA, SCN and ARN compared to the group which received 
diamorphine alone. However, the ratio was unaffected in the ME of this group.
(iii) U-50488H
Administration of U-50488H brought about significant decreases of the ratio of 
DHPG/NA in the MPOA, SCN and ARN compaied to the saline-treated animals. 
The ratio was not significantly changed in the ME.
(iv) U-50488H + MR2266
Treatment with the K-opioid agonist plus MR2266 significantly raised the ratio of 
DHPG/NA in the MPOA, SCN and ME compared to those receiving U-50488H 
alone, but it had no effect in the ARN.
(v) DPDPE
The ratio of DHPG/NA was significantly decreased by DPDPE in the MPOA, SCN 
and ARN compared to the control group values. However, there was no 
significant alteration of the DHPG/NA ratio in the ME.
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(vi) DPDPE + Naloxone
This treatment caused no significant changes in the ratio of DHPG/NA in any of the 
four hypothalamic areas studied.
f) Ratio of 5-HIAA/5-HT
The ratio of 5-HIAA/5-HT in the MPOA, SCN, ME and ARN of the conscious 
control group at 19,00h were 0.962 ± 0.140, 1.311 ± 0.300, 1.172 ± 0.234 and 
1.379 ± 0.329 respectively (results expressed as Mean ± SEM).
(i) Diamoiphine
The ratio of 5-HIAA/5-HT was not significantly affected by diamoiphine in the 
SCN, ME and ARN, however, it was significantly reduced only in the MPOA 
compared to the control group values.
(ii) Diamoiphine + Naloxone
Treatment with diamoiphine plus naloxone produced a significantly higher ratio of
5-HIAA/5-HT in the MPOA compared to the group which received diamoiphine 
alone. However, the 5-HIAA/5-HT ratio was not significantly altered in the other 
hypothalamic ai'eas.
(iii) U-50488H
(iv) U-50488H + MR2266
(v) DPDPE
(vi) DPDPE + Naloxone
None of these dmg regimes significantly changed the ratio of 5-HIAA/5-HT in any 
of tlie hypothalamic regions examined.
g) Luteinising Hormone
LH results observed in individual animals are shown in the Tables 4.5 to 4.11. In 
the saline controls, plasma LH levels (ng/ml ± SEM) at the 15.00h, 16.00h, 
17.00h, IS.OOh and 19.00h sampling intervals on the afternoon of the pro-oestrus 
were 3.6 ± 1.5, 12.7 ± 4.4, 28.8 ± 8.6, 29.2 ± 8.7, 25.8 ± 6.5 respectively. 
Although the blood sampling commenced at 13.00h, we found no detectable 
changes in circulating LH levels before 15.00h. In some cases, although the 
indwelling cannula was heparinised, blood samples could not be obtained due to 
spontaneous blockage. In four out of 16 control animals no LH surge was seen.
129
Therefore, the mean values indicated above are taken from those in which the 
plasma LH levels were detectable.
(i) Diamorphine
The q-opioid agonist tended to suppress plasma LH levels. Some of the 
diamorphine-injected animals showed detectable changes in LH levels over the 
17.00h, IS.OOh and 19.00h sampling periods. These changes were not found to 
be statistically significant compared to the saline-treated group.
(ii) Diamoiphine + Naloxone
In some of the diamoiphine with naloxone co-administered animals, plasma LH 
concentrations were elevated over the 16.00h, 17.00h, IS.OOh, 19.00h sampling 
intervals.
(iii) U-50488H
Plasma LH levels were undetectable in all the K-agonist-injected animals
(p<0.001).
(iv) U-50488H + MR2266
In only one out of nine animals which received U-50488H with MR2266 LH surge 
was seen. In the remainder of the animals LH levels were all undetectable.
(v) DPDPE
The 0-opioid agonist either reduced or completely inhibited the pre-ovulatory LH 
surge (p<0.05). Plasma LH concentrations were below the limit of detection in 
eight out of 10 DPDPE-injected animals. Only in two animals, some rises in LH 
levels were observed over the 17.00h, IS.OOh and 19.00h sampling periods, but 
these increases did not reach the levels seen in the controls.
(vi) DPDPE 4- Naloxone
When naloxone was co-administered with DPDPE, plasma LH levels were elevated 
at various sampling intervals on the afternoon of pro-oestrus. In three out of eight 
animals in this group no LH surge occuiTcd.
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Discussion  
Luteinising Hormone
In the conscious group, the LH surge was seen in approximately 70% of the 
control animals (n:16). In these, it occurred late on the afternoon of pro-oestrus 
reaching a peak at 17.00-1 S.OOh and then beginning to decline. This indicates that 
there may be an increase in the GnRH discharge and also an enhanced response of 
the pituitary gonadotrophs to the GnRH signal on the afternoon of pro-oestrus. 
Although the blood sampling commenced at 1 S.OOh, there was no detectable 
changes in circulating LH levels before 1 S.OOh. This slight delay in the pre­
ovulatory LH surge could be a result of the mild stress caused by the surgery and 
by the halothane anaesthesia. The animals were operated upon on the late morning 
of pro-oestrus and the entire procedure did not take longer than 25 minutes. These 
LH results are consistent with those reported by Dow et al. (1994) using the same 
experimental technique. In their study, the LH surge was observed after 16.00h 
on the afternoon of pro-oestrus. Unexpectedly, in four (out of 16) control animals 
no rises in LH levels were seen over the hourly sampling periods. In some cases, 
the animals had to be handled for the collection of the blood samples. However, 
this was done very gently. Since vaginal smearing had been peifoimed on these 
rats for at least three weeks, it is thought that they would have been accustomed to 
handling. Perhaps, the surgery might have caused a degree of stress to these 
animals, however, the underlying basis for this effect is unclear. As it will be 
detailed later in this chapter, NA levels in the specific regions of the hypothalamus 
in these rats were also high.
The ability of K-, }X- and 6-opioid agonists to suppress the pre-ovulatory LH surge 
may result from the inhibition of the pituitary responsiveness to GnRH in the rats. 
The hypothalamus is densely populated by opioid receptors while the anterior 
pituitary contains only a very low density of these (Khachaturian et al, 1985). 
Since the opioids have been shown to have no direct action on LH release from the 
anterior pituitary (Bicknell, 1985), it is suggested that the opioid agonists under 
investigation in this study have exerted their inhibitory effects at the hypothalamic 
level. This is in line with the evidence that administration of morphine suppresses 
the release of GnRH (Mehmanesh et al, 1988) and naloxone infusion increases its 
secretion from the MBH-preoptic area in vitro (Leadem et al, 1985). 
Furthermore, stimulation of LH release by NA may be the consequence of
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hypersecretion of GnRH into the hypophyseal portal system (Negro-Vilar et al, 
1980).
It has been widely reported that administration of morphine inhibits the surge 
release of LH on the day of pro-oestrus (Leadem and Kalra, 1985; Pfeiffer et al, 
1987). Work from this laboratory has also shown that high doses of a long acting 
p-opioid agonist, duromorph, abolishes the LH surge when administered before 
the critical period on pro-oestrus (Brown et al, 1994). The present study confirms 
these findings that activation of the p-opioid receptors with diamorphine brings 
about the suppression of the pre-ovulatory LH surge. However, four of the 
diamorphine-treated animals (n: 10) showed some rises in LH levels during the 
17.00h, IS.QOh and 19.00h sampling periods, but these increases did not reach the 
levels seen in the responsive controls. This could imply a recovery in plasma LH 
levels, since diamoiphine is a rapid-acting drug. However, this supposition is 
unlikely because hypothalamic NA concentrations were still significantly lower at 
19.00h than those in the controls. Moreover, diamorphine is known to be more 
lipid soluble than morphine and is slowly metabolised to morphine, thus its higher 
concentrations occur in the CNS (Kruk and Pycock, 1993). It could also be that 
since the drugs were administered systemically, the effective dose acting upon the 
cential opioidergic system might, in these cases, have been low. It has been 
shown that low doses of morphine and duromorph stimulate the LH surge (Pang et 
al, 1977; Brown et al, 1994). Overall, these results also indicate that a decrease in 
the central opioidergic tone during the critical period on pro-oestrus is associated 
with the LH surge.
When diamorphine was co-administered with naloxone, the opioid inhibition of the 
LH release was prevented. This indicates that increased LH release results from 
the antagonism of EOP secretion by acting at post-synaptic q-receptors. Also, the 
inhibitory opioidergic tone, although decreased, is not totally eliminated during the 
critical period. Administration of naloxone alone has been shown to enhance the 
amplitude of the pre-ovulatory LH surge (Crowley, 1988; Kalra et al, 1989).
There are conflicting reports on the involvement of K-opioid receptors in the 
suppression of LH secretion. Inhibition of LH release occurs after administration 
of specific K-opioid agonists (Leadem and Yagenova, 1987; Gopalan et al, 1989a). 
However, the specificity of the K-opioid effect has been questioned since the 
[l-opioid antagonist, naloxone, reversed the K-agonist’s effects (Pfeiffer et al.
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1987). In the present study, the LH surge was completely abolished by a more 
selective K-agonist, Lf-50,488H, throughout the afternoon of pro-oestrus following 
its administration at 13.00h. These results thus provide further evidence for the 
involvement of the K-opioid receptor subtypes in the inhibition of LH secretion. 
Furthermore, the effect is thought to be exerted via the central noradrenergic 
system. The K-opioid action on LH release is also believed to be mediated at the 
level of the hypothalamus, since K-agonists have been shown to inhibit GnRH 
release in vitro (Leposavic et al, 1991). Contrary to the expectation, MR2266, a 
K-opioid receptor antagonist, failed to reverse the suppressive effects of U-50488H 
on plasma LH levels. Only one U-50488H plus MR2266-treated animal showed a 
LH surge late on the afternoon of pro-oestrus. It has previously been noted that 
MR2266 also failed to elevate LH levels in young rats (Cicero et al, 1988). It 
seems that this opioid antagonist either has no affinity for the K-opioid receptors or 
that the relevant EOP ligands are absent. Although the present results appear to 
suggest the participation of K-opioid receptors in the LH secretory systems, further 
studies, using more selective antagonists when they aie available may reveal 
additional information.
The significance of 6-opioid receptors in the regulation of LH release is poorly 
understood. Activation of the 6-opioid receptors have been shown to suppress 
GnRH and LH secretion on the day of pro-oestrus (Leadem and Yagenova, 1987). 
However, their involvement in this process has been questioned since a specific
6-opioid antagonist has failed to elevate plasma LH levels (Cicero et al, 1988; 
Leposavic et al, 1991). We have shown that administration of DPDPE, a 6-opioid 
agonist, reduced or completely blocked the pre-ovulatoiy LH surge. Recently 
there have been reports of cross-communication between the 6- and |X-opioid 
receptor subtypes in the brain (Stadimis and Young, 1992; Tray nor and Elliott, 
1993). In the present experiment, the tonic inhibition of the LH surge by DPDPE 
was largely reversed by naloxone, the non-specific opioid antagonist. These 
results therefore indicate that both jii- and 6-opioid receptors may mediate the 
inhibitory effects of DPDPE, Alternatively, naloxone may have affinity towards
6-opioid receptors along with its well-known actions at p,-opioid subtypes. The
6-opioid receptors may thus be involved in the neuroendocrine conti'ol of the pre­
ovulatory LH surge.
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In conclusion, the results from the present experiment indicate that opioidergic 
influence on the LH release is inhibitory and multiple opioid receptors may be 
involved in mediating these effects.
Hypothalamic Aminergic Activity
As stated in the Experiment I, DHPG and 5-HIAA were the only metabolites of the 
biogenic amines under investigation which appealed within the detectable limits of 
the HPLC-ECD system employed. When raised concentrations of NA or 5-HT 
were detected, increased levels of DHPG or 5-HIAA were almost always observed 
in the four hypothalamic regions studied. This indicates that when the release of 
the neurotransmitter is elevated, its synthesis is also stimulated by an autoregulation 
mechanism. These premises will be discussed in detail in the General Discussion 
chapter.
The results of this experiment show that the aminergic activity in the MPOA, SCN, 
ME and ARN of the rat hypothalamus is high at 19.00h on the afternoon of pro­
oestrus. Similarly, the opioid drugs administered before the critical period are able 
to extend their modulatoiy effects on the hypothalamic monoamine concentrations 
towards the end of the pre-ovulatory LH surge. It has already been demonstrated 
that the monoamine levels within the discrete hypothalamic ai'eas are high at early 
stages of pro-oestrus and during the afternoon LH surge (Barraclough et al, 1984; 
Dyer era/, 1988). These results indicate that the neural circuitry upon which the 
opioids exert their actions is still active even at the time of the LH surge. 
However, previous work from this laboratory has also shown that opioid agonists 
aie relatively ineffective at altering neurotransmitter levels at 1 S.OOh following their 
administration at 12.30h on the same day. It was thought that the drugs might 
have been metabolised to their inactive forms by this time. However, this 
supposition is unlikely as duromorph is known to have potent analgesic effects up 
to 24h and can be detected in the circulation throughout this period (Johnston, 
1990). Moreover, of all the opioid agents investigated, duromorph had the least 
effect on the biogenic amine concentrations (Brown et al, 1994). It thus appears 
that lack of effects of the opioids can not be attributed to breakdown during the 
course of experiment.
In the present experiment, plasma LH levels started to rise after 15.00h. It has 
been documented that in the rat the total pre-ovulatory LH surge occurs in about
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270 minutes (Barraclough et al, 1984). Increased NA release/tumover within the 
specific regions of the hypothalamus has been con-elated with the LH surge on the 
afternoon of pro-oestrus (Ranee and Barraclough, 1981). Therefore, it is expected 
to see such an enhanced activity in the central aminergic system even at 19.00h on 
the late afternoon of pro-oestrus.
In this study, all three opioid receptor agonists tested significantly reduced the NA 
content in all the hypothalamic areas examined concomitantly with the abolition of 
the pre-ovulatory LH surge. These dmg regimes also lowered DHPG levels, the 
NA metabolite, in the same hypothalamic regions. From this experiment, it is 
apparent that a close relationship exists between the increased NA release and 
turnover in the preoptico-MBH and the GnRH pulse generator which in turn 
induces the pulsatile secretion of the LH surge. It has previously been suggested 
that NA plays a crucial role in the generation of the pre-ovulatory LH surge 
(BaiTaclough et al, 1984; Ramirez et al, 1984). However, inhibitory effects of this 
catecholamine has also been reported in the absence of steroid milieu in the ovx rat 
(Dotti and Taleisnik, 1984; Bergen and Leung, 1987). It appears that the steroid 
hoimones determine the direction of NA action on the pulsatile LH release through 
their receptors on the noradrenergic nerve terminals (Sar, 1984; Lehman and 
Karsch, 1993). Phamiacological work by Kalra and Simpkins (1981) has 
provided indirect evidence for this hypothesis by showing that opioids inhibit tire 
positive feedback effects of E2 and P on LH release via their action on the 
noradrenergic system.
A considerable amount of literature available appears to attribute a greater 
significance to the activity of NA in the MPOA on LH release (Honma and Wuttke, 
1980; Grossman and Dyer, 1989). However, it has been suggested that the 
effective site of NA in evoking GnRH release is not solely the MPOA, but also 
involves other components of the preoptico-suprachiasmatic-tuberoinfundibular 
GnRH system (Barraclough, 1994). Noradrenergic nerve terminals have been 
observed to make synaptic contacts with the GnRH neurons in the MPOA and to a 
lesser extent with GnRH nerve terminals in the ARN and ME (Watanabe and 
Nakai, 1987). These results support the concept that NA concentrations were 
decreased by the opioid agonists and raised by their respective antagonists in the 
MPOA, SCN, ME and ARN. Changes in the NA content of the ME is also likely 
to affect GnRH release since this area is regarded as the final common pathway in 
regulating LH secretion. Indeed, increased NA activity within this hypothalamic
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ai'ea has been considered to be important in initiating the pre-ovulatory LH surge 
(Ranee a/, 1981).
The ability of morphine to suppress LH secretion has been shown in a variety of 
experimental conditions (see Kalra et al, 1989) and the effect has been attiibuted to 
an inhibition of release of NA from its nerve terminals (BaiTaclough, 1994). It has 
been demonstrated that naloxone is able to activate the brain catecholaminergic 
systems which in turn enhance the release of GnRH (Kalra and Kalra, 1985). The 
findings presented here indicate that naloxone negated the inhibitory influence of 
diamorphine on the concentrations of NA and its metabolite in all four areas 
studied. In some cases, in the diamoiphine+naloxone-treated group, amine levels 
were found to be even higher than those seen in the controls. Naloxone has been 
shown to have its own stimulatory action on NA release and/or turnover within the 
hypothalamus during the afternoon of pro-oestrus (Akabori and Barraclough, 
1986; Gopalan et al, 1989a). The presence of p-opioid receptors has been 
visualised in the hypothalamus as well as in the other brain areas (Mansour et al,
1988). In addition, the noradrenergic terminals contain a mixed population of 
opioid receptors. This provides a functional relationship between the 
noradrenergic and opioid peptidergic systems in the brain. It is therefore 
suggested that modulatory effects of opioids on the central noradrenergic 
neurotransmission aie exerted via the p-opioid subtypes, which is inhibitory.
U-50488H brought about significant decreases in both NA and DHPG levels in all 
the hypothalamic regions examined. When MR2266 was co-administered with 
this K-opioid agonist, the falls in both amine and metabolite concentrations were 
prevented in the SCN, ME and ARN, but not in the MPOA. The lack of effect of 
MR2266 was unexpected because the K-opioid receptors are found in the MPOA as 
well as in the other hypothalamic sites (Mansour et al, 1988). It has' been 
suggested that the EOPs alter NA neurotransmission by their action at pre-synaptic 
nerve terminals. Reduction of the amount of neurotransmitter released is a 
common feature of opioid action (Grossman and Dyer, 1989). It is thought that 
U-50488H lowers NA synthesis by inhibiting its release from the nerve terminals, 
as both NA and DHPG concentrations were reduced in parallel. Prevention of the 
falls in the amine levels by MR2266 would point to a specific K-opioid action in 
discrete hypothalamic aieas. It was also found that U-50488H lowered the ratio of 
DHPG/NA in the MPOA, SCN and ARN, but not in the ME. The K-opioid 
antagonist negated these effects of U-50488H. It also raised the ratio of
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DHPG/NA in the ME compai’ed to those values seen in the K-opioid agonist-treated 
animals. Previously, a highly selective K-agonist has been reported to cause a 
significant decrease in NA turnover in the SCN and VMH (Burkard, 1984).
The 5-opioid receptor agonist reduced the secretion of LH on the afternoon of pro­
oestrus and concomitantly decreased concentrations of both NA and its metabolite 
DHPG within the hypothalamus in a naloxone-reversible manner. In some cases, 
in the DPDPE+naloxone-treated group, amine levels were even higher than those 
values observed in the controls. DPDPE significantly lowered the ratio of 
DHPG/NA in the MPOA, SCN and ARN. The 5-opioid receptors have a more 
restricted distribution than those of p- and K-opioid receptors in the rat brain. 
Dense areas of 5-opioid receptors have been found in several other brain ai’eas 
including the brain stem. In the hypothalamus, the highest concentration of 
5-receptors have been located in the SCN and MPOA (Mansour et al, 1988; 
Desjardins et al, 1990). The 5-opioid receptors aie known to have great affinity 
towards enkephalin neurons (Traynor and Elliott, 1993). The presence of 
enkephalin-containing neurons in most hypothalamic regions, including the 
preoptic area, and in other brain aieas has been demonstrated (Schafer et al, 1991). 
In view of these reports and the present findings, it is suggested that the 6-opioid 
receptors have modulatory effects on NA release and turnover around the time of 
the pre-ovulatory LH surge.
The central dopaminergic system has been implicated in the regulation of LH 
release. However, its role in the intact female rat is less clear-cut, as it appeal's to 
have both stimulatory and inhibitory effects on LH release depending on the site of 
action (Ramirez et al, 1984; MacKenzie et al, 1988). Neurons of the TIDA 
dopaminergic system originate in the ARN and PeVN, and project to the ME 
(Lindvall and Bjorklund, 1982). A second group of DA neurons, the 
incertohypothalamic tract is of extrahypothalamic origin and projects principally to 
the MPOA. It has been suggested that DA is stimulatory in the MPOA (Kawakami 
et al, 1975) and ZI (MacKenzie et al, 1988) but inhibitory in the ARN and ME 
(Rose and Weick, 1986; He et al, 1994) to LH secretion. In this study, there were 
isolated area-dependent effects in the rats treated with diamorphine or DPDPE. 
We observed significant decreases in the DA levels in the MPOA following the 
administration of both diamoiphine and DPDPE and this was accompanied by tlie 
abolition of the LH surge. These suppressive effects of both \x~ and 6-opioid
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agonists were reversed by naloxone in the same hypothalamic region. This 
suggests that both ji- and 6-opioid receptors have inhibitory effects on the 
dopaminergic activity in this area. Interestingly, U-50488H did not alter DA levels 
in any of the hypothalamic areas examined. The co-administration of MR2266 
with U-50488H significantly elevated DA concentrations in the ME, however, this 
effect was not consistently seen in the other three areas. It might thus appear that 
the central dopaminergic system may not be involved in mediating the inhibitory 
effects of the K-opioid receptors on LH release. However, it has been reported 
that activation of K-opioid receptors reduces DA release from the MBH in vitro 
(Heijna et al, 1991) and inhibits the TIDA dopaminergic neurons (Manzanares et al, 
1992).
Systemic administration of morphine has been shown to lower the rate of synthesis 
and turnover of DA in the ME by inhibiting the activity of the TIDA neurons (Alper 
et al, 1980). Similarly p-endorphin decreases the hypothalamic DA release from 
the TIDA dopaminergic neurons (van Loon et al, 1980; Wilkes and Yen, 1980). 
On the contrary, the activity of the TIDA neurons has been reported to be increased 
following the activation of 6-opioid receptors (Manzanai*es et al, 1993). Of the 
opioid agonists investigated in this study, only DPDPE significantly reduced the 
concentrations of DA in both the ME and ARN. Further, the opioid inhibition of 
dopaminergic activity was prevented by naloxone in these areas. It is therefore 
suggested that opioidergic influence on DA release via the 6-opioid receptors is 
inhibitory. Although DA levels were also detected in the SCN, no significant 
alterations were found in this hypothalamic aiea following the administration of 
DPDPE alone or together with naloxone. This is surprising because the SCN is 
known to contain DA projections (Bjorklund et al, 1975).
The studies on the involvement of the serotonergic system upon LH release have 
been controversial; both a stimulatory and an inhibitory role of 5-HT on LH 
secretion have been reported (Vitale and Chiocchio, 1993; Rodriguez et al, 1994). 
5-HT may mediate, at least in part, the effects of the EOPs on the LH secretory 
systems. Morphine stimulates LH release in the presence of exogenous 5-HT, but 
is inhibitory in its absence (Lenahan et al, 1987). Synaptic contacts between the 
serotonergic terminals and immunoreactive GnRH perikarya have been visualised 
in the rat hypothalamus (Kiss and Halasz, 1985; King et al, 1986). The )i-opioid 
agonist, diamorphine reduced the LH surge in association but had no effect on 
5-HT levels in any of the four areas studied. However, it selectively decreased the
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concentrations of 5-HIAA in the MPOA and ME in a naloxone-reversible fashion. 
Moreover, the ratio of 5-HIAA/5-HT was also lowered in the MPOA, and the 
effect was negated by naloxone in this area. It has previously been suggested that 
naloxone enhancement of the pre-ovulatory LH surge is primarily mediated by 
5-HT in the MPOA (Brown et al, 1994). These results would point to a 
modulatory action of the |i-opioid subtype on the 5-HT metabolism (or turnover) in 
the MPOA and ME rather than its release from the nerve terminals. However, it 
was expected that the opioids would reduce not only the metabolism of this 
indoleamine but also its release as well.
Although U-50488H was very successful in blocking the LH surge, it did not alter 
the concentrations of 5-HT or its metabolite in any of the hypothalamic areas 
examined except that 5-HIAA levels were lowered in the ME. Interestingly, 5-HT 
levels were elevated in the MPOA, SCN and ARN following the co-administration 
of U-50488H with MR2266. This K-opioid antagonist also increased 
concentrations of 5-HIAA in only the ARN in comparison to those rats receiving 
U-50488H alone. Activation of K-opioid receptors has been shown to pre- 
synaptically inhibit 5-HT release in the DRN (Pinnock, 1992). The results of the 
present study were not consistent and difficult to interpret. Previous attempts to 
reveal the putative nature of interaction between K-opioid receptors and 
serotonergic neurotransmission have also been inconclusive (Gopalan et al, 
1989b). Perhaps direct infusion of opioid drugs into specific hypothalamic areas 
where rich serotonergic projections have been demonstrated (Steinbusch, 1984) 
would pinpoint the site of action of the K-opioid types on 5-HT release/turnover.
In this study, the most conclusive evidence for the serotonergic mediation of opioid 
inhibition of the pre-ovulatory LH surge resulted from experiments in which 
DPDPE was administered. This 6-opioid agonist significantly decreased 
concentrations of both 5-HT and its metabolite in parallel in all the hypothalamic 
regions examined (except 5-HIAA in the SCN) concomitant with the suppression 
of the LH surge. Furthermore, naloxone prevented these inhibitory actions of 
DPDPE in the MPOA, ME and ARN and SCN. However, the ratio of 5-HIAA/ 
5-HT was unaffected in the hypothalamus following administration of DPDPE 
alone or together with naloxone. These results thus provide the first direct 
evidence for 6-opioid modulation of 5-HT release and metabolism in the specific 
regions of the hypothalamus at the time of the afternoon LH surge. It is thought 
that DPDPE exerts its inhibitoi-y effects at pre-synaptic 5-HT terminals. It has
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been suggested that in the MBH, 5-HT exerts its inhibitory influence on LH 
secretion whereas the MPOA represents the region where the stimulatory effect 
takes place on the afternoon of pro-oestrus (King et al, 1986; Johnson and 
Crowley, 1986). On the other hand, it has also been shown that the DRN exerts a 
stimulatory influence on the pre-ovulatory LH surge by means of its serotonergic 
projections to the ME (Kerdelhue et al, 1989). Accordingly, 5-HT stimulates 
GnRH release from the ME in vitro (Vitale et al, 1986). Phaimacological 
manipulation with 5-HT antagonists blocks the LH surge and hence ovulation 
(Dow et al, 1994). The present study, together with the above reports, appear to 
suggest a stimulatory role for 5-HT in the generation of the pre-ovulatory LH 
surge. It may also be concluded that site of action of 5-HT is not only the MPOA, 
but also likely to be the ME, ARN and SCN.
In summary, we conclude that the inhibitory effects of the EOPs on the surge 
release of LH may be mediated in large part by NA, and also by DA and 5-HT. It 
appears that an increase in the hypothalamic NA activity may be a critical event in 
triggering the surge release of GnRH and LH. Both the dopaminergic and 
serotonergic neurotransmitter systems may facilitate the pre-ovulatory LH surge, 
although their effects ate thought to be minor in this process.
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Serum LH levels (ng/ml)
Animal
ID 13.00h 14 .00h 15 .00b 16 .00h 17 .00b 1 8 .00b 19 .00b
C-8 LOW LOW LOW NS NS LOW LOW
C-9 LOW LOW LOW 1.96 10.8 16.6 15.9
C-15 LOW LOW LOW LOW LOW LOW LOW
C-16 NS NS NS NS NS NS 10.2
C-23 LOW LOW LOW LOW LOW 3.3 2.8
C-27 LOW 1.66 NS NS NS NS NS
C-33 LOW LOW LOW LOW LOW LOW LOW
C-39 LOW 1.2 15.8 16.8 17.5 10.4 9.5
C-64 NS NS 2.38 31.6 64.5 NS 38.0
C-65 NS NS 3.26 36.4 65.0 50.7 38.5
C-67 NS NS 2.54 1.80 1.25 1.53 1.96
C-70 NS NS 1.84 2.5 34.78 45.84 46.14
C-73 NS NS 2.18 2.63 24.61 62.41 63.45
C-77 NS NS 1.4 8.0 1.6 NS NS
C-78 NS NS 1,5 NS NS NS 31.5
C-88 NS NS 1.38 12.7 1.44 NS 1.64
Table 4 .5 . Plasma LH levels (ng/ml) recorded in individual conscious animals at 
hourly intervals between 1 S.OOh and 19.00h on the afternoon of pro-oestms following 
intraperitoneal saline administration at 1 S.OOh. LOW: concentration below the limit of 
detection, NS: no sample obtained due to the spontaneous blockage of the indwelling 
cannula.
Serum LH levels (ng/m I)Animal
ID 13 .00b 14 .00b 1 5 .00b 16 .00h 17.00b 18 .00b 19 .00b
C-3 NS NS LOW LOW LOW LOW LOW
C-5 LOW LOW LOW LOW LOW LOW LOWC-34 LOW LOW LOW LOW LOW 10.7 9.2
C-35 LOW LOW LOW 5.06 16.5 11.5 9.8
C-38 NS LOW LOW LOW LOW NS 18.5
C-41 LOW LOW LOW LOW 28.8 24.4 16.8
C-47 LOW LOW LOW LOW 11.9 20.2 14.7
C-51 NS NS LOW LOW LOW LOW 1.20
C-58 NS NS 2.65 3.08 1.96 2.61 1.49
C-89 NS NS 1.69 2.89 2.21 2.47 1.53
Table 4 ,6 . Plasma LH levels (ng/ml) seen in individual animals at hourly intervals 
between 1 S.OOh and 19.00h on the afternoon of pro-oestrus following intraperitoneal 
diamoiphine administration at 1 S.OOh. LOW: concentration below the limit of detection, 
NS: no sample obtained due to the spontaneous blockage of the indwelling cannula.
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Serum LH levels (ng/ml)
Animal
ID 13.00b 1 4 .00b 15 .00b 16 .00h 17 .00b 18 .00b 19 .00b
E-40 NS LOW LOW LOW LOW LOW LOW
E-41 NS NS NS NS NS NS 5.2
E-50 NS LOW LOW NS NS NS LOW
E-53 NS LOW LOW LOW 11.75 18.7 22.35
E-55 NS 33.45 NS NS NS NS 7.10
E-56 NS LOW LOW 8.95 1 7.25 4.70 5.57
Table 4 .7 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 13.00h and 19.00h on the afternoon of pro-oestrus following 
intraperitoneal diamoiphine plus naloxone administration at 1 S.OOh. LOW: 
concentration below the limit of detection, NS: no sample obtained due to the 
spontaneous blockage of the indwelling cannula.
Serum LH levels (ng/ml)
Animal
ID 13 .00b 1 4 .00b 15 .00h 16 .00h 17.00b 18 .00h 19 .00b
C-2 NS NS LOW NS NS NS LOW
C-40 LOW LOW LOW LOW LOW 0.34 LOWC-42 0.4 LOW LOW LOW LOW LOW LOWC-44 LOW LOW LOW LOW LOW LOW LOW
C-49 LOW NS NS NS NS NS LOW
C-50 LOW LOW LOW LOW LOW LOW LOWC-56 NS NS LOW LOW LOW LOW LOW
C-59 NS NS LOW NS NS NS LOW
Table 4 .8 . Plasma LH levels (ng/ml) observed in individual animals at hourly 
intervals between 13.00h and 19.00h on the afternoon of pro-oestrus following 
intraperitoneal U-50488H administration at 13.00h. LOW: concentration below the limit 
of detection, NS: no sample obtained due to the spontaneous blockage of the indwelling 
cannula.
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Serum LH levels (ng/ml)
Animal
ID 13 .00h 14.00h 15 .00b 16 .00b 17 .00b 18 .00b 19 .00h
D-11 NS LOW LOW LOW LOW NS LOW
D-12 NS LOW LOW LOW LOW 5.2 19.5
D-13 NS LOW LOW LOW LOW NS LOW
D-15 NS LOW LOW LOW NS LOW LOW
D-17 NS LOW LOW LOW LOW NS LOW
D-19 NS LOW LOW LOW LOW NS LOW
D-21 NS LOW LOW LOW LOW LOW LOW
D-25 NS LOW NS NS NS NS LOW
D-28 NS LOW LOW LOW LOW LOW LOW
Table 4 .9 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 1 S.OOh and 19.00h on the afternoon of pro-oestrus following 
intraperitoneal U-50488H plus MR2266 administration at 1 S.OOh. LOW: concentration 
below the limit of detection, NS: no sample obtained due to the spontaneous blockage 
of the indwelling cannula.
Serum LH levels (ng/ml)
Animal
ID 13.00b 14.00b 15 .00h 16 .00b 17 .00b 1 8 .00b 19 .00hC-45 NS NS 5.9 18.7 18.8 NS 15.1
C-46 NS NS NS LOW NS NS LOWC-52 NS NS LOW LOW LOW LOW LOW
C-53 NS LOW LOW LOW LOW LOW LOW
C-54 NS NS LOW LOW 1.6 2.7 2.0
C-55 LOW LOW NS NS NS NS LOWC-60 NS LOW LOW LOW LOW NS LOWC-74 NS NS LOW LOW LOW LOW LOWC-83 LOW LOW 1.4 1.1 NS NS 1.3C-84 NS NS 2.2 NS NS NS 19.0
Table 4 .10 . Plasma LH levels (ng/ml) observed in individual animals at hourly 
intervals between 1 S.OOh and 19.00h on the afternoon of pro-oestrus following 
intraperitoneal DPDPE administration at 1 S.OOh. LOW: concentration below the limit of 
detection, NS: no sample obtained due to the spontaneous blockage of the indwelling 
cannula.
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Serum LH levels (ng/ml)
Animal
ID 13 .00b 14 .00b 15 .00b 16 .00b 17 .00b 18 .00b 19 .00b
D-49 LOW LOW 1.25 34.3 NS NS 44.3
D-50 NS LOW 1.0 0.5 LOW LOW LOW
D-54 LOW 0.5 2.6 NS 0.63 1.65 8.3
D-64 NS NS NS NS NS NS LOW
E-2 NS LOW 0.22 0.25 NS NS 12.0
E-19 NS LOW LOW LOW LOW NS 11.0
E-23 LOW 0.75 12.2 61.5 21.2 NS 16.0
E-29 NS LOW LOW NS NS NS LOW
Table 4 .1 1 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 1 S.OOh and 19.00h on the afternoon of pro-oestrus following 
intraperitoneal DPDPE plus naloxone administration at 1 S.OOh. LOW: concentration 
below the limit of detection, NS: no sample obtained due to the spontaneous blockage 
of the indwelling cannula.
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EXPERIMENT III
Opioid modulation of the hypothalamic monoamine content 
during the anticipated LH surge in the ovx and steroid- 
primed rat
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As detailed in the Introduction, opioid modulation of the central noradrenergic, 
dopaminergic and serotonergic systems has been reported. There is a bulk of 
evidence suggesting that activation of different opioid receptor subtypes brings 
about a reduction in the hypothalamic NA concentrations and opioid antagonists, 
such as naloxone, reverses these effects. It is well documented that NA may play 
a crucial role in the generation of the LH surge in the rat. Therefore, opioid- 
induced decreases in the hypothalamic NA content may account for the opioid 
suppression of the LH surge. However, the nature of interaction(s) between 
opioids, DA and 5-HT have been controversial. Both stimulatoiy and inhibitory 
actions of opioids on dopaminergic and serotonergic release and/or turnover in die 
MPOA, SCN, ME and ARN have been suggested. The results from Experiment 
II have shown that direction of opioid action on hypothalamic NA, DA and 5-HT 
release and/or turnover may be inhibitory at the time of the LH surge.
This experiment was undertaken to further investigate the effects of various 
selective opioid receptor agonists and antagonists on hypothalamic monoamine 
concentrations and plasma LH levels in the ovx and steroid-primed rat. Diugs or 
saline were centrally administered at 14.00h on the afternoon of the anticipated LH 
surge. It was expected that plasma LH levels would be elevated by prior 
administration of E2 plus P and the anticipated LH surge would be timed more 
precisely.
Some of the drugs (diamorphine, naloxone, DPDPE) selected for this experiment 
had already been used in Experiments I and/or It; in which they were injected IP at 
IB.OOh on the afternoon of pro-oestrus. In the present experiment, it was intended 
that icv infusion of these opioid agonists and their respective antagonists would 
demonstrate more clearly the mechanism(s) by which the neural control of LH 
secretion is exercised. It was also thought that the peptidergic ligands under 
investigation would act directly at the hypothalamic sites without, if any, a blood 
brain barrier following icv infusion.
M a te r ia ls  a n d  M e th o d s
The design of this experiment has already been explained in details in the Materials 
and Methods.
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Adult female Sprague/Dawley rats were ovx and allowed to recover for a period 
ranging between 10 to 21 days before use. They were subcutaneously injected 
with E2 48h before and P 4h prior to experimentation. On the afternoon of the 
anticipated LH surge, the animals were anaesthetised with Vetalar. A heparinised 
cannula (Portex, outside diameter 0.63mm) was inserted into the right femoral 
artery. The animals were then mounted on a stereotaxic frame and icv infused 
with either diamorphine (25|ig/10|il), U-69593 (50p.g/10|il), DPDPE (50p.g/10|il), 
diamorphine plus naloxone (60|ig/10|il), U-69593 plus MR1452 (lOOp.g/lOp.1), 
DPDPE plus ICI 154,129 (60|ig/10jxl) or DPDPE plus naloxone (60p,g/10p,l) at
14.00h on the afternoon of the anticipated LH surge. Controls received sterile 
saline (10|i.l) alone.
Tmnk blood (200fxl) was collected via the indwelling cannula at hourly intervals 
throughout the afternoon. Anaesthesia was maintained by periodic intramuscular 
injections of Vetalar. The animals were kept warm throughout the experiment by 
the use of a heating lamp and were killed by decapitation just after the final blood 
collection at 19.00h. The number of animals in each group is shown in the Tables 
and Figures.
Results
The monoamine results are summarised in Tables 5.1 to 5.5 and Figures 5.1 to 
5.16.
a) Noradrenaline
Control group values for the NA concentrations in the MPOA, SCN, ME and ARN 
at I9 .OOI1 were 59.7 ± 5.1, 58.2 ± 3.9, 54.6 ± 5.6 and 54.6 ± 4.1 pg/fig protein ± 
SEM respectively.
(i) Diamorphine
This p,-opioid agonist significantly reduced NA concentrations in all the 
hypothalamic regions examined in comparison to the saline controls.
(ii) Diamoiphine + Naloxone
When diamorphine was co-administered with naloxone, NA concentrations were 
significantly elevated in all the hypothalamic regions examined compared to the 
group which received diamoiphine alone.
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(iii) U-69593
This K-opioid agonist also significantly reduced NA levels in all four areas 
examined compai'ed to the controls.
(iv) U-69593 + MR1452
The K-opioid receptor antagonist significantly increased NA concentrations 
compared to the group receiving U-69593 alone in all four hypothalamic areas 
following its co-administration with U-69593.
(v) DPDPE
This 6-opioid agonist significantly lowered NA concentrations in all the 
hypothalamic regions examined compared to the saline-treated animals.
(vi) DPDPE + ICI 154,129
NA concentrations in all hypothalamic regions examined were significantly raised 
following the co-administration of DPDPE with the 6-opioid antagonist compared 
to the DPDPE-treated animals.
(vii) DPDPE 4- naloxone
NA levels in the four hypothalamic areas were significantly increased following the 
co-administration of DPDPE with naloxone compared to the DPDPE-treated group.
b) 3,4-Dihydroxyphenylglycol
Control values for DHPG concentrations in the MPOA, SCN, ME and ARN at 
19.00h were 22.9 ± 2.9, 20.6 ± 2.6, 25.8 + 4.5 and 23.1 ± 3.2 pg/|Llg protein ± 
SEM respectively.
(i) Diamorphine
Diamorphine significantly decreased DHPG concentrations in the hypothalamus 
compared to those seen in control animals.
(ii) Diamorphine + Naloxone
Treatment with diamorphine plus naloxone caused no significant changes in DHPG 
levels in any of the hypothalamic areas examined compared those animals which 
received only diamorphine.
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(iii) U-69593
DHPG concentrations were significantly reduced in the hypothalamus by the 
K-opioid agonist compared to the control values.
(iv) U-69593 + MR1452
The co-administration of the K-opioid agonist and antagonist resulted in significant 
increases in DHPG levels in the hypothalamus in comparison to the animals in (iii) 
above.
(v) DPDPE
DPDPE significantly decreased DHPG concentrations in all the hypothalamic 
regions examined compared to the saline-treated animals.
(vi) D P D P E ICI 154,129
When DPDPE was co-administered with ICI 154,129, DHPG levels were 
significantly elevated in the hypothalamus compared to those rats which received 
DPDPE alone.
(vii) DPDPE + Naloxone
The treatment with DPDPE plus naloxone had no significant effects on DHPG 
levels in the MPOA, SCN or ARN, but levels in the ME were significantly raised 
in comparison to the group receiving DPDPE alone.
c) Dopamine
Dopamine levels (Mean ± SEM) in the MPOA, SCN, ME and ARN of the control 
animals at 19.00h were 9.9 ± 1.1, 9.9 ± 1.0, 38.2 ± 3.8 and 10.1 ± 1.1 pg/|xg 
protein respectively.
(i) Diamorphine
Diamorphine significantly reduced DA levels in the MPOA, SCN and ME in 
comparison to saline-treated animals. However, there was no statistically 
significant alteration of DA levels in the ARN.
(ii) Diamoiphine + Naloxone
DA concentrations were significantly increased in the MPOA, SCN and ME 
compared to diamorphine-treated animals following the co-administration of
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diamorphine with naloxone. Again, the DA levels were not significantly altered in 
the ARN of this group.
(iii) U-69593
The K-opioid agonist caused significant decreases in the DA concentrations in all 
hypothalamic areas examined in comparison to control group values,
(iv) U-69593 + MR1452
When U-69593 was co-administered with MR1452, DA levels were significantly 
elevated in the hypothalamus compared to values seen in the U-69593-treated 
animals.
(v) DPDPE
The 6-opioid receptor agonist significantly decreased DA concentrations in the 
hypothalamus compared to the controls.
(vi) DPDPE+ IC I154,129
Treatment with the 6-opioid agonist plus ICI 154,129 had no significant effects on 
DA levels in any of the hypothalamic regions examined.
(vii) DPDPE + naloxone
DA concentrations were significantly elevated following the co-administration of 
DPDPE plus naloxone in the MPOA, SCN and ME compared to the group which 
received DPDPE alone, but levels in the ARN were not significantly altered.
d) 5-Hydroxyindoleacetic Acid
Concentrations of 5-HIAA (Mean ± SEM) in the MPOA, SCN, ME and ARN of 
the control animals at 19.00h were 16.1 ± 2.7, 13.3 ± 1.8, 13.2 ± 1.8, 12.1 ± 2.1 
pg/jxg protein respectively.
(i) Diamorphine
Diamorphine brought about significant decreases of 5-HIAA concentrations only in 
the MPOA compared to the control group values.
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(ii) Diamoiphine + Naloxone
5-HIAA levels were significantly elevated following the co-administration of 
diamoiphine plus naloxone in all hypothalamic regions examined in comparison to 
the diamorphine-treated animals.
(iii) U-69593
This K-opioid agonist significantly reduced concentrations of 5-HIAA in the 
MPOA, SCN and ME compared to values seen in the saline-treated animals. 
However, 5-HIAA levels were not significantly altered in the ARN.
(iv) U-69593+MR1452
When U-69593 was co-administered with MR1452, 5-HIAA concentrations were 
significantly increased in all hypothalamic areas examined compared to the group 
which received U-69593 alone.
(v) DPDPE
Administration of the 5-opioid agonist resulted in significant decreases in the 
5-HIAA levels in the MPOA and ARN compared to the control group. However, 
DPDPE had no significant effect on the 5-HIAA concentrations in the SCN and 
ME.
(vi) DPDPE + ICI 154,129
The CO-administration of DPDPE and ICI 154,129 caused no significant changes of 
5-HIAA concentrations in any of the hypothalamic regions examined.
(vii) DPDPE + Naloxone
5-HIAA levels were significantly increased following the co-administration of 
DPDPE and naloxone in all hypothalamic regions examined compared to the 
DPDPE-treated animals.
e) Serotonin
Control values (Mean ± SEM) found for 5-HT in the MPOA, SCN, ME and ARN 
at 19.00h were 16.0 ± 1.9, 15.3 ± 1.7, 14.5 ± 1.4 and 14.5 ± 2.0 pg/pg protein 
respectively.
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(i) Diamoiphine
This p-opioid receptor agonist significantly reduced concentrations of 5-HT in the 
hypothalamus compared to values recorded in the saline-treated animals.
(ii) Diamorphine + Naloxone
When diamorphine was co-administered with naloxone, 5-HT levels were 
significantly elevated in the MPOA, ME and ARN in comparison to the 
diamoiphine-treated group, but they were not significantly affected in the SCN.
(iii) U-69593
U-69593 caused significant decreases of the 5-HT concentrations in the 
hypothalamus compared to the control group values.
(iv) U-69593+ MR1452
5-HT levels were significantly raised in the hypothalamus following the co­
administration of the K-opioid agonist with MR1452 compared to the group which 
received U-69593 alone.
(v) DPDPE
DPDPE significantly reduced 5-HT concentrations in the SCN, ME and ARN 
compared to levels observed in the saline-treated animals. However, there was no 
significant effect in the MPOA.
(vi) DPDPE + ICI 154,129
When DPDPE was co-administered with the 5-opioid receptor antagonist, 5-HT 
concentrations remained unaffacted in the SCN, ME and ARN, but were 
significantly decreased in the MPOA compared to the DPDPE-treated animals.
(vii) DPDPE + Naloxone
Co-administration of DPDPE with naloxone significantly increased the 
concentrations of 5-HT in all hypothalamic areas examined in comparison to 
DPDPE-treated animals.
e) Ratio of 5-HIAA/5-HT
The ratio of 5-HIAA/5-HT in the MPOA, SCN, ME and ARN of the control group 
at 19.00h were 1.209 ± 0.262, 0.811 ± 0.093, 0.919 ± 0.103 and 0.881 ± 0.157 
respectively (results expressed as Mean ± SEM).
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(i) Diamoiphine
The ratio of 5-HIAA/5-HT was not significantly affected by diamoiphine in any of 
the hypothalamic regions examined.
(ii) Diamorphine + Naloxone
Naloxone significantly increased the 5-HIAA/5-HT ratio after its co-administration 
with diamorphine, in the MPOA, ME and ARN compared to the group which 
received diamorphine alone. However, this tieatment had no significant effect on 
the ratio of 5-HIAA/5-HT in the SCN.
(iii) U-69593
The K-opioid agonist caused no significant changes in the ratio of 5-HIAA/5-HT in 
any of the hypothalamic aieas studied.
(iv) U-69593+ MR1452
The co-administration of U-69593 with MR1452 likewise had no significant effect 
on the ratio of 5-HIAA/5-HT in any of the four areas examined.
(v) DPDPE
DPDPE significantly increased the ratio of 5-HIAA to 5-HT in only the ME 
compared to control group values.
(vi) DPDPE + ICI 154,129
This treatment resulted in a significant increase in the ratio of 5-HIAA/5-HT in tlie 
MPOA and ARN compared to the DPDPE-treated animals, but not in the SCN or 
ME.
(vii) DPDPE + Naloxone
When DPDPE was co-administered with naloxone, the ratio of 5-HIAA/5-HT was 
significantly increased only in the MPOA and ARN, but not in the SCN and ME, 
compared to the group which received DPDPE alone.
f) Ratio of DHPG/NA
The control group values for the ratio of DHPG/NA in the MPOA, SCN, ME and 
ARN at 19.00h were 0.388 ± 0.034, 0.367 ± 0.039, 0.467 ± 0.063 and 0.424 ± 
0.046 respectively (results expressed as Mean ± SEM).
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(i) Diamoiphine (ii) Diamorphine + Naloxone
Neither the p-opioid agonist alone nor its co-administration with naloxone 
significantly altered the ratio of DHPG/NA in any of the hypothalamic regions 
examined.
(iii) U-69593
U-69593 significantly lowered the ratio of DHPG/NA in the hypothalamus 
compared to control group values.
(iv) U-69593 + MR1452
When the K-opioid agonist was co-administered with MR 1452, the ratio of 
DHPG/NA was significantly increased in the MPOA and SCN, but not in the ME 
and ARN, compared to values seen in the U-69593-treated group.
(v) DPDPE (vi) DPDPE + ICI 154,129 (vii) DPDPE + Naloxone
None of these treatments significantly altered the ratio of DHPG/NA in any of the 
hypothalamic areas studied.
g) Luteinising Hormone
Results are shown in Tables 5.5 to 5.14.
In some of the control animals (eight out of 15) there were rises in plasma LH 
levels at various times on the afternoon of the anticipated LH surge. However, in 
the remainder of the saline-treated animals LH levels were undetectable.
(i) Diamoiphine
Although some rises in plasma LH levels were seen in the diamorphine-treated rats, 
these were not different from those seen in the controls.
(ii) Diamoiphine + Naloxone, (iii) U-69593, (iv) U-69593 f  MR1452, (v) 
DPDPE, (vi) DPDPE + ICI 154,129, (vii) DPDPE + Naloxone
None of these treatments had any significant effect on plasma LH levels. In most 
instances LH levels were undetectable.
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Discussion  
Luteinising Hormone
In the present experiment, the animals were anaesthetised with Vetalar (ketamine) 
in order to perform icv infusion of the opioid agents under investigation. Since it 
appeared from the work described in Experiment I that urethane disrupted the 
expected pre-ovulatory LH surge, a careful selection of anaesthetics for this 
experiment had to be made. Following a detailed literature search, saffan and 
ketamine were chosen so that they would have the least effect on hoimone secretion 
patterns. However, preliminaiy studies using both anaesthetics showed that 
plasma LH levels in the saffan-anaesthetised rats were very low while they seemed 
less affected by ketamine anaesthesia. Previous work from this laboratory had 
produced inconsistent results using saffan anaesthesia. Vetalar was therefore 
selected to anaesthetise the animals throughout Experiment III.
There were some rises in plasma LH levels in seven out of 15 control animals. 
However, in the remainder and also in the various opioid agonist and antagonist- 
treated groups LH levels were consistently either low or below the limit of 
detection. Interestingly, two of the diamoiphine-treated animals showed some 
rises in LH levels at the 17.00h, IS.OOh and 19.00h sampling intervals.
It has been documented that activation of both p.- and K-opioid subtypes by specific 
agonists brings about an inhibition of the LH surge (Grossman and Dyer, 1989). 
These effects were confirmed in Experiment II. It was also observed that the 
selective 5-opioid receptor agonist, DPDPE, is as effective as the p- and K-agonists 
in suppressing the LH surge. In this experiment, only moderate doses of 
diamorphine, U-69593 and DPDPE were administered icv to the ovx and steroid- 
primed rats to further elaborate the participation of multiple opioid subtypes in the 
central regulation of LH release. Plasma LH levels were found to be either low or 
undetectable at all sampling intervals following the administration of diamoiphine, 
U-69593 or DPDPE on the afternoon of the anticipated LH surge. These findings 
were expected and confirmed the inhibitory effects of the EOPs on pulsatile LH 
secretion. However, when all three opioid agonists were co-infused into the 
lateral ventricle with their respective antagonists, the anticipated rises in plasma LH 
concentrations were not observed. Naloxone is able to overcome moiphine- 
induced suppression of the LH surge (Piva et al, 1985; Allen et al, 1987). It also
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reversed the inhibitory effects of DPDPE in the conscious animal model as reported 
in Experiment II. Here, naloxone and two other opioid receptor antagonists 
studied, MR1452 and ICI 154,129, failed to elevate plasma LH levels in tlie 
ketamine-anaesthetised animals. It is therefore difficult to interpret these results 
and draw any conclusions regaiding specific actions of different opioid receptor 
subtypes on the anticipated LH surge.
There have been previous reports in the literature on the use of ketamine and saffan 
as anaesthetic agents in neuroendocrine experiments (Sherwood et al, 1980; Ching, 
1982; Matzen et al, 1987; Hartman et al, 1989). It has been claimed that in 
ketamine-anaesthetised rats, peak LH responses are not significantly different from 
those in unanaesthetised control animals (Hartman et al, 1989). Furthermore, in 
the latter study ketamine appealed to have no effect upon the NA-induced LH 
surge. It has also been reported that ketamine and saffan do not significantly 
influence plasma LH levels in the male rat (Matzen et al, 1987). Previously, the 
GnRH rise measured in the hypothalamo-hypophyseal portal blood under ketamine 
and/or saffan anaesthesia has been found to be of sufficient magnitude to initiate the 
spontaneous LH surge in the pro-oestrous rat (Sherwood et al, 1980; Ching, 
1982). In contrast to earlier findings, the results described here have indicated that 
both saffan and ketamine administration either abolished or greatly reduced the 
anticipated LH surge, but did not alter hypothalamic NA release and/or turnover. 
This is surprising, because a reduction in LH release is usually associated with a 
fall in hypothalamic NA activity and a decrease in GnRH secretion into tlie 
hypophyseal portal blood vessels (for review see Ramirez et al, 1984; Barraclough, 
1994; the current Introduction). However, it would appear that under the ketamine 
and saffan anaesthesia utilised in this experiment, the GnRH pulse generator and its 
essential component, the central noradrenergic system, were unaffected. Instead 
of acting at the hypothalamic level, perhaps these anaesthetics inhibited the LH 
surge by reducing the pituitary responsiveness to the GnRH discharge. 
Nevertheless, the mechanisms by which saffan and ketamine might produce such 
effects are currently unknown.
As mentioned earlier in Experiment I, hypothermia has been postulated as the 
primary cause of LH pulse suppression in anaesthetised animals. It is unlikely that 
hypothermia occurred under ketamine anaesthesia since the animals were kept 
warm by the use of a heating lamb throughout this experiment. Also, amongst a 
number of anaesthetics, ketamine has been shown to have the least effects on the
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core temperature (Wixson et al, 1987). Furthermore, this anaesthetic causes 
minimal respiratory depression and therefore minimal hypoxia. Indeed, no 
anaesthetic-related mortality was observed during the entire course of the 
experiment. Unrecognised hypothermic effects of drug treatments may also 
suppress LH pulses (Strutton and Coen, 1996). However, those drugs employed 
in the present study are unlikely to have caused hypothermia since they were 
infused icv. Previously, opioids have been shown to inhibit LH secretion without 
having hypothermic effects following icv administration (Leadem and Kalra, 1985; 
Jansky, 1990).
In conclusion, it is thought that the ketamine anaesthesia may abolish the 
anticipated LH surge by reducing the pituitaiy responsiveness to GnRH release. 
Although ketamine has been suggested as a safe anaesthetic with the least effects on 
the LH secretoi-y systems compared to other anaesthetics (Hartman et al, 1989), 
care should always be taken when using general anaesthetics in neuroendocrine 
studies.
Hypothalamic Aminergic Activity
It has been confirmed in this experiment that following icv infusion of opioid 
agonists and antagonists at the time of the anticipated LH surge, the release and/or 
turnover of biogenic amines in the specific hypothalamic regions is inhibited. 
Furthermore, it appears that these inhibitory effects on aminergic 
neurotransmission are exerted via multiple opioid receptor subtypes.
Administration of diamorphine significantly decreased concentrations of both NA 
and DHPG in all four areas studied. Naloxone antagonised the effects of the 
p,-opioid agonist on NA content of the hypothalamus, but had no effect on its 
metabolite (DHPG) levels. However, the ratio of DHPG/NA was significantly 
elevated in all the hypothalamic regions examined after the co-administration of 
naloxone with diamorphine. These results aie consistent with previous reports 
suggesting that opioids inhibit NA release and/or turnover via opioidergic receptors 
located at the noradrenergic nerve terminals (Grossman and Dyer, 1989). 
Morphine decreases noradrenergic activity in the MPOA and ME of ovx and 
steroid-primed rats (Akabori and Barraclough, 1986). In vitro, activation of 
p- and 5-opioid receptors inhibits electrically-stimulated release of NA from slices 
of the MPOA (Diez-Guerra et al, 1987). Naloxone has been shown to stimulate
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NÂ release within the hypothalamus (Nishihara et al, 1991). It is thus confirmed 
that opioid modulation of the noradrenergic neurotransmission via p-opioid 
subtypes is inhibitory.
There have been several attempts to demonstrate the involvement of the K-opioid 
subtypes in the modulation of NA neuronal activity within the hypothalamus. 
Activation of K-opioid receptors has been shown to cause a significant decrease in 
NA turnover in the SCN and VMH (Burkard, 1984). It has also been reported 
that K-opioid agonists increase NA turnover in the whole hypothalamus (Gopalan 
et al, 1989a). However, it should be noted that by measuring amine levels in the 
entire hypothalamus, it is not possible to localise the effects of a particular drug, the 
actions of which may differ in specific regions. The results of the present 
experiment have indicated that icv infusion of a selective K-agonist, U-69593, 
reduces NA release and turnover in the MPOA, SCN, ME and ARN. Therefore, it 
is suggested that, consistent with previous findings (Experiment II), K-opioid 
influence on the noradrenergic system is inhibitory. Prevention of the decreases in 
the concentrations of both NA and DHPG by the K-antagonist, MR1452 would 
point to a specific K-opioid action.
The 5-agonist, DPDPE, reduced levels of NA and DHPG in paiallel within all the 
hypothalamic regions examined. These findings appear to support the concept that 
5-opioid receptors may also have inhibitoiy effects on NA release and turnover at 
the time of the LH surge. Naloxone, the non-selective opioid antagonist, 
prevented these suppressive effects of DPDPE. Due to the putative cross­
communication between \i- and 5-opioid subtypes (Stadimis and Young, 1992; 
Tray nor and Elliott, 1993), it was suggested that both receptor types could be 
involved in mediating the effects of DPDPE on NA neuronal activity (Experiment 
II). The results of the present experiment revealed that a selective 5-opioid 
antagonist, ICI 154,129 was as effective as naloxone in negating the inhibitory 
effects of DPDPE on the hypothalamic NA release and turnover. Thus it appears 
that the 5-opioid action on the central noradrenergic neurotransmission may operate 
independent of the p-opioid receptors. Activation of 5-opioid receptors has been 
shown to inhibit NA release from slices of the MPOA in vitro (Diez-Gueii'a et al, 
1987).
The EOPs differentially affect activity of various DA-containing neurons and 
pathways in the brain, particularly in the hypothalamus at the time of the LH surge
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(reviewed in the Introduction). The DA results obtained from icv administration of 
various opioid agonists and antagonists to ovx and steroid-primed rats appeal' to 
confirm the observations made in Experiment II i.e. that activation of multiple 
opioid receptors inhibits DA release in discrete hypothalamic areas. Diamoiphine 
reduced DA concentrations in the MPOA, SCN and ME in a naloxone-reversible 
manner. Paradoxically neither diamorphine alone nor, its administration together 
with naloxone, significantly altered DA levels in the ARN where short 
dopaminergic neurons are found (Lindvall and Bjorklund, 1982). It has been 
reported that the DA content of the ME is significantly reduced at the time of the LH 
surge compared to the values seen on the morning of the pro-oestrus (Akabori and 
Barraclough, 1986). Pharmacological stimulation of the p-opioid receptors has 
resulted in an inhibition of evoked DA release from the MBH in vitro (Heijna et al, 
1991). However, p-opioid agonists have also been suggested to have no effects 
on the TIDA dopaminergic neurons (Manzanai*es et al, 1992). The present results 
further demonstrate that activation of p-opioid receptors inhibits the cenhal 
dopaminergic system.
DPDPE significantly reduced the DA content in all the hypothalamic regions 
examined. Naloxone prevented the negative effects of DPDPE on DA release in 
the MPOA, SCN and ME. As mentioned earlier, a cross-communication between 
the p- and 5-opioid receptor subtypes in the brain has been postulated. It has been 
suggested that this 5-agonist may exert its effects on DA release by acting at both 
5- and p-opioid receptors (Experiment II). The specificity of 5-opioid modulation 
of the dopaminergic neuronal activity was tested by icv co-administration of 
DPDPE with ICI 154,129. Surprisingly, this selective 5-opioid antagonist did not 
significantly alter DA levels in any of the hypothalamic areas examined. 
Therefore, it is suggested that the modulatoiy actions of DPDPE on DA release 
may be exerted via p-opioid receptors rather than those of 5-subtypes. It has been 
shown that in the rat brain p- and 5-receptors can exist on the same neuron and aie 
physically associated (Schoffelmeer et al, 1987). It is not inconceivable that the 
activation of the 5-receptors would allosterically influence p-receptor activity 
(Passarelli and Costa, 1989). Naloxone can apparently therefore directly 
antagonise the inhibitory actions of DPDPE on dopaminergic neurotransmission by 
preventing its binding to the p-opioid subtypes. However, this hypothesis 
remains to be further investigated.
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Activation of the K-opioid receptors results in an inhibition of the TIDA 
dopaminergic neuronal activity (Manzanares et al, 1992). Previous work from this 
laboratory has shown that a K-agonist, tifluadom, increases DA turnover in the 
MPOA of pro-oestrous rats (Gopalan et al, 1989a). However, DA turnover has 
also been found to be elevated following the administration of a non-specific opioid 
antagonist, naloxone, in the same hypothalamic area. These contradictoiy results 
have been explained by a possible increase in the number of p-opioid receptors on 
the afternoon of pro-oestrus as reported by Casulari et al (1987). However, it has 
been suggested that a decrease in the inhibitory opioid peptidergic tone occurs at the 
time of the LH surge (Kalra et al, 1989). It has recently been shown that the 
density of p-opioid receptors declines as a result of elevated circulating gonadal 
steroids on the afternoon of pro-oestrus when plasma LH levels begin to rise 
(Maggi et al, 1993). Thus, it is possible that numbers of K-opioid receptors may 
also fluctuate during the oestrous cycle depending on the steroid milieu. In the 
present study, icv infusion of the specific K-opioid agonist (U-69593) reduced the 
concentrations of DA in all the hypothalamic regions studied. Prevention of the 
falls in DA levels by a selective K-antagonist, MR1452, in the same hypothalamic 
regions clearly indicates that these effects are specifically exerted via the K-opioid 
subtypes. In contrast to the earlier reports (outlined above) these results show that 
opioidergic influence on DA release via the K-opioid receptors is also inhibitory.
As mentioned in the Introduction, it has been suggested that the EOPs alter the 
central serotonergic neurotransmission by their action at pre-synaptic nerve 
terminals. In the experiment described in this chapter, 5-HT concentrations in all 
four hypothalamic regions examined were significantly reduced following icv 
administration of diamorphine, DPDPE and U-69593 (except for the action of 
DPDPE in the MPOA). All three opioid agonists also decreased 5-HIAA levels in 
the MPOA, but had selective effects in the other three hypothalamic regions. 
Furthennore, the suppressive effects of these opioid agonists on the content of both 
5-HT and its metabolite were prevented by their respective receptor antagonists. 
These results thus indicate that opioid inhibition of the serotonergic system within 
the hypothalamus may be exerted through multiple opioid receptor subtypes. It is 
thought that the exogenous opioids studied lower 5-HT synthesis by inhibiting its 
release from the nerve tenninals as, in most cases, both 5-HT and 5-HIAA 
concentrations were reduced in parallel (this will be reviewed in the General 
Discussion). Unexpectedly, the ratio of 5-HIAA/5-HT was not significantly
178
changed by diamoiphine and U-69593 in any of the hypothalamic areas. 
Surprisingly, DPDPE raised the ratio in only the ME compared to the control group 
values. Of the opioid antagonists investigated, only naloxone produced consistent 
effects. It significantly increased the ratio between 5-HIAA and 5-HT in the 
MPOA, ME and ARN compared to the animals receiving diamorphine or DPDPE 
alone. The relative concentrations of 5-HT and 5-HIAA were used to estimate the 
ratio of 5-HI A A/5-HT as described by Shannon et al (1986). However, it appears 
that this method may not necessarily reflect the turnover rate of 5-HT. Therefore, 
the conclusions regarding 5-HT neuronal activity (above) were based directly on 
the indoleamine levels detected in the discrete hypothalamic regions and not solely 
on the ratio of 5-HIAA/5-HT.
Interestingly, as in the case of DA release (explained earlier), the 5-opioid 
antagonist, ICI 154,129 failed to prevent the suppressive actions of DPDPE on the 
hypothalamic 5-HT and 5-HIAA levels. An enhanced serotonergic activity was 
observed after icv infusion of the 5-agonist concomitantly with naloxone. 
Therefore, it is postulated that DPDPE may influence 5-HT release and turnover 
primaiily by acting at p,-opioid receptors. However, the nature of this interaction 
awaits further investigation.
It has been postulated that opioids may abolish the surge release of LH by 
inhibiting the serotonergic neurotransmission on the afternoon of pro-oestrus 
(Brown et al, 1994). All the opioid agonists investigated appealed to affect 
hypothalamic 5-HT release and turnover around the time of the anticipated LH 
surge in the ovx and steroid-primed rats. However, the present experiment failed 
to demonsti’ate such interactions between the EOPs and the serotonergic system in 
the control of LH release due to inteiference by the ketamine anaesthesia.
5-HT metabolism may also influence other neurotransmitter systems. 
Serotonergic innervation of the TIDA dopaminergic neurons has been demonstrated 
in the ZI and ARN (Bosier et al, 1984; Willoughby and Blessing, 1987). 
Therefore, suppression of serotonergic activity by the opioids may indirectly 
account for the reduced DA release within discrete hypothalamic areas.
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Plasma LH levels (ng/ml)
AnimalID
14 .00h IS.OOh 16 .00h 17.00b 18 .00b 19 .00b
C-85 2.45 1.25 2.9 17.3 1.1 1.5
C-86 2.35 2.8 4.4 7.25 NS NS
D-2 NS 3.1 1.75 5.5 5.1 4.2
D-3 NS 1.1 1.0 0.75 4.1 6.5
D-6 NS 0.5 0.65 0.8 NS 2.5
D-9 NS LOW LOW LOW LOW 2.0
D-14 NS 2.7 1.4 6.2 4.85 4.3
D-16 NS LOW LOW LOW LOW LOW
D-61 1.65 1.1 2.3 1.35 1.3 2.8
E-9 LOW LOW LOW LOW LOW LOW
E-10 LOW LOW LOW LOW LOW LOW
E-12 LOW LOW LOW LOW LOW LOW
E-15 LOW LOW LOW LOW LOW LOW
E-24 LOW LOW LOW LOW LOW LOW
E-46 LOW LOW LOW LOW LOW LOW
Table 5 .6 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv sterile saline infusion at 14.00h. 
LOW: concentration below the limit of detection, NS: no sample obtained.
Plasma LH levels (ng/ml)
Animal
ID
14.00b 15 .00b 16 .00b 17 .00b 18 .00b 19 .00b
D-48 1.50 0.43 0.40 0.38 1.35 1.10
D-59 0.70 1.45 0.70 1.10 1.00 1.65
D-67 1.75 1.10 . 1.20 1.45 1.08 1.09
D-68 1.10 1.50 0.80 1.15 2.60 14.0
D-69 3.30 0.75 2.35 2.75 6.30 1.11
D-75 1.50 1.35 0.95 0.93 1.50 1.8()
E-42 LOW LOW LOW LOW LOW LOW
Table 5 .7 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv diamorphine infusion at 14.00h. 
LOW: concentration below the limit of detection, NS: no sample obtained.
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Plasma LH levels (ng/ml)
Animal
ID
14 .00h 15 .00b 16 .00b 17 .00b 18 .00b 1 9 .00b
E-13 LOW LOW LOW LOW LOW LOW
E-14 LOW LOW LOW LOW LOW LOW
E-22 LOW LOW LOW LOW LOW LOW
E-25 LOW LOW LOW NS NS NS
E-26 LOW LOW LOW LOW LOW LOW
E-27 LOW LOW LOW NS LOW LOW
E-28 0.45 1.6 LOW LOW LOW LOW
E-30 LOW LOW LOW LOW 1.45 2.0
Table 5 .8 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv diamoiphine plus naloxone 
infusion at 14.00h. LOW: concentration below the limit of detection, NS: no 
sample obtained.
Plasma LH levels (ng/ml)
Animal
ID 14 .00h 15 .00b 16 .00b 17 .00b 18 .00b 19 .00b
E-34 LOW LOW LOW NS NS LOW
E-36 LOW LOW LOW LOW LOW LOW
E-37 LOW LOW LOW LOW LOW LOW
E-38 LOW LOW LOW LOW LOW LOW
E-39 LOW LOW LOW LOW LOW LOW
E-47 LOW LOW LOW LOW LOW LOW
D-56 0.85 0.80 0.35 LOW 0.85 LOW
D-66 LOW 0.55 1.20 0.65 0.84 1.60
Table 5 .9 . Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv U-69593 infusion at 14.00h. 
LOW: concentration below the limit of detection, NS: no sample obtained.
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Plasm a LH  levels (ng/ml)
Animal
ID
1 4 .00h 1 5 .0 0 h 1 6 .0 0 h 1 7 .00b 18 .0 0 b 1 9 .0 0 b
E-5 LOW LOW LOW LOW LOW LOW
E-7 LOW LOW LOW LOW LOW LOW
E-8 LOW LOW LOW LOW NS NS
E-11 LOW LOW LOW LOW LOW LOW
E-16 LOW LOW LOW LOW LOW LOW
E-17 LOW LOW LOW LOW LOW 0.85
E-18 LOW LOW LOW LOW NS LOW
E-35 LOW LOW LOW LOW LOW LOW
Table 5.10. Plasma LH levels (ng/ml) observed in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv U-69593 plus MR1452 infusion 
at 14.00h, LOW: concentration below the limit of detection, NS: no sample 
obtained.
Plasm a LH levels (ng/ml)
Anim al
ID
1 4 .0 0 h 1 5 .0 0 b 1 6 .0 0 b 1 7 .0 0 b 1 8 .0 0 h 1 9 .0 0 b
D-45 LOW LOW LOW LOW LOW LOW
D-47 LOW LOW LOW LOW LOW LOW
D-53 LOW LOW LOW LOW LOW LOW
D-55 LOW LOW LOW LOW LOW LOW
D-63 LOW LOW LOW NS NS LOW
D-65 LOW LOW LOW LOW LOW LOW
E-31 LOW LOW LOW LOW 0.30 LOW
E-32 LOW LOW LOW LOW LOW LOW
Table 5.11. Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv DPDPE infusion at 14.00h. LOW: 
concentration below the limit of detection, NS: no sample obtained.
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Plasma LH levels (ng/ml)
AnimalID 14 .00h 15 .00h 16 .00b 17 .00b 18 .00b 19 .00b
D-51 LOW LOW LOW LOW LOW LOW
D-52 LOW LOW LOW LOW NS LOW
D-57 0.25 LOW 0.35 LOW LOW 0.43
D-58 0.42 0.33 LOW LOW 0.12 LOW
E-1 LOW LOW LOW LOW LOW LOW
E-3 LOW LOW LOW LOW LOW LOW
E-20 LOW LOW LOW LOW LOW LOW
E-21 LOW LOW LOW LOW LOW LOW
Table 5 .12 . Plasma LH levels (ng/ml) seen in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv DPDPE plus naloxone infusion at 
14.00h. LOW: concentration below the limit of detection, NS: no sample 
obtained.
Plasma LH levels (ng/ml)
AnimalID 14.00b 15 .00b 16 .00b 17.00b 18 .00b 19 .00b
E-43 LOW LOW 1.35 1.30 0.40 1.0
E-45 2.15 LOW 1.0 1.8 2.15 1.45
E-48 0.45 0.70 0.60 0.40 1.25 4.35
E-49 LOW LOW LOW LOW LOW LOW
E-52 LOW LOW LOW LOW LOW LOW
E-54 LOW LOW LOW LOW LOW LOW
E-57 LOW LOW LOW LOW LOW LOW
Table 5.13. Plasma LH levels (ng/ml) recorded in individual animals at hourly 
intervals between 14.00h and 19.00h on the afternoon of the anticipated LH surge 
in the ketamine-anaesthetised rats following icv DPDPE plus ICI 154,129 
infusion at I4.00h. LOW: concentration below the limit of detection, NS: no 
sample obtained.
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Plasma LH Leves (ng/ml)
Sampling
Intervals
Individual animals
C-66 C-69 C-71 C-72 C-75 C-80 C-82
13.00 h 0.80 LOW 0.65 0.95 0.70 1.30 1.10
14.00 h 0.80 0.65 0.85 0.80 0.85 0.90 1.05
15.00 h 0.70 0.80 0.75 0.95 0.85 1.05 2.50
16.00 h 0.72 0.75 0.65 0.80 0.65 0.95 0.90
17.00 h 0.70 0.75 0.65 0.80 0.85 0.90 1.00
18.00 h 0.72 0.90 0.80 0.90 0.65 1.05 1.00
19.00 h 0.63 0.80 0.70 0.75 1.05 1.15 0.90
Table 5.14. Plasma LH concentrations (ng/ml) of individual animals at various 
times after icv administration of sterile saline (10^1) at 14.00h on the afternoon of 
the anticipated LH surge in the saffan-anaesthetised rats. LOW; Plasma hormone 
levels below the limit of detection.
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Figure 5.15. ( a ,  h, c, d). Concentrations of NA, DA, 5-HT and 5-HIAA in 
the MPOA, SCN, ME and ARN of the saffan-anaesthetised control animals at 
19.00h on the afternoon of the anticipated the LH surge.
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Figure 5.16. (a, b, c). DHPG concentrations and ratios of DHPG/NA and 
5-HIAA/5-HT in the MPOA, SCN, ME and ARN of the saffan-anaesthetised 
control animals at 19.00h on the afternoon of the anticipated the LH surge.
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GENERAL DISCUSSION
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Site of Action of Opioids
Opioids have been shown to inhibit both basal and GnRH-induced LH release from 
cultured pituitary cells (Blank et al, 1986). However, they have also been reported 
to have no direct effects on LH release from the anterior pituitary (Bicknell, 1985). 
The anterior pituitary is relatively poor in opioid receptors (Khachaturian et al, 
1985). It is therefore most likely that the endogenous opioid control of LH 
secretion is caused by actions and/or interactions within the brain; in particular, by 
modulating the secretion of GnRH into the hypophyseal portal system, 
p-endoiphin inhibits GnRH secretion by preventing its release from the ME 
(Bonavera et al, 1993). Increased GnRH concentrations have been detected in the 
MPOA, ME and ARN at the time of the pre-ovulatory LH surge on the afternoon of 
pro-oestrus (Painet et al, 1990). Furtheimore, concentrations of GnRH in the 
hypophyseal portal blood have been well correlated with plasma LH levels in 
circulation following systemic administration of catecholaminergic drugs (Sarkar 
and Fink, 1981). These observations support the concept that drugs administered 
systemically exert their effects on LH release mainly through the hypothalamus.
In the rat, the response of the anterior pituitary to GnRH release increases steadily 
during the oestrous cycle and reaches maximum levels on the afternoon of pro- 
oestms (Blake, 1976). It is known that the presence of steroid hormones in the 
circulation influences the way in which the gonadotrophs respond to the GnRH 
discharge (Everett, 1994). Elevated plasma levels of E2 have been detected at the 
time of the pre-ovulatory LH surge, when a rapid increase in the GnRH content of 
the MBH occurs (Kalra, 1986). It has been suggested that opioid peptides might 
also alter the responsiveness of the pituitary to this neural signal from the 
hypothalamus (i.e. GnRH). However, this mechanism of opioid action is thought 
to be of least physiological importance since such an effect has not been shown in 
vivo.
In this study, exogenous opioid agonists and antagonists were administered 
systemically or icv to pro-oestrous or ovx and steroid-primed rats. The central 
effects of opioids on LH secretion may result from their action at one or several 
hypothalamic regions and perhaps also at extrahypothalamic loci. In the rat brain, 
the septal-preoptic-tuberal region is regarded as the final common pathway 
controlling LH secretion (Everett, 1994). The distribution of GnRH perikarya and 
neuronal processes mainly follow the discrete regional extension of this pathway in
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the diencephalon (Silverman et al, 1994; for review see Introduction). Implants 
containing naloxone or icv infusion of naloxone into the MPOA and ME-ARN 
regions readily stimulated LH secretion (Kalra and Simpkins, 1981). However, 
implantation of naloxone into the regions outside the hypothalamus failed to elevate 
LH release in ovx and steroid-treated rats. Furthermore, naloxone also elicits the 
efflux of GnRH from the preoptic aiea-MBH zone in vitro (Leadem et al, 1985). 
Thus, the regional specificity of naloxone action indicates that the effective site of 
the opioids is confined to the preoptic-tuberal pathway. Here, the opioid drugs 
may directly affect the GnRH perikarya and nerve terminals. Alternatively, they 
may also alter the activity of the central aminergic system whose nerve terminals 
make synaptic contacts with tlie GnRH neurons (described in detail in the 
Introduction). Additional brain loci have also been implicated in the regulation of 
LH release. Changes in dopaminergic activity in the ZI and lesions of this brain 
region have been shown to alter LH release (MacKenzie et al, 1988). 
Microinjection of moiphine into the DRN or MRN blocked the pre-ovulatory LH 
surge and ovulation (Johnson et al, 1986) and injection of opioids into the 
amygdaloid complex suppressed LH secretion (Lakoski and Gebhart, 1982). 
These findings indicate that the opioids may also exert their effects on the neuronal 
systems outwith the hypothalamus which project to the GnRH neurons in the 
preoptic-tuberal pathway.
Opioids and the Blood Brain Barrier
Capillaries in the brain, unlike those of most other organs, do not have pores 
between adjacent endothelial cells. Instead, these endothelial cells aie fused 
together by tight junctions. Therefore, the brain cannot obtain molecules (such as 
drugs) from the blood plasma by a non-specific filtering process. Alternatively, 
the molecules within the brain capillaiies are transported through the endothelial 
cells by either diffusion, active transport, endocytosis or exocytosis. This 
imposes a very selective blood brain barrier. However, the circumventricular 
organs such as the ME and OVLT do not have a functional blood brain barrier as 
these aieas contain fenestrated capillaries.
Since the systemic (IP) route of administration was employed in Experiments I and 
II, it is necessary to consider the permeability of the blood brain barrier to the drugs 
investigated. Initially peptides were believed to be too large and unstable to cross 
the blood brain barrier to any significant extent. Although the precise pathways
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(i.e. intracellulai', extracellular, transmembrane) for passage of blood-borne 
peptides into the CNS seems equivocal, it has now been documented that the 
peptides (e.g. enkephalins, dynorphins) cross the blood brain barrier by saturable 
and nonsaturable mechanisms in amounts sufficient to affect CNS functions 
(Banks and Kastin, 1990), Recently a microdialysis study has provided even 
more direct evidence for the new concept by indicating that moiphine is found in 
the dialysate of the striatum after systemic administration (Aasmundstad et al, 
1995). It is therefore believed that the opioid peptides studied here passed through 
the blood brain barrier in amounts sufficient to exert effects at the hypothalamic 
and/or extrahypothalamic loci. Delivery of substances into the brain ventricular* 
system however does not involve the blood brain barrier. The monoamine results 
from Experiment II, where the systemic route was used, have been found to be 
broadly in agreement with those obtained following icv administration of opioid 
agonists and antagonists to the ovx steroid-primed rats. These findings also 
appear to support the concept outlined above that opioids cross the blood brain 
barrier.
Opioids, Neuronal Activity and Monoamine Concentrations
It is generally accepted that opioid peptides depress spontaneous neuronal activity 
and hence neuronal transmission by hyperpolarising the membrane of their target 
cells (Henderson, 1983; Jiang and North, 1992). For ligands of j l - ,  k -  and 
0-opioid receptors, the inhibitory hyperpolarisation results from activation of a 
calcium-sensitive potassium conductance (Williams et al, 1982; Lagrange et al, 
1995). However, a second mechanism for action of the K-opioid receptors has 
been suggested, i.e. that activation of these receptor subtypes decreases the 
voltage-dependent calcium conductance by reducing channel opening time 
(Macdonald and Werz, 1986). Thus it appears that EOPs decrease spontaneous 
electrical activity and the amount of neurotransmitter released from their target 
neurons in the brain.
As detailed in the Introduction, aminergic neurotransmitters are synthesised in the 
cell bodies and transported via the axon to the nerve terminals where they are stored 
in vesicles. Upon depolarisation, the stored transmitters are released into the 
synaptic cleft. Hence, they can be found both intra- and extra-cellularly. 
Subsequently, the released amines are rapidly metabolised and taken up into their 
respective neurons (for review see Rang and Dale, 1991). Perikarya of tire
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noradrenergic and dopaminergic neurons lie outwith the MPOA, SCN, ME and 
ARN in which the monoamine measurements in the present study were made using 
HPLC-ECD. The four hypothalamic regions are also densely innervated by 5-HT 
projections from the raphe nuclei (Steinbusch, 1984). It appears that the majority 
of the amines detected in this study were situated within the nerve terminals of their 
respective neurons.
Since the specific hypothalamic regions were isolated by the micropunch technique, 
biogenic amines in both intra- and extra-cellular compartments were collected. 
Hence, an increase in amine concentrations in the micropunched hypothalamic 
samples could be a result of increased release, synthesis and/or axonal transport. 
It is well established that secretion of neurotransmitters stimulates their own 
synthesis and axonal transport by an autoregulation mechanism (Kr'uk and Pycock, 
1993). Therefore, the more amine released pre-synaptically the more produced by 
the neurons. Alternatively, raised concentrations of amines may also reflect a 
reduced release. However, results obtained in the present study do not support the 
latter assumption. Raised concentrations of NA or 5-HT were almost always 
accompanied by an increase in the levels of DHPG and 5-HIAA in the same 
hypothalamic samples, respectively. Production of DHPG or 5-HIAA directly 
reflects secretion of NA and 5-HT, respectively (Shannon et al, 1986). It thus 
appears that when release is elevated, so too is synthesis.
When a composite mixture was run through the reverse phase HPLC column, the 
retention time of ADR was between that of NA and the internal standard (DHBA) 
in the chromatogram (see Figure 2.9.a). However, it was observed that 
concentrations of this catecholamine were below the limit of detection in most of 
the hypothalamic samples examined. Therefore, those few results obtained have 
not been presented. The content of ADR in the rat brain is considered to be very 
low (Mefford, 1987). Indeed, previous work from this laboratory has also failed 
to detect ADR levels in the whole or in the specific regions of the hypothalamus 
(Gopalan cr/, 1989a).
The metabolites of DA, DOPAC and HVA were consistently below the limit of 
detection in the supernatant sample of the hypothalamic areas. The conclusions 
made regarding hypothalamic DA release and neuronal activity were therefore 
based on only the concentrations of this neurotransmitter. As mentioned above, 
decreases in NA and 5-HT levels were accompanied by reduced concentrations of
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their metabolites, DHPG and 5-HIAA, respectively. These findings thus indicate 
that the opioid agonists studied decrease the synthesis of NA and 5-HT by 
inhibiting their pre-synaptic release. In view of this, it is not inconceivable that 
when the DA release is reduced, the rate of its synthesis would also be lowered by 
the opioids.
Effects of Opioids on LH Release
It has been argued that a decrease in the EOP tone on the afternoon of pro-oestms 
is an important event in the initiation of the pre-ovulatoiy LH surge (Allen and 
Kalra, 1986). Also, the number of opioid receptors fluctuate throughout the 
oestrous cycle (Limonta et al, 1989). The p-opioid binding sites have been 
demonstrated to decline on the afternoon of pro-oestrus when plasma Eg and P 
levels are elevated (Maggi et al, 1993). Naloxone antagonism of the inhibitory 
opioidergic actions on both GnRH and LH release has been widely reported (Van 
Vwgtetal, 1981; Pivaef a/, 1985; Kim et al, 1991). Administration of morphine 
suppresses GnRH release (Mehmanesh et al, 1988) and naloxone infusion 
increases its secretion from the MBH-POA in vitro (Leadem et al, 1985). These 
observations imply that the opioidergic tone is not completely eliminated on the 
afternoon of pro-oestrus. In contrast to this hypothesis, Gabriel et al (1986) have 
reported that naloxone had no effect on LH release. The present results together 
with the previous work from this laboratory (Brown et al, 1994) appear to support 
the concept that the EOP tone persists to some degree during the LH surge.
The ability of morphine to inhibit both basal and surge release of LH has been 
demonstrated under various experimental conditions (Pfeiffer et al, 1987; 
Grossman and Dyer, 1989). It appears that suppression of the LH surge is a 
result of reduced GnRH release into the hypophyseal portal system since a 
p-opioid agonist (DAMGO) has recently been shown to inhibit GnRH neuronal 
activity and thus its release in vitro (Lagrange et al, 1995). In the present study, 
activation of the p-opioid receptors with diamoiphine tended to lower the pre­
ovulatory LH surge prior to 17.00h following its administration before the critical 
period on the afternoon of pro-oestrus. However, four of the 10 diamoiphine- 
treated animals showed some rises in plasma LH levels, but only towards the end 
of the critical period. This observation is similar to previously reported work 
where low doses of morphine elevated surge release of LH (Pang et al, 1977; 
Barraclough, 1994). These results may provide qualitative evidence for a
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stimulatoi-y opioidergic input to the LH surge-generating system as suggested by 
others (Pivaefa/, 1986). However, the involvement of putative autoreceptors in 
this response is unknown as their presence has not been demonstrated on EOP 
neurons.
Although activation of K-opioid receptors has been shown to inhibit LH and GnRH 
release (Leadem and Yagenova, 1987; Leposavic et al, 1991) the specificity of 
K-opioid action has been questioned since naloxone, a predominantly p-opioid 
antagonist, prevented the K-agonist-induced LH inhibition (Pfeiffer et al, 1987). 
A highly specific K-opioid agonist, U-50488H (Cicero et al, 1988) was used in the 
present study. The pre-ovulatory LH surge was completely abolished for seven 
hours by U-50488H on the afternoon of pro-oestrus. Unexpectedly, MR2266, a 
K-opioid receptor antagonist, failed to reverse the suppressive effects of U-50488H 
on plasma LH levels. It could be that this opioid antagonist may not have affinity 
for the K-opioid receptors or the dose used was insufficient to overcome the effects 
of U-50488H. However, these assumptions seem unlikely since the same 
treatment significantly increased the hypothalamic noradrenergic neuronal activity 
in the same animals (this is detailed later in this discussion). Possible modulatory 
effects of K-opioid receptors were further investigated by using a different 
K-agonist and an antagonist in the ovx and steroid-primed rat model. Icv infusion 
of U-69593 decreased, and its co-administration with MR1452 increased, NA and 
DHPG concentrations within the hypothalamus. However, neither U-69593 alone 
nor together with MR1452 caused significant changes in plasma LH levels due to 
the interference by the ketamine anaesthesia (as explained in the Experiment III). 
It is most likely that the complete cessation of the pre-ovulatory LH surge, evident 
after IP administration of U-50488H, results from a specific action at K-opioid 
receptor subtypes.
To date, much of what is known regarding the effects of opioids on GnRH and LH 
release has been based upon studies using opioidergic compounds which act at 
either |i- or K-opioid receptors. There have been relatively few attempts to study 
the significance of 0-opioid receptors in the regulation of LH release. Activation 
of 6-opioid receptors have been shown to suppress LH secretion on the day of pro­
oestrus (Leadem and Yagenova, 1987). However, specificity of 6-opioid action 
appears to be controversial, since a specific 6-opioid receptor antagonist has failed 
to reverse the inhibition of LH release (Leposavic et al, 1991). In Experiment II, 
the use of a highly selective 6-agonist, DPDPE, profoundly inhibited the pre­
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ovulatory LH surge, and its effects were reversed by naloxone. Naloxone exerts 
its antagonistic effects by acting predominantly at ji-receptor sites (Bicknell, 
1985). 6-opioid receptors have a more restricted distribution than those of |x- and 
K-opioid receptors in the brain (Mansour et al, 1988; Desjardins et al, 1991). It 
has recently been reported that there may be interaction between the 6- and ja-opioid 
receptor subtypes in the CNS (Stadimis and Young, 1992; Tray nor and Elliott, 
1993). The 6-opioid receptors are known to have great affinity towards 
enkephalin neurons (Traynor and Elliott, 1993). Furthermore, in the rat brain, 
ji- and 6-receptors can exist on the same neuron (Schoffelmeer et al, 1988). 
Therefore, it is possible that both receptor subtypes may mediate the inhibitory 
effects of DPDPE on the LH secretion. In order to reveal the specific site of 
6-opioid action, DPDPE was co-administered (icv) with ICI 154,129, a selective 
6-antagonist, and with naloxone to the ovx and steroid-primed rats on the afternoon 
of the anticipated LH surge. The LH results from that experiment have proved to 
be inconclusive since the ketamine anaesthesia again dismpted the expected surge 
release of LH. However, specific 6-opioid effects were observed on the 
hypothalamic amine (particularly NA) concentrations within the specific 
hypothalamic regions of the same animals. It is suggested that inhibitoiy effects of 
EOPs on LH secretion are also exerted via the 6-opioid subtypes. The nature of 
6-opioid involvement in this process has to be further elucidated when more 
selective 6-opioid antagonist agents become available.
In conclusion, all three of the opioid receptor subtypes investigated appear to 
inhibit LH release when activated by their respective agonists on the afternoon of 
the pro-oestrus.
NA Mediation of Opioid Effects on LH Release
As detailed in the Introduction, it is generally believed that the noradrenergic 
system in the brain is stimulatoiy to GnRH and thus also LH release in the 
presence of circulating ovar ian steroids but, inhibitory in their absence (See Kalra 
et al, 1989; Kordon et al, 1994). Blockade of the a-adrenoreceptors in the 
preoptic/AHA, ARN and ME as well as systemic application of the catecholamine 
synthesis inhibitor, diethyl dithiocarbamate, inhibits the LH surge and also basal 
LH pulses (Estes et al, 1982; Al-Hamood et al, 1985; Jarry et al, 1990). 
Noradrenergic nerve terminals make synaptic contacts with the GnRH neurons in 
the MPOA and to a lesser extent with GnRH nerve terminals in the ARN and ME
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(Watanabe and Nakai, 1987). The noradrenergic terminals within the 
hypothalamus possess a mixed population of opioid receptors; which aie inhibitoiy 
to GnRH release, and stimulation of opioidergic activity inhibits GnRH release. 
Morphine-induced suppression of LH secretion has been attributed to an inhibition 
of release of NA from its nerve terminals (Kalra et al, 1989; Barraclough, 1994).
In view of the reports outlined above, opioid suppression of LH release would be 
expected to involve a reduced NA activity in the hypothalamic areas containing 
GnRH neurons or terminals. In the present study, administration of specific 
K- and 0-opioid agonists significantly decreased the concentrations of NA and its 
metabolite (DHPG) in the MPOA, SCN, ME and ARN concomitantly with the 
inhibition of the pre-ovulatory LH surge. These inhibitory effects of U-50488H 
and DPDPE were prevented following co-administration with their respective 
antagonists. Similar results were observed in all the hypothalamic regions 
examined after icv infusion of opioid agonists and/or antagonists to the ovx and 
steroid-primed rats under ketamine anaesthesia. However, the anticipated LH 
surge was blunted in all the drug treatment groups by ketamine itself. As 
activation of opioid receptors depresses spontaneous neuronal activity and hence 
neuronal transmission (Jiang and North, 1992), the present results suggest that 
opioid agonists studied suppress LH release. This action may involve a reduction 
in the hypothalamic noradrenergic neurotransmission.
It has previously been reported that administration of naloxone stimulates NA 
release and/or turnover within the hypothalamus during the pre-ovulatoiy LH surge 
(Akabori and Barraclough, 1986). Naloxone-induced increase in the 
noradrenergic activity enhances release of GnRH (Kalra et al, 1989). Consistent 
with these observations, the results presented here indicate that naloxone 
stimulation of the surge release of LH involves a greatly increased hypothalamic 
NA release and/or turnover within the preoptic-tuberal pathway. It thus appears 
that it is the changes in the hypothalamic NA content by which the opioid 
antagonist influences LH release. Indeed pharmacological studies have shown that 
naloxone-stimulated LH release is prevented by inhibitors of the noradrenergic 
synthesis (Van Vugt et al, 1981; Kalra and Simpkins, 1981).
During the pre-ovulatory LH surge, all GnRH neurons synchronise to initiate 
synthesis of this neuropeptide (Silverman and Witkin, 1994). This co-ordination 
of GnRH synthesis is achieved by intercellulai* communications through numerous
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collateral synaptic contacts between GnRH-producing neurons and putative GnRH 
receptors (Wetsel et al, 1992). The simultaneous firing of many, if not all, GnRH 
neurons is required for the pulsatile dischaige of GnRH. In the MPOA of the 
K-opioid agonist and antagonist-treated group, there was no significant increase in 
NA concentrations. Perhaps the lack of an essential stimulatory noradrenergic 
component to the GnRH neurons in the MPOA accounts for the failure of MR2266 
to elevate plasma LH levels. This suggestion is supported by the findings of 
Honma and Wuttke (1980) who concluded that the stimulatory effects of NA on 
GnRH and hence LH release are exerted within the MPOA.
There are claims that the central noradrenergic system also exerts an inhibitory 
effect on LH release (Dotti and Taleisnik, 1984; Leipheimer and Gallo, 1985; 
Bergen and Leung, 1987). However, the results described here have clearly 
indicated that a decrease in the hypothalamic NA content was associated with the 
inhibition of the pre-ovulatory LH surge in the pro-oestrous rats. These 
contradictoiy findings can be explained by the lack of a steroidal environment in the 
ovx animal models used in those studies reported above. Because the ovarian 
hormones have been reported to have a determining role on the action of NA which 
is considered to provide an essential stimulatory input to the LH secretory systems. 
It this context, it should be noted that there is usually an increase in the opioidergic 
neuronal activity in the absence of ovarian steroids (Genazzani et al, 1990). 
Opioids inhibit the stimulatory noradrenergic input to the LH secretory 
mechanisms. However, the EOP neurons contain and are themselves inhibited by 
circulating E2 (Grossman and Dyer, 1989). Thus, increasing levels of E2 on the 
afternoon of pro-oestrus frees the excitatory NA input from the tonic inhibition of 
the EOPs and leads to the pre-ovulatory LH surge. Likewise, enhanced 
noradrenergic content and turnover in the specific regions of the hypothalamus 
were detected following icv infusion of sterile saline or various opioid receptor 
antagonists to the ovx and steroid-primed rat model utilised in this study. 
However, these findings could not be correlated with the anticipated LH. surge, 
again due to the unexpected interference by ketamine anaesthesia in the same 
animals (this was detailed in the Experiment III).
GABAergic neurons may function as inhibitory interneurons between the 
noradrenergic terminals and GnRH neurons. Activation of GAB A neurons with 
muscimol and baclofen (GABA^ and GAB As receptor agonist, respectively) 
reduces NA release in the MPOA and MBH in association with a sustained
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decrease in serum LH levels (Demling et al, 1985; Adler and Crowley, 1986). On 
the other hand, stimulation of noradrenergic input projecting to the MPOA, results 
in GAB A release in ovx rats when levels are relatively low, but not when they 
are high (Herbison et al, 1989). Furthermore, GAB A may also modulate GnRH 
neuronal responsiveness to NA and its withdrawal at the time of the LH surge; this 
action would allow a greater NA release (Banaclough, 1994). These findings are 
taken to indicate that elevated E% levels on pro-oestrus also eliminate the inhibitory 
GABAergic influence on the excitatory NA input to the GnRH secretory system. 
Such a deteiTOining role of E% on this GABAergic action has indeed been reported 
(Flugge et al, 1986). Thus, it appears that expression of the tiiggering neural 
signal of NA for the LH surge may result from a reduction in the hypothalamic 
GABAergic activity (Jarry et al, 1991), Although the hypothalamic GAB A release 
was not monitored in this study, the increased NA release and turnover in the 
MPOA, SCN, ME and ARN would indicate that the GABAergic neuronal activity 
was decreased or completely eliminated by the auotoregulatory mechanisms at the 
time of the LH surge. These results thus support the hypothesis that a decrease in 
GAB A release would also contribute to the GnRH pulse generating system.
DA Mediation of Opioid Effects on LH Release
There have been controversial reports about the involvement of the central 
dopaminergic system in pulsatile LH release; both stimulatory and inhibitoiy 
actions of DA have been suggested (Ramirez et al, 1984; MacKenzie et al, 1988). 
However, DA is not considered to play a primary role in the generation of the LH 
surge under physiological conditions.
Pharmacological manipulations of the dopaminergic systems projecting to the 
preoptic-tuberal pathway have been shown to alter LH secretion. Administration 
of DA antagonists inhibits the LH surge, and thus ovulation, when given to the 
pro-oestrous rat (MacKenzie et al, 1988). Conversely, infusion of DA or its 
agonists into the ZI elevates plasma LH levels and advances the LH surge (James et 
al, 1987). Lesions of the ZI have been demonstrated to disrupt the LH surge 
(Sanghera et al, 1991a). As mentioned in the Introduction, the dual effects of DA 
on LH release have been attributed to the pathway involved; the 
incertohypothalamic system appears to be stimulatory in the MPOA and SCN with 
the TIDA being inhibitory in the ARN-ME. Indeed, DA has been shown to be 
excitatory in the MPOA (Kawakami et al, 1975; MacKenzie et al, 1988) where
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dopaminergic and GnRH neurons make synaptic contacts (Leranth et al, 1988a). 
Therefore, a decrease in DA levels of the MPOA would be expected following 
administration of opioid agonists which inhibit LH secretion. Both diamoiphine 
and DPDPE reduced the DA concenti'ations in this hypothalamic area concomitantly 
with inhibition of the LH surge. Furthermore, naloxone-stimulation of LH release 
involved an increase in the DA activity both in the MPOA and SCN. It is 
suggested that EOPs may exert their effects, at least in part, on LH secretion also 
via a dopaminergic mechanism. This modulatory action of the opioids appeal's to 
be inhibitory in the MPOA and SCN.
DA has been suggested to be inhibitory to LH secretion in the ARN and ME (Rose 
and Weick, 1986). Morphine-induced LH inhibition involves an increase in the 
dopaminergic activity in these hypothalamic regions (He et al, 1994). In contrast, 
moiphine has also been reported to lower the rate of synthesis and turnover of DA 
in the ME by inhibiting the activity of the TIDA neurons (Alper et al, 1980). 
Similarly p-endoiphin decreases the hypothalamic DA release from the TIDA 
neurons (van Loon etal, 1980; Wilkes and Yen, 1980). In the present study, of 
the opioid agonists investigated, only DPDPE significantly reduced DA 
concentrations in the ME and ARN concomitantly with the inhibition of the pre­
ovulatory LH surge. It may therefore be inferred that opioids decrease the TIDA 
dopaminergic activity too, during the pre-ovulatory LH surge.
It has vei-y recently been reported that opioidergic suppression of LH release is 
accompanied by an inhibited dopaminergic input to the LH secretoi-y systems 
(Chandolia et al, 1997). In the present study, DA concentrations were 
significantly increased in all the hypothalamic regions examined following the co­
administration of naloxone with diamoiphine or DPDPE. These results thus 
further indicate that naloxone-stimulation of the pre-ovulatory LH surge involves 
an increase in DA release in specific hypothalamic regions on the afternoon of pro­
oestrus.
Administration of the K-agonist, U-50488H, reduced the hypothalamic DA content 
in association with the abolition of the pre-ovulatory LH surge. However, the 
decreases in DA levels were not found to be statistically significant. Previous 
work from this laboratoiy using a different K-opioid agonist, tifluadom, have also 
produced inconsistent results (Gopalan et al, 1989a; Brown et al, 1994). 
Activation of K-opioid receptors has been shown to inhibit DA release from the
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MBH slices in vitro (Heijna et al, 1991). Based on the findings here from 
administration of the |Li- and 5-opioid agonists, it has been suggested that an 
increase in the hypothalamic DA release (particulai'ly in the MPOA and SCN) may 
be stimulatory to LH release. If so, failure of the combination of MR2266 with U- 
50488H to elevate plasma LH levels in the pro-oestrous rats may be attributed to 
lack of effects of the K-opioid antagonist on the DA content in the MPOA and 
SCN.
In the ovx and steroid-primed rats, central administration of p.-, K- and 5-opioid 
receptor agonists brought about significant decreases in DA levels in all the 
hypothalamic regions examined (except for the action of diamoiphine in the ARN). 
Thus these results further demonstrate that the effects of opioids on DA release is 
inhibitory at the time of the LH surge regardless of the dopaminergic pathway 
involved. Furthennore, prevention of opioid-induced falls in the hypothalamic DA 
content by naloxone, MR 1452 and ICI 154,129 indicates that these inhibitory 
actions of the opioids are exerted via specific opioid receptor subtypes.
Direct neurohumoral effects of DA on prolactin release from the anterior pituitary 
have been well-documented (See Kordon et al, 1994). Dopaminergic projections 
to the external layer of the ME secrete this catecholamine into the hypophyseal 
portal system as a prolactin inhibiting factor (Ben-Jonathan, 1985). Naloxone 
inhibits prolactin secretion by increasing the outflow of DA from the ME and 
morphine produces the opposite effects (Pfeiffer et al, 1987). The possibility 
exists that the raised DA levels in the ARN-ME observed during the present study 
may be a reflection of naloxone's action on the regulation of prolactin secretion. 
Naloxone-enhancement of the dopaminergic activity in all the hypothalamic regions 
studied concomitant with the pre-ovulatory LH surge is therefore not surprising. 
It is known that dopaminergic drugs affect plasma LH levels, however, their action 
is exerted within the brain rather than at the anterior pituitary level. Indeed, a 
functional relationship between the dopaminergic and GnRH systems has been 
demonstrated in discrete hypothalamic areas. The action of DA neurotransmission 
is probably mediated by axo-axonic contacts between GnRH and DA fibres in tlie 
ME (Ramirez etal, 1984). The results of the present study also appear to support 
the concept that it is changes in the hypothalamic activity of this catecholamine 
which may influence LH dischai'ge from the anterior pituitary.
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In conclusion, although the dopaminergic system may be of minor importance in 
the mediation of opioid inhibition of LH release, an increase in its activity may 
facilitate the pre-ovulatory LH surge.
5-HT Mediation of Opioid Effects on LH Release
The physiological significance of the serotonergic system in the cential regulation 
of LH secretion has not been well-established. Both stimulatory and inhibitory 
effects of 5-HT on LH release have been reported (See Vitale and Chiocchio, 1993; 
Kordon ef aZ, 1994).
There is compelling evidence to suggest that 5-HT is excitatory to GnRH and hence 
LH release (Walker, 1983; James et al, 1989; Dow et al, 1994). Administration of 
a 5-HT agonist stimulates LH secretion. In addition, impainnent of the 
serotonergic transmission abolishes the LH surge (Walker, 1980). In vitro, 5-HT 
stimulates GnRH release from ME fragments taken from the pro-oestrous rats 
(Vitale et al, 1987). The results of the present study have shown that there is 
usually an increase in the concentrations of 5-HT and its metabolite, 5-HIAA, in 
specific hypothalamic regions of the saline-treated animals at the time of the LH 
surge. Similar findings have previously been reported that an increase in 
serotonergic activity occurs in association with the pre-ovulatory LH surge on pro­
oestrus (Kerdelhue et al, 1989). These observations appeal' to indicate a 
facilitatory role for 5-HT in the control of LH secretion.
There are reports of 5-HT mediation of opioid effects on LH release (Lenahan et al, 
1987; Gopalan etal, 1989b). High numbers of the various opioid receptors have 
been detected in the raphe nucleus (Mansour et al, 1988). In the DRN, activation 
of K-opioid receptors decreases the response of 5-HT-sensitive neurons to electrical 
stimulation suggesting that EOPs may pre-synaptically inhibit 5-HT release in this 
brain ai'ea (Pinnock, 1992). Thus, opioid agonist inhibition of the LH surge 
should involve a reduced 5-HT activity in the hypothalamus, if opioid effects on 
LH aie mediated by 5-HT neurons. The hypothalamus receives dense 
serotonergic projections from the raphe nuclei (Steinbusch, 1984). Icv infusions 
of diamoiphine, U-69593 and DPDPE have cleai'ly indicated that all three (ja, K, 
and 5) opioid agonists have modulatory effects on the hypothalamic serotonergic 
system at the time of the anticipated LH surge. The direction of the opioidergic 
action on the 5-HT neuronal activity appears to be inhibitory. Systemic
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administration of diamoiphine and U-50488H had area-dependent effects on the 
concentrations of 5-HT and 5-HIAA in the MPOA, SCN, ME and ARN. 
However, the 0-opioid agonist, DPDPE, significantly reduced the levels of both 
5-HT and its metabolite in all the hypothalamic regions examined (except 5-HT in 
the SCN) concomitantly with the abolition of the pre-ovulatory LH surge. Thus, 
these results reaffinn the hypothesis that opioids may exert their inhibitory effects 
on LH secretory systems, at least in part, via a 5-HT mechanism.
It has previously been suggested that naloxone enhances LH secretion by 
increasing the hypothalamic 5-HT content and/or turnover (Brown et al, 1994). 
The results described here have clearly indicated that naloxone-stimulation of LH 
release involves an increase in the serotonergic neurotransmission in the MPOA, 
SCN, ME and ARN on the afternoon of pro-oestrus. Administration of naloxone 
antagonises the inhibitory effects of diamoiphine on 5-HT release and/or turnover 
by acting principally at the |X-opioid receptor subtypes. These findings thus 
support the concept that the 5-HT system provides a stimulatory input to the LH 
surge generating system.
In conclusion, the serotonergic system may be involved in opioid inhibition of the 
LH surge. It is also believed that although 5-HT may facilitate the LH release, its 
role in this process appears to be of minor importance under physiological 
conditions.
Urethane and Ketamine Anaesthesia in Neuroendocrine Studies
There is increasing concern about the use of anaesthetics in neuroendocrine 
experiments. Several anaesthetics e.g. pentobarbitone, alphaxolone, ketamine, 
urethane, ether and chloral hydrate have been reported to influence LH release in 
the female rat, however, the results aie often conflicting (Kimura and Sano, 1995; 
Hartman etal, 1989; de Greef etal, 1987; Dyer and Mansfield, 1984; Sherwood et 
al, 1980).
The employment of urethane as a useful anaesthetic in neuroendocrine studies has 
been recommended as it has been claimed that it does not prevent the occurrence of 
LH pulses, although it reduces their amplitude (de Greef et al, 1987; Matzen et al, 
1987). Despite using the minimum effective dose in this study, urethane 
completely abolished the LH surge for seven hours on the afternoon of pro-oestrus
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(see Experiment I). Furthermore, the overall hypothalamic monoamine 
concentrations, in particular those of NA and its metabolite (DHPG), in the 
urethane-anaesthetised animals were found to be significantly lower than those seen 
in the conscious, unrestrained rats. Pentobarbitone and chloral hydrate have also 
been reported to reduce NA turnover and release respectively, concomitant with 
their inhibition of the LH surge (Ranee and BaiTaclough, 1981). An increase in 
the hypothalamic noradrenergic activity has been conelated to the pre-ovulatory LH 
surge, and the absence of this stimulatory neural signal may be responsible for the 
failure of ovulation (Ramirez et al, 1984; Akabori and Barraclough, 1986). The 
present results therefore indicate that urethane may have interfered with the GnRH 
surge secretory systems by decreasing the concentrations of NA and its metabolite 
(DHPG) in the specific hypothalamic regions.
Differential effects of anaesthetic agents on plasma LH levels have been explained 
by a different mechanism by Kimura and Sano (1995). These authors have 
reported that pentobarbitone anaesthesia arrested the anticipated LH surge in the 
afternoon, while it had no effect on pulsatile LH release when given in the morning 
of the same day. Furthermore, naloxone infusion increased the activity of GnRH 
neurons and plasma LH levels in the pentobarbitone-anaesthetised rats on the late 
morning of pro-oestrus (Fuiiabashi et al, 1997), These findings were taken to 
suggest that separate GnRH pulse and surge generators exist in the hypothalamus 
and that these control basal and surge release of LH, respectively. In the present 
study, plasma LH levels were not monitored on the morning of pro-oestrus in the 
urethane-anaesthetised rats. However, it has previously been reported that this 
anaesthetic does not prevent basal release of LH in the male rat (Matzen et al, 
1987). Therefore, it is suggested that urethane may exert its effects by a similai’ 
mechanism (see above) since it completely blocked the pre-ovulatory LH surge on 
the afternoon of pro-oestrus.
In contrast to the earlier reports (Sherwood et al, 1980; Ching, 1982; Hartman et 
al, 1989), it was found in the present study that ketamine anaesthesia also 
suppresses LH release from the anterior pituitary (see Experiment III), 
Interestingly, ketamine did not seem to dismpt cential aminergic 
neurotransmission, as biogenic amine levels were largely in parallel with the values 
obtained from the conscious animals in which the LH surge took place. These 
findings suggest that the inhibition of the LH surge may be a result of reduced 
pituitary responsiveness to GnRH release in the ketamine-anaesthetised rats. It is
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also suggested that the GnRH surge generator may still be active in these rats, since 
a GnRH surge has previously been detected in the portal blood of the ketamine- 
anaesthetised rats (Sherwood et al, 1980).
To date it would appeal* that there is no anaesthetic which does not interrupt the 
reproductive neuroendocrine axis in female rats. Therefore, it is recommended 
that use of general anaesthetics should be avoided if at all possible in such studies.
Conclusions
The results reported here provide strong evidence for the paiticipation of K - and 
5-opioid receptors in the central regulation of LH release. Thus it appears that 
multiple opioid receptor subtypes are involved in the opioid inhibition of the pre­
ovulatory LH surge.
Since all three opioid receptors agonists significantly reduced concentrations of NA 
and DHPG in all the hypothalamic regions examined, concomitantly with the 
abolition of the LH surge (except diamoiphine), it is suggested that the inhibitory 
actions of EOPs on LH release are mediated in large part by NA. These findings 
suggest that an increase in hypothalamic noradrenergic activity may be a critical 
event in triggering the surge release of GnRH and LH. Both the dopaminergic and 
serotonergic neurotransmitter systems may also facilitate the pre-ovulatory LH 
surge, although their effects aie thought to be of minor importance in this process.
Icv administration of diamorphine, U-69593 and DPDPE resulted in significant 
decreases in the hypothalamic biogenic amine levels. These results therefore 
indicate that modulatoiy actions of opioids on the hypothalamic noradrenergic, 
dopaminergic and serotonergic neurotransmission aie inhibitory. The prevention 
of these effects by selective opioid antagonists would point to specific mediation 
via \L~, K - and 5-opioid receptors.
DPDPE inhibited the pre-ovulatoi*y LH surge in association with a decrease in the 
hypothalamic NA levels in a naloxone reversible-manner. Due to the postulated 
cross-communication between the jx- and 5-opioid subtypes, it is suggested tliat 
both fx- and 5-opioid receptors may mediate the inhibitory effects of DPDPE.
2 2 2
Recommendation for future work
In the experiments presented here, opioid suppression of the pre-ovulatory LH 
surge by a mixed population of receptors has been shown. Furthermore, the 
results have indicated that direction of opioidergic action on the central
noradrenergic, dopaminergic and serotonergic neurotransmission via |X-, k- and
5-opioid receptors is inhibitory. To further investigate the above findings, acute
central administration of the opioids could be used. To this end, indwelling 
intracranial cannula could be placed (under halothane anaesthesia) to allow for icv 
administration of drugs to conscious, unrestrained animals. Blood samples would 
be collected from conscious animals at half hourly intervals for LH determination 
by RIA on the afternoon of pro-oestrus. Such an experimental design would 
provide for the deposition of drugs in predominantly hypothalamic loci and 
eliminate a possible interference caused by anaesthetic agents. At the end of the 
critical period, the animals would be decapitated, brains removed and MPOA and 
ME isolated as described earlier. The monoamine contents of these two 
hypothalamic regions would then be determined by HPLC-ECD.
To further investigate the opioid receptor subtypes involved, selective antagonists 
of each opioid receptor subtype could be co-administered with their respective 
agonists, and the effects on LH secretion, and monoamine activity in the 
hypothalamus, determined. To further elucidate the role of hypothalamic 
monoamines in the mediation of the effects of the opioids on LH secretion, 
microdialysis technique would be employed to deliver opioids and collect 
extracellular fluid for the measurement of monoamines in the MPOA and ME of 
conscious animals. Microdialysis would provide a clearer index for the release of 
monoamines in dialysates at the time of the LH surge.
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